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PHARMACOLOGICAL APPROACHES TO PRESERVE RENAL GRAFTS AND TO 
OPTIMIZE IMMUNOSUPPRESSION IN RENAL TRANSPLANTATION 
Harisudhan Thanukrishnan, PhD 
University of Pittsburgh, 2019 
Renal transplantation has evolved as the best therapeutic option for patients with end stage renal 
diseases. Several risk factors such as ischemia reperfusion injury (IRI), delayed graft function, 
under or over-immunosuppression and drug toxicity can affect the renal graft function and 
survival. This work focused on pharmacological approaches to address two of the modifiable risk 
factors associated with early post-transplant graft survival, namely IRI and optimization of 
immunosuppression. The first part of work evaluated supplementation of the renal cold 
preservation solution with treprostinil to attenuate IRI injuries due to its vasodilatory, anti-platelet 
aggregatory and cytoprotective properties. Isolated rat kidneys were stored at 4°C for 24 h with or 
without treprostinil and reperfused in vitro to mimic post-transplant conditions. Cold stored 
kidneys showed a significant loss in renal function and treprostinil addition (20 ng/mL) to 
preservation significantly improved the filtration fraction, urine flow and showed a trend to 
increase the anionic and cationic tubular secretion. Treprostinil addition to storage and reperfusion 
attenuated the IR induced changes in certain gene expression, indicating protection against the IR 
induced effects and the need for a follow-up of its effects in an in vivo transplant setting. The 
second part of this work examined early (week 1) post-transplant pharmacologic measures in 
association with incidence of rejections (clinical and subclinical) at week-13 and infections at 
month-12 in renal transplant patients. The pharmacologic measures for exposure and efficacy to 
mycophenolic acid (MPA) and exposure to tacrolimus were obtained by sparse sampling. Patients 
with lower exposure to both drugs tended to have higher incidence and odds of rejection, when 
  v 
compared to patients who had optimal exposure to both tacrolimus and MPA (46 vs 23 %, NS, 
odds ratio of 3.0; p =0.3414 for rejections). A composite scoring using pharmacologic measures 
such as the total 12 h exposure to MPA, tacrolimus, IMPDH activity and genotype of p-
glycoprotein on peripheral blood mononuclear cells revealed an increasing incidence of rejections 
in patients with higher scores. This observation emphasizes potential role for early post-transplant 
monitoring using sparse sampling in individualized therapy of kidney transplant patients, in order 
to further improve overall outcomes. 
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1.0  INTRODUCTION 
  
  2 
1.1 BURDEN OF RENAL DISEASE 
Chronic kidney disease (CKD) is a major health problem with a global prevalence rate of  
around 11-13 % 1, when patients at all stages (1-5) of the disease are considered. The staging of 
kidney function is indicative of the progression in kidney disease and is based on an assessment 
of the renal function (estimated glomerular filtration rate- eGFR) and kidney damage (albumin 
creatinine ratio ACR)1,2. The normal healthy adult kidney has an eGFR around 120 ml/min/1.73m2 
with an ACR of < 3 mg albumin per mmol of creatinine. The respective cut-off values for the 
staging for eGFR expressed in “ml/min/1.73m2” and ACR expressed in “mg/mmol” are: Stage-1 
(eGFR>90 with ACR>30), Stage-2 (eGFR 60–89 with ACR>30),  Stage-3 (eGFR 30–59),  Stage-
4 = (eGFR 29–15) and Stage-5 (eGFR<15). As of early 2016, the number of patients in United 
States reported with end stage renal disease (ESRD, Stage 5) was around 7 million3. ESRD 
primarily results from diabetes (37-46 %), hypertension (23 %),  glomerulonephritis (14 %), cystic 
kidney (9 %) and other unknown reasons (18 %)4,5. Patients with ESRD often require “renal 
replacement therapy” that is offered by periodic dialysis or with renal transplantation. Renal 
transplantation is considered the best treatment choice for patients with ESRD. 
1.2 RENAL TRANSPLANTATION 
Renal transplantation offers survival advantage for patients with ESRD, with the risk of 
death being reduced by less than half in comparison to being maintained on dialysis6. In the long 
term, transplantation is also more cost effective with better quality of life than maintenance on 
dialysis, even after adjusting for differences in the quality of the transplanted kidney7.  However, 
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due to the larger number of patients with ESRD relative to the number of available kidneys for 
transplantation, there is a long waiting list prior to someone receiving a kidney transplantation. 
Renal transplant data for 2018 shows that, out of an estimated active waiting list of around 65,500 
patients with ESRD, only around 21,167 received a kidney transplant8,9. This included 6442 
kidneys provided by living donors (30 %) with the remaining 70% coming from cadaveric donors9. 
Unlike in few other countries, the majority of transplanted kidneys in United States are obtained 
from deceased donors. With new patients constantly being added to the waiting list and with the 
growing demand for transplantable kidneys, the optimal use of cadaveric kidneys by increased 
utilization of marginal donors as well as decreasing the number of discarded kidneys, have all been 
pursued as viable alternatives10. As such kidneys are more susceptible to ischemia reperfusion 
injury (IRI), strategies aimed at preventing or minimizing IRI would be beneficial for post-
transplant graft and patient survival. On the other hand, with higher number of transplants, the 
successful maintenance of good organ function over time is also of great importance4,10 and 
requires careful optimization of immunosuppression in individual patients. 
1.3 STATEMENT OF THE PROBLEM 
Improving the long-term patient outcome is an ultimate goal in transplantation, as there are 
several immunological and non-immunological risk factors in the donor as well as the recipient 
that can affect the renal graft function and survival. Few of the risk factors are modifiable, such as 
ischemia reperfusion injury, delayed graft function, avoiding under or over-immunosuppression 
(rejection or infection), non-adherence and calcineurin inhibitor toxicity (Figure 1.1). The research 
work in this dissertation addresses two of the modifiable risk factors that can affect early graft 
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survival and benefit the recipients of kidney, namely ischemia reperfusion injury and optimal 
immunosuppression to avoid rejections and infections. 
 
Figure 1.1 Factors that can alter the function and survival of renal allografts 
1.3.1 Ischemia reperfusion injury 
Ischemia reperfusion (IR) injury is an inevitable consequence of transplantation when a 
kidney is subject to sequential procedures like, isolation from donor, absence of blood flow, 
preservation in cold solution until transplantation and warm reperfusion with recipient blood 
during implantation. Reperfusion associated injury does not occur during ischemia, but during 
reperfusion at the time of implantation of kidney in the recipient. IR injury is also a known risk 
factor for acute kidney injury, delayed graft function (DGF) or acute and chronic rejection after 
transplant11-13. Hence, improving the cold preservation as well as attenuating injury during 
reperfusion offer potential opportunities to promote graft survival and decrease patient morbidity 
after renal transplant. 
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1.3.2 Acute cellular rejections 
Renal transplant recipients receive immunosuppression with tacrolimus and 
mycophenolate mofetil (MMF) for prevention of graft rejection.  Early after transplantation, the 
occurrence of rejection (acute) is confirmed on an indication biopsy, prompted by changes in graft 
function. However, silent (subclinical) rejections can occur without measurable changes in graft 
function and are only detected during a screening (protocol) biopsy. The occurrence of acute 
cellular rejections (clinical/subclinical) have been associated with chronic allograft injury14,15 and 
reduced graft survival14-16. The presence of inflammation during early protocol biopsy, has also 
been associated with progression of fibrosis at 1 year17 with an elevated risk for poor long-term 
outcomes18. The initial post-transplant graft conditions can thus impact the long-term graft survival 
but can be modified by providing optimal immunosuppression to the patients. Hence 
understanding the relationship of early acute cellular rejections (clinical + subclinical) to the 
combined immunosuppression exposure (tacrolimus + MPA) and to the efficacy of MPA 
(inhibition of IMPDH activity) at early post-transplant, will help in optimizing 
immunosuppression in individual patients. 
1.3.3 Infections 
Infectious complications remain a significant cause of morbidity and mortality in renal 
transplant patients. Immunosuppression predisposes renal transplant recipients to a variety of 
infections of bacterial, viral, fungal or parasitic origin from either the donor or nosocomial as well 
as community sources. Most infections are reported during the first year after transplantation with 
approximately 70% of the infections occurring within 3 months of transplantation19.  In transplant 
  6 
patients, apart from the exposure to infection, the main risk factor for infections is the dose, 
duration or the “intensity” of immunosuppression therapy20. Observational evidence has indicated 
that long-term graft survival have not improved in renal transplantation and this was attributable 
to the side effects related to the level of immunosuppression including opportunistic infections 
such as BK or CMV or JC virus21.   
It has been suggested that cadaveric kidney recipients are predisposed to infectious 
complications on account of increased immunosuppression needed due to higher HLA 
mismatching22. The risk of infections are also shown to vary with the immunosuppressive agent 
used. The initial induction therapy with lymphocyte depleting agents like thymoglobulin was 
shown to increase the risk of CMV viral infection in renal transplant patients23. Further, higher 
blood levels of tacrolimus or plasma levels of mycophenolic acid were also associated with risk of 
infections.  For tacrolimus, a blood level above 10 ng/ml and a dose greater than 0.15 mg/kg/day 
prevented acute cellular rejections, but was shown to decrease renal function and increase 
infectious disease in first 30 days after transplantation24. Similarly, higher MPA exposure (AUC 
≥ 60 µg*h/mL) was statistically associated with increased odds of viral infections, namely CMV 
and BKV viremia, and increased the risk of neutropenia25.  The occurrence of CMV infection or 
BK nephropathy are associated with development of rejection and graft loss, independent of  
reduction of immunosuppression 26.  
So, a delicate balance in immunosuppression is required as too little suppression can be 
associated with rejection and graft loss, while overimmunosuppression can lead to infections and 
malignancy in the long term. Hence, monitoring of immunosuppression after renal transplantation 
is necessary to prevent infectious complications.  
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1.4 BACKGROUND 
1.4.1 ISCHEMIA REPERFUSION INJURY 
1.4.1.1 Cold storage of donor kidneys 
Kidneys isolated from donors are subject to warm ischemia owing to the lack of blood 
supply. The ischemia leads to a series of noxious events like ATP depletion, loss of the Na+- K+ 
pump, elevated hypoxanthine levels, increase in cytosolic calcium levels, cell swelling, and most 
organs lose complete function beyond 30-60 min27. To prevent progression of ischemic damage 
and cell death, immediately after isolation, kidneys are flushed in-situ at a rapid rate with a 
preservation solution, followed by rapid cooling to 4 °C.  It has been shown that during 
hypothermia the demand for oxygen goes down by as much as 97% in comparison to renal 
perfusion at body temperature28.  Energy dependent (ATP) metabolic reactions are almost halved 
for every 10º C decrease in temperature29. Thus, a prolonged ischemia is possible with cold storage 
and enables transport of the kidney to the recipient located elsewhere. The early organ preservation 
solution (Collins) had high concentrations of glucose and electrolytes resembling the normal 
physiological status30. The Collins solution was later improved to enable longer duration of cold 
storage as well as organs other than kidney with the formulation of University of Wisconsin 
solution (UW)31. Some of the improvements in UW solution included replacing glucose with an 
impermeant like lactobionate, along with raffinose and hydroxyethyl starch which prevented 
hypothermia induced cellular swelling, minimized acidosis and improved osmotic support31.  
Allopurinol and glutathione were included to suppress superoxide anions generated by xanthine 
oxidase during IR as well as from hypoxanthine, a breakdown product of adenosine present in UW 
solution. 
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1.4.1.2 Metabolic changes during cold storage 
Static cold storage (SCS) of kidneys is still widely used due to simplicity and convenience 
when compared to machine perfusion that requires specialized perfusion devices. The hypothermia 
during static cold storage slows down the capacity of cells to supply energy, affects stability of 
proteins and inhibits enzymatic reactions that utilize cellular stores such as ATP, leading to 
metabolic uncoupling32. During hypothermia with hypoxia, oxidative phosphorylation becomes 
ineffective, since oxygen is not available for ATP generation and in addition, adenosine 
diphosphate cannot penetrate mitochondrial membrane due to the deactivation of the enzyme 
adenosine diphosphate translocase during hypothermic storage8. 
Hence, renal cells tend to produce ATP by anaerobic glycolysis, which in fact, is less efficient than 
aerobic glycolysis and leads to intracellular accumulation of lactic acid, further initiating noxious 
events like mitochondrial dysfunction and activation of lysosomal enzymes33,34. The presence of 
buffers in the preservation solution can help to counteract this acidosis.  Consequent to the shortage 
of ATP, a functional loss of  Na -K-ATPase activity occurs which can then lead to intracellular 
entry of sodium and chloride along with water leading to cellular edema33. Hence, presence of an 
impermeant like lactobionate or mannitol in preservation solution is essential to counteract this 
edema. 
The rapid depletion of ATP is also associated with deactivation of calcium sodium 
exchange system, leading to massive influx of calcium into cytosol following the influx of sodium. 
Subsequent changes in the calcium-calmodulin complex can also generate mitochondrial and 
membrane dysfunction, damaging the phospholipid nature of these structures by activating the 
phospholipase pathway with production of prostaglandin derivatives34, which can eventually affect 
the endothelial cells. 
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Figure 1.2. Anaerobic (oxygen absent) glycolysis during hypothermic preservation 
1.4.1.3 Reperfusion injury 
Reactive oxygen species (ROS) 
Cold stored kidney is reperfused with warm recipient blood during implantation. Ironically, 
though reperfusion is critical for restoring the renal function, most of the damaging effects of IR 
injury occur and are manifested during and after reperfusion. IR injury is a complex and multi-
factorial pathophysiological process that causes significant metabolic, structural and functional 
damage to the organ.  The sudden increase in the availability of oxygen in an acidic environment 
with the accumulation of hypoxanthine during ischemia, triggers production of xanthine and 
superoxide anion by xanthine oxidase. The superoxide produced from oxygen introduced during 
reperfusion, can further react with itself to produce hydrogen peroxide that can yield hydroxyl 
radicals which can impair the cellular function by oxidizing cell membranes and proteins34,35.  In 
addition, ROS can trigger the opening of mitochondrial membrane transition pores subsequent to 
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the increased mitochondrial calcium content due to hypoxia and can lead to cell death36. The ROS 
can trigger adhesion of leukocytes to renal vascular endothelium by production of mediators like 
platelet activation factor which can lead to migration of neutrophils and macrophages. Neutrophils 
can cause proteolytic damage to the kidney leading to microcirculatory disturbances and mediate 
local tissue injury. 
Innate and adaptive immune response 
Consequent to free radical and neutrophil mediated tissue injury there is a release of cellular 
injury factors and damage associated molecular patterns (DAMPs). DAMPs can activate toll like 
receptors (TLRs) that can further recruit molecules within cytoplasm to activate transcription 
factors like NFΚB, MAP kinase and Interferon I pathways 37. The TLRs are usually expressed on 
immune cells such as macrophages, neutrophils, dendritic cells but are also expressed by the 
injured renal tubular cells and mesangial cells during IRI 38. 
The transcription factor NFΚB plays a central role in both the tubular epithelial cells and 
inflammatory cells in generation of an inflammatory response by activating pro-inflammatory 
factors such as IL-1β, tumor necrosis factor (TNF)-α, or interferon (IFN)-γ, chemokines such as 
IL-8, MCP-1 39 and genes related to cell adhesion and growth control 38. 
Vascular components of IRI 
Endothelial cells play an important role in vascular tone and leukocyte function and with 
an injury there is an enhanced vasoconstriction leading to small vessel occlusion. IR leads to 
endothelial cell swelling, loss of glycocalyx, breakdown of the actin cytoskeleton and fluid leak 
into the interstitium 40.  Further, activation of endothelial-leukocyte interactions and coagulation 
results in local compromise of the microcirculation and regional ischemia, especially in the outer 
renal medulla 12. Hence during reperfusion, though cortical circulation is established, 
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hypoperfusion still persists in the outer part of medulla, characterized by congestion of peritubular 
capillaries with swelling of the endothelial cells, increased paracellular permeability and increased 
expression of adhesive molecules, such as intercellular adhesion molecule 1 (ICAM-1),  E- and P-
selectins and leukocyte accumulation with platelet aggregation39.  Excessive platelet aggregation 
and release of platelet-derived mediators can exacerbate tissue injury following ischemia and 
reperfusion.  The proximal tubular injury also results in an inadequate sodium reabsorption with 
more solute delivery to the distal nephron leading to tubulo-glomerular feedback in reducing the 
forces for filtration 12. 
 
 
Figure 1.3. Renal endothelium, interstitum and tubule in normal kidney (A) and 
after ischemia reperfusion (B)  
 [With copyright permission from Bonventre and Yang12] 
1.4.1.4 Post-transplant impact of Ischemia-Reperfusion Injury 
Delayed graft function (DGF) 
Delayed graft function in the immediate post-transplant period is a consequence of IR 
injury, primarily due to tubular dysfunction but may also be due to enhanced graft 
immunogenicity, dysfunction and rejection 40. DGF is defined as the failure of the transplanted 
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kidney to function immediately, hence necessitating renal replacement therapy within the first 
week after transplant surgery. Previous studies have identified extended cold ischemic time (time 
between cessation of donor circulation and vascular reperfusion in the recipient) as an independent 
risk factor for DGF 5. ECD kidneys from old donors are also at a higher risk of DGF after IR 41. 
Hence, there is a great interest in strategies for improved preservation of allograft during cold 
storage in order to prevent DGF. The relationship of DGF with acute rejections of kidney is 
controversial, however, the combined occurrence of DGF with T-cell mediated rejection or graft 
inflammation is reported to worsen graft survival with poor outcomes42,43. 
Immunogenicity of the allograft 
The IR mediated injury can augment graft immunogenicity subsequent to the activation of 
adaptive immunity and thereby increases the possibility of immunologic recognition and graft 
rejection 11. Following IRI, apoptotic cells are not rapidly cleared after the initial injury and 
secondary necrosis occurs due to loss of membrane integrity leading to the release of endogenous 
adjuvants (damage-associated molecular patterns-DAMPs). Inflammatory DAMPs, including 
Heat-Shock proteins (HSP), HMGB-1 and DNA fragments, are recognized by specific receptors 
such as TLR-2 and TLR-4 which, in turn, trigger inflammatory and cytotoxic responses.  The 
massive release of pro-inflammatory cytokines, such as IL-1α and tumor necrosis factor (TNF), 
from damaged cells during ischemia-reperfusion injury causes donor dendritic cells to become 
activated and migrate from the donor graft to the recipient lymph nodes and spleen, thus sensitizing 
recipient T-cells which can recognize donor MHC molecules on the surface of donor antigen-
presenting cells (APCs), leading to an immune response. 
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Renal transporters 
Renal clearance is a predominant pathway of drug elimination which includes three 
concurrent processes occurring in the nephron, viz. glomerular filtration, tubular secretion, and 
tubular reabsorption. Glomerular filtration is a passive process while tubular secretion, and 
sometimes reabsorption, involves a variety of transporters located on the basolateral and luminal 
membranes of the tubular epithelium. These transporters are predominantly expressed in the 
proximal tubule and work in tandem to eliminate drugs from the blood circulation to the urine and 
to reabsorb essential substrates. Both basolateral and apical transporters tend to be charge selective 
for anionic and cationic drugs, although studies indicate some degree of overlap. The major renal 
drug transporters engaged in the secretion of anionic drugs include organic anion transporters 1 
and 3 (hOAT1 and hOAT3), multidrug resistance-associated proteins 2 and 4 (hMRP2 and 
hMRP4) and breast cancer resistance protein (BCRP). The transporters for cationic drugs include 
organic cation transporter 2 (hOCT2), multidrug and toxin extrusion proteins 1 and 2-K (hMATE1 
and hMATE2-K) and P-glycoprotein (P-gp) (facilitate excretion of larger and more hydrophobic 
cations)44.  In addition, several closely related transporters/co-transporters like urate anion 
transporter (URAT), sodium dependent glucose transporter (SGLT), monocarboxylate transporter 
(MCT),  renal sodium dependent dicarboxylate transporter (NADC) and sodium-hydrogen 
antiporter (NHE) are present in the proximal tubules that contribute to renal handling of 
endogenous substrates and metabolic wastes.  
After IR, morphological changes can occur in the proximal tubules, including loss of 
polarity, loss of brush border as well as redistribution of integrins and Na/K-ATPase to the apical 
membrane.  Impaired Na+ reabsorption during IR is due to dysregulation of the basolateral Na+/K+ 
ATPase, leading to disruption of the concentration gradient for apical Na+ uptake. This could have 
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been due to the impaired mitochondrial function with a decrease in ATP synthesis after IR, as the 
activity of Na+/K+-ATPase per se was shown not to be affected45.  Further, IR induced inhibition 
of several Na+ dependent cotransporters can impair reabsorption of glucose and influx of metabolic 
substrates like alpha keto glutarate and succinate46. 
Ischemia mediated renal injury has been shown to decrease clearance of the organic anion 
transporter substrate para-aminohippurate (PAH) for at least 7 days after transplantation. The 
delayed elimination of PAH was shown to result from downregulation of oat1 and oat3 after IR in 
preclinical studies. The mRNA and protein expression levels of organic anion transporters, oat1 
and oat3 were suppressed in a rat model of IR and was accompanied by significant elevation in 
serum levels of indoxyl sulfate, a uremic toxin that is a substrate of the above anion transporters47. 
Transporter expression, tubular function and usually GFR can recover within a few days after IR. 
In addition to IR, inflammation and immune activation due to complications associated with renal 
transplantation may down regulate renal anionic transporters and this effect may be more 
pronounced in renal allografts with BK virus nephropathy or TCMR, as shown by decreased renal 
secretion of a OAT1/3 and MRP2/4 substrate, cidofovir in allografts with BK virus nephropathy48. 
1.4.1.5 Studies with ex-vivo supplementation to preservation solution 
The improvement in organ preservation after retrieval and attenuation of reperfusion injury 
are two primary objectives for the supplementation of preservation solution with pharmacological 
agents. Due to the multifactorial nature of IR associated injury, several approaches targeting 
different pharmacological pathways have been attempted to improve the organ preservation. 
Examples include targets involved in inflammation, coagulation, oxidative stress, mitochondrial 
protection, apoptosis and the hypoxia response following an ischemia–reperfusion sequence49. 
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Polyethylene glycol (PEG) is a polymer of ethylene oxide with a hydroxyl terminal having oncotic 
properties and can bind to phospholipids on cell membranes. Addition of PEG 35 was shown 
decrease ROS, improve renal cell viability and preserve the ATP content of tissue in porcine   
kidneys.  Supplementation of Trimetazidine, an anti-ischemic agent into UW or EC solutions was 
shown to improve function of the reperfused rat and pig kidneys. Further in a pig transplant model, 
trimetazidine was shown to decrease DGF, due to its effect of preserving Ca2+ homeostasis and 
mitochondrial function during cold storage50.  Supplementation of the UW solution with a unique 
combination of trophic factors like Substance-P, IGF-I, nerve growth factor and bactenecin 
resulted in marked suppression of cold ischemic injury in an experimental dog kidney transplant 
model, possibly due to the preservation of graft ATP content during cold storage. Melatonin is an 
endogenous antioxidant, also shown to mitigate the pathological effects of IRI in experimental 
models of supplementation to UW solution. Melatonin was shown to effectively preserve rat 
kidney for up to 48 h with minimal production of malondialdehyde, suggesting its antioxidant 
effect. 
Preservation trials have also been carried out in presence of alternate gases like carbon 
monoxide (CO), xenon, hydrogen sulphide (H2S).  Xenon was shown to upregulate HIF-1 alpha 
and decrease histologic changes with improvement of graft function in lewis rat model51. Though 
CO is not an antioxidant by itself, it can induce the expression of antioxidant genes like superoxide 
dismutase or catalase, but due to its unfavorable effect on hemoglobin, other synthetic CO 
releasing molecules (CORM) have been evaluated.   Supplementation of CORM to UW solution 
was shown to improve renal perfusion and glomerular filtration rate. Hydrogen sulfide (H2S) 
showed protective effects as supplementation to UW solution in both syngeneic and allogeneic 
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models of rat kidney transplantation, due to its modulatory effects on inflammation and oxidative 
stress52. 
1.4.1.6 Prostacyclins 
Prostacyclin (PGI2), is endogenously produced by vascular endothelial and smooth muscle 
cells and has a potent vasodilator and anticoagulant effect. PGI2 mediates its biological effects 
through binding to cell surface prostacyclin receptors (IP), coupled to stimulatory G protein and 
increases the intracellular cyclic adenosine monophosphate (cAMP) signaling, which acts as a 
second messenger to inhibit platelet aggregation, cell proliferation and inflammatory mediator 
release. The IP receptor is located on a variety of cells, including platelets, vascular smooth muscle, 
and endothelial cells, where PGI2  has local effects. At the endothelial level, prostacyclin exerts 
anti-inflammatory and anti-platelet activity and promotes an antithrombotic surface, which is 
required for proper function and maintenance of vascular integrity.  
Treprostinil (Remodulin®) is a chemically stable analog of prostacyclin (PGI2), with potent 
pulmonary and systemic vasodilation and anti-platelet aggregation effects along with 
cytoprotective properties. Treprostinil is approved by the U.S. Food and Drug Administration for 
the treatment of pulmonary artery hypertension (PAH). Treprostinil has improved stability and has 
a longer elimination half-life of around 4 h. Treprostinil has a favorable pharmacological profile 
for activity against several pathways that are known to be activated during IR. Treprostinil has 
antioxidant and anti-inflammatory effects, decreases intracellular calcium levels leading to 
vascular smooth muscle relaxation, inhibits platelet aggregation and downregulates pro-
inflammatory cytokines. Hence, it may favorably decrease ischemic effects by restoring blood 
flow and minimize damaging effects of reactive oxygen species and inflammatory mediators, 
during reperfusion. Previous studies have shown treprostinil to attenuate the significant decrease 
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in ATP content of 24 h cold preserved livers and decreased hepatic IR injury in an orthotopic rat 
liver transplant model53.  With favorable pharmacological profile and encouraging previous 
evidence, treprostinil was chosen for ex vivo addition to cold preservation solution as well as for 
treatment during reperfusion of rat kidney in an isolated rat kidney perfusion model. 
1.4.2 IMMUNOSUPPRESION IN RENAL TRANSPLANTATION 
1.4.2.1 Induction and maintenance 
Renal transplant recipients require chronic immunosuppression to prevent rejection of the 
transplanted kidney, excepting in some rare instances of donor being the identical twin. The initial 
therapy (induction) is usually started before or immediately after transplantation, with a biological 
agent like a lymphocyte depleting agent (anti-thymocyte globulin, Alemtuzumab) or an interleukin 
2 receptor antagonist (basiliximab, daclizumab) to prevent T-cell immune response against the 
graft at the time of implantation. Induction therapy is completed within the first few days after 
transplantation. 
Maintenance immunosuppression is a chronic therapy usually with one or a combination 
of several drugs with different mechanisms of action to avoid the rejection of kidney graft and to 
ensure optimal graft function. Currently, four classes of drugs are available for maintenance 
immunosuppression, viz. corticosteroids (prednisone), calcineurin inhibitors (cyclosporine, 
tacrolimus), antimetabolites (azathioprine, mycophenolic acid)  and target of rapamycin inhibitors 
(sirolimus, everolimus). A carefully monitored dosing of immunosuppressive drug is essential to 
balance the risk of rejection with that of the side effects. The most notorious adverse post-
transplant events (e.g., infection, malignancy) are associated with the net state of 
immunosuppression; hence it is essential that maintenance immunosuppression be gradually 
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decreased after the initial post-transplant period and then maintained in an optimal range to avoid 
rejections as well as adverse events. In renal transplant patients, the current standard maintenance 
immunosuppressive therapy includes tacrolimus with mycophenolic acid with steroids being 
optionally used based on risk factors in the patient. 
1.4.2.2 Tacrolimus 
Tacrolimus (FK506) is a 23-membered macrocyclic lactone that binds to a cytosolic 
immunophilin (FK binding proteins 12 and 52). The complex of TAC–FK binding protein inhibits 
the phosphatase activity of calcineurin and interrupts the calcium-dependent signal transduction 
pathway in T-cells to produce immunosuppressive effect. The pharmacokinetic parameters of 
tacrolimus are highly variable among patients. Much of the variability is due to the pre systemic 
metabolism by cytochrome P450 (CYP) 3A4/3A5 isoenzymes and efflux transport by P-
glycoprotein (P-gp) in the intestinal mucosa. Tacrolimus has rapid absorption (peak concentration 
occurring at 0.5 – 1 h) from the gastrointestinal tract, but has a poor oral bioavailability ranging 
between 5 - 93% 54 and the bioavailability is decreased by food 55. 
Tacrolimus is primarily distributed within the erythrocytes and is approximately 83 % 
(range 75-95 %) bound to the erythrocytes. Due to this extensive binding to red blood cells, 
transplant patients have a significantly higher blood tacrolimus concentrations (mean 15-fold;  
range 4 to 114-fold) than the corresponding plasma concentrations. Binding of tacrolimus to 
erythrocytes may be due to an affinity for a protein similar to FKBP present within the erythrocytes 
and this binding could protect tacrolimus from hepatic metabolism. Around 16 % of tacrolimus is 
reported to be bound to  plasma components such as lipoproteins, α-acid glycoprotein, albumin 
and globulin 56. On an average, around 0.6 % of tacrolimus in blood is associated with the 
lymphocyte fraction with the remaining 0.4 % being the unbound or free fraction.  
 19 
The lymphocytes are the proposed site of action of tacrolimus, and also are reported to 
show a high variability in the percent tacrolimus content (0.1 – 1.5%).  It was also reported that 
tacrolimus lymphocyte content is significantly less in liver transplant patients experiencing 
rejection in comparison with stable recipients (0.3-0.5 vs 0.8 %,  p=0.012)56. It was further 
proposed that pulse steroid doses in patients with rejection, could impact on the expression of 
MDR1 and CYP 3A enzyme in the lymphocytes, contributing to the  variability in lymphocyte 
distribution of tacrolimus56. In transplant patients, the inherent variability in the activity of MDR1 
expressed on the lymphocytes, based on genotype of patients, can further limit tacrolimus entry 
into the lymphocyte and cause differences in immunosuppression despite identical whole blood 
concentrations.   
The whole blood clearance (CL) of tacrolimus also shows high interindividual variability 
and ranges from 3–35 L/h. Tacrolimus is primarily metabolized by CYP3A4/3A5 isozymes in the 
liver with at least 15 metabolites, with the major metabolite being 13-O-demethyl-tacrolimus. 
Many factors have been identified to be associated with the variability in tacrolimus 
pharmacokinetics, with the CYP3A5 being the most prominent with carriers of *1 allele requiring 
almost a two-fold higher dose57. In addition, CYP3A4*22 has also been shown to influence 
tacrolimus dose requirements and pre-dose concentrations in white renal transplant recipients, 
though to a lesser extent than CYP3A558. Other factors include age, gender, body mass index, 
adherence, drug-interactions, to name a few.  In renal transplant recipients, a good correlation was 
reported between CL and hematocrit (r=0.8) as well as albumin (r=0.7) and oral steroid doses 
(r=0.9) over the first 12 weeks post-transplant59. Biliary excretion and fecal elimination are 
responsible for the major clearance of the metabolites of tacrolimus, whereas renal excretion plays 
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only a small role 55. The terminal half-life of tacrolimus in kidney transplant recipients is 
approximately 15.6 h but can range between 8 - 19 h54,60.  
Exposure to  tacrolimus and outcomes in renal transplant patients 
The Area under curve (AUC 0-12 h) is generally considered as the ideal marker of drug 
exposure but it is difficult to obtain in patients due to practical and cost considerations. Since 
tacrolimus has a narrow therapeutic index and has a high inter-individual variability, monitoring 
trough whole blood concentrations is recommended in all transplant patients, as trough levels show 
a good correlation with total exposure. Ideally, target concentrations of 8-12 ng/mL are desired in 
the first 3 months post-renal transplant but the target concentrations are lowered beyond that time 
point61,62, based on empirical observations, to maintain efficacy with a good allograft function and 
at the same time decreasing the adverse effects. 
The correlation between trough and AUC for tacrolimus is not always consistent and is 
reported to be better in the earlier post-transplant phase than at later time period62,63. C0 of 
tacrolimus, is still considered as a surrogate for the AUC. The use of trough (C0)  blood 
concentrations to adjust tacrolimus dose is based on historical observations on the association 
between a target C0 and clinical outcome of acute rejections. In an early investigative trial for C0 
of tacrolimus, decreasing rejection was observed with increasing C0 while increasing toxicity 
occurred beyond a limit, thereby a range of 5-15 ng/mL was proposed during the first 7 weeks 
post-renal transplant64.  Multiple studies have shown lower tacrolimus trough levels at first week, 
or at discharge or at first month and during first 6 weeks post-transplant to be significantly 
associated with higher incidence of biopsy proven acute rejections (BPAR) 54,65.  A significant 
relationship between tacrolimus trough concentrations and the development of rejection in the first 
month after transplant was also shown with median concentration of 9.2 ± 3.5 ng/ml in non-
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rejectors versus 5.1 ± 1.2 ng/mL in patients with BPAR 65,66. Another study67 also derived an 
effective target C0 of 9.3 ng/mL on day 5 post-renal transplantation and C0 values below the cut-
off were associated with a shorter graft survival. Beyond the initial 3 months, tacrolimus target 
goal is decreased in stable renal transplant patients, and a study68 showed association of time-
varying tacrolimus levels with acute rejections, as there was a 7% increase in the risk of rejection 
for every unit decrease in average tacrolimus trough levels during the first 6 months post-
transplant.  
In contrast to the above studies, few other studies did not show a significant association 
between C0 and rejection 69,70. One of the reason could be the evolution of tacrolimus target trough 
concentrations, that has slowly seen a shift from higher concentrations of around 20 ng/mL in 
earlier years of use to lesser concentrations during recent times mainly with co-administration with 
another immunosuppressant drug, mycophenolic acid71.  Further, the target C0 associated with 
avoiding rejections were comparatively lower in some studies performed at later post-transplant 
periods, owing to the lack of steroid co-therapy. Overall, during the first year post-transplant, on 
co-therapy with mycophenolate, steroids and anti-IL-2 induction therapy,  a target C0 between 5-
10 ng/mL during the first year could be considered as the therapeutic range for tacrolimus62. In 
contrast to rejections, tacrolimus trough concentration have been shown to be significantly, but not 
consistently, higher in recipients with an incidence of infection in week 6 post-transplant, though 
the mean daily drug dose did not differ between the patient sub-groups72.  
Though trough blood concentrations (C0) of tacrolimus are routinely used in TDM for 
clinical practicality, the association of C0 with the true exposure (AUC0-12 h) as well as the clinical 
outcomes has been a matter of debate62,63,73,74. The relationship of tacrolimus exposure to clinical 
outcome has also been investigated in several studies. It has been shown that patients experiencing 
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rejections have lower tacrolimus AUC during the early post-transplant period 75. An AUC 
exceeding 200 ng*h/mL was suggested for tacrolimus during the early post-transplant period for 
avoiding the risk of acute rejections75,76. Another study had shown exposures of 210 ng*h/mL and 
125 ng*h/mL as optimal limit for tacrolimus, until the first 6- and 52-weeks post-transplant, 
respectively 73. In another study of 100 de novo renal transplant recipients, patients with tacrolimus 
AUC below 150 ng*h/mL and MPA AUC below 45 µg*h/mL on day 7 post-transplant, tended to 
have higher incidence of rejections  (26 %) in comparison to patients that reached both target 
values (8 %) 72.  The authors also reported significantly higher AUC in patients with incidence of 
CMV or herpes infections during the first 6 weeks post-transplant (average 197.4 vs 160.5 
ng*h/mL). 
Abbreviated exposure methods for tacrolimus  
Even after vast clinical experience with tacrolimus, there is a lack of clear target AUC that 
can be used during both early as well as late phase of renal transplantation and due to a lack of 
prospective studies focusing on targeting a specific AUC in relation to outcomes. In addition, 
performing a total exposure study is too tedious, hence calculation of AUC based on a limited 
number of blood samples strategy (LSS), is a possible alternative. Bayesian estimation is an 
analytical technique that allows the use of previous information in a population in conjunction 
with observed data in individual patients to estimate the most likely value of pharmacokinetic 
parameters of interest in those patients. On the other hand, linear regression (LR) based methods 
can be used to derive equation from many drug concentration measurements within a steady-state 
interval in several patients. Initially a reference AUC is determined by the trapezoidal method, 
followed by multiple regression analysis of all combinations of time points to identify the 
combination with the best correlation between the estimated AUC and the reference AUC. 
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The Bayesian estimation using LSS sample concentrations provides more clinical 
flexibility in time points than the regression method which is simpler yet practically difficult to 
implement due to strict restrictions on the sampling point deviations. In general, with a 
compromise between accuracy of LSS and clinical feasibility it is preferable to limit the clinical 
sampling times to less than 4 hours post dosing. 
Several studies have reported on the estimation of AUC using Bayesian approach with an 
appropriate pharmacokinetic model for tacrolimus derived in kidney transplant patients and a 
review 77 of these methods revealed satisfactory performance in the estimation of tacrolimus AUC. 
The nature of studies used to develop population models for tacrolimus differed over a wide range, 
including post-transplant days ranging from immediate to several years after transplantation and 
sample size ranging from 12- 262 patients, with almost 80% of studies having less than 100 
patients. Further, retrospective data collection and the use of trough concentrations were widely 
utilized in tacrolimus model developments. The structural model mostly used one and two 
compartment models with a first order elimination. The most common covariates identified for 
tacrolimus whole blood CL/F were the post-transplant time, CYP3A5 genotype, hematocrit, body 
weight and Aspartate aminotransferase.  
The application of Bayesian estimation in clinical study also ranged from early to several 
years post-transplant, however a majority were within the 1 year of transplant. The D-optimality 
based selection of time points that could in theory give more valuable information on exposure 
were used for the LSS and studies identified 0, 1 and 3 h or 1,3 and 6 h or 1,3 and 8 h or 0, 1.5 or 
4 h as the optimal time points, where 0 is the steady state trough (12 h) concentration.  The 
combination of time points at pre-dose, 1 and 3 h post-dose were found to consistently show lower 
bias and imprecision values (< 15 %)77, when considered across the different transplant 
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populations. Despite developments in LSS application for AUC estimation, there are no reports on 
their regular application for TDM of tacrolimus, excepting a few reports of unpublished inhouse 
applications. These reports do show the feasibility of LSS in accurate estimation of total AUC for 
tacrolimus, which is required for assessing various clinical outcomes. 
1.4.2.3 Mycophenolic acid 
After oral administration, MMF is rapidly absorbed and undergoes hydrolysis by esterases 
into the active mycophenolic acid (MPA). MPA is 98-99% bound to plasma proteins, mainly to 
albumin78. The major route of metabolism of MPA involves glucuronidation to the 
pharmacologically inactive MPA 7-O glucuronide (MPAG), by the hepatic UGT1A9 in addition 
to UGT1A8, UGT1A1, UGT1A7 and UGT1A10 in intestine and kidneys79. MPAG is 
approximately 80% bound to serum albumin and is excreted by the kidney via glomerular filtration 
and tubular secretion. MPAG is subjected to enterohepatic recirculation mediated by multidrug-
resistant protein-2 (MRP-2) and can be converted back to MPA in the gastrointestinal tract. MPA 
is also metabolized to a minor active acyl-glucuronide (AcMPAG) metabolite, primarily by 
UGT2B7. 
Mycophenolic acid blocks DNA synthesis or replication by non-competitive and reversible 
inhibition of ionosine monophosphate-5′-dehydrogenase (IMPDH) types 1 and 2 and thereby 
inhibiting proliferation of T and B-lymphocytes. MPA is five times more potent as an inhibitor of 
the type II isoform of IMPDH, which is expressed in activated T and B lymphocytes, than of the 
type I isoform, that is expressed in most cell types80.  Hence, MPA suppresses both cell and 
antibody-mediated responses, which are major factors in acute and chronic allograft rejections. 
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Variability in clinical PK of Mycophenolic Acid 
A range of clinical factors are known to contribute to the large interpatient and within 
patient variability in MPA PK in renal transplant patients. Mycophenolic acid released from MMF 
has a different pharmacokinetic profile from EC-MPA (delayed release) and as such, they are not 
considered bioequivalent, even though the amount of active MPA (739 mg) from 1 g of MMF is 
approximately equal to the 720 mg released from EC-MPA. Unbound MPA is hypothesized to be 
responsible for MPA efficacy, however due to the cost and difficulty, determination of free MPA 
is not a clinically routine procedure. Further as only free MPA is subject to metabolism, and total 
MPA concentration may fluctuate in the absence of a change in free concentration (due to protein-
binding displacement by concurrent albumin-binding drugs like MPAG or uremic toxins and 
hypoalbuminemia), for a low extraction drug like MPA, there is an alteration in total but not free 
MPA clearance and this makes it difficult to establish a therapeutic range based on total MPA. 
A slowly recovering kidney graft function is observed after renal transplant, which also could 
differ between patients. Many studies have reported accumulation and impaired renal excretion of 
the metabolite MPAG or uremic toxins in patients with delayed graft function that can displace 
MPA from the binding with albumin, thus increasing the free MPA available for hepatic 
glucuronidation, during early post-transplant period. With improvement in renal function and 
subsequent recovery in albumin levels, MPAG excretion as well as MPA binding are increased 
leading to a comparative decrease in MPA clearance or an increase in total MPA exposure 
compared to the immediate post-transplantation, after the same dose of MMF. Hence differences 
in renal function recovery, albumin as well as steroid doses are factors suggested to contribute to 
the interpatient variability, during early post-transplant81. The 8 h exposure of total MPA 
immediately after renal transplant was around 30-50% of those in the 3-month post-transplant 
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period, due to impact of the above clinical variables. However, beyond 3 months, the PK of MPA 
after oral administration in renal transplant patients was reported to be comparable with healthy 
individuals82. 
 In addition to the above factors, variation in the formation and disposition of the 
glucuronide metabolites can increase interpatient variability in MPA concentrations. MPA 
glucuronides are excreted unchanged in the urine, but can also undergo enterohepatic recirculation 
(EHR), mediated via MRP-2 mediated biliary secretion and hydrolysis by β-glucuronidase in the 
gut, resulting in the regeneration of a significant amount of MPA. The exposure of MPA can 
decrease by 30-40% when combined with cyclosporine due to its effect on the inhibition of EHR 
mediated MPA formation from MPAG. In addition, the variability in the metabolism and 
subsequent EHR process due to various polymorphisms in UGTs and MRP-2 can also contribute 
to variability in the plasma drug concentration-time curves of MPA83. Schaik et al. had shown low 
exposure of MPA due to high clearance in patients with genotypic variants of UGT1A9 (−275 
T>A and -2152C>T), which was further associated with significantly higher odds of acute 
rejection in renal transplant patients (OR 13.3, 1.1–162.3; P<0.05)84. 
In summary, due  to the variability in clinical PK of MPA in renal transplant patients, 
monitoring of MPA was suggested at end of first post-transplant week, 2nd week and at months 1 
and 285. 
Population pharmacokinetics of Mycophenolic Acid 
The initial population pharmacokinetic (POPPK) models for MPA were published in 1999 
and since then, most of the studies used parametric estimation approach, using NONMEM as the 
software for the non-linear mixed effects modeling. The objectives of POPPK models for MPA 
were to estimate typical values for PK parameters like clearance (CL), volume of distribution (V), 
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absorption (Ka, Tlag), in addition to determination of the between subject or within subject 
variability in parameters and characterizing the influence of various covariates on the PK of MPA. 
The models for MPA in the literature for renal as well as other transplant populations were 
developed after consideration of the nature of study from which MPA concentrations were 
obtained including the time post-transplant, range of available time points across the patients, co-
administered drugs (cyclosporine versus tacrolimus), the formulation of MPA used (MMF or EC-
MPS), the covariates that were available to explain variability in MPA PK, to name a few. The 
availability of sensitive and accurate LCMS methods to analyze concentrations of MPA and its 
metabolites also has an impact on the evolution of POPPK models. As a result, even within renal 
transplant population, the structural part of the models for MPA were evolving continually from 
simple 1 or 2-compartment models with first order absorption and elimination to more complex 
models for absorption or considering multiple compartments with inclusion of  free MPA, 
metabolites and enterohepatic recirculation (EHR) to describe the PK of total MPA, free MPA as 
well as the phenolic or acyl glucuronide metabolites. Most of POPPK models for MPA have found 
the 2-compartment model to adequately describe the PK of MPA.  
An overview of POPPK models in literature, revealed numerous attempts for 
characterizing the complex PK characteristics of MPA, including EHR, absorption after MMF or 
EC-MPS, protein binding and metabolite profile, in order to improve the estimation of parameters 
like CL/F and V/F. A majority of the early as well as recent population models for MPA are 
developed in the renal transplant patient population after dosing of MMF with the co-administered 
drugs, either tacrolimus or cyclosporine and steroids.  Further most of models used the first order 
conditional estimation with or without interaction. One of the first population model for MPA by 
Funaki 86 was an attempt to model enterohepatic recirculation of MPA after dosing of MMF. Other 
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published models in early 2000s included attempts to model MPA using bi-exponential elimination 
with absorption lag time 87,88, zero order absorption model89, two compartment model with first 
order absorption 90,91 or  four compartment model including MPAG with EHR92. A double gamma 
absorption model was used by Premaud et al93 using an alternative in-house software for describing 
MPA profiles in recent as well as stable renal transplant patients using a single compartment. Later 
POPPK studies on MPA in renal transplant patients focused more on including metabolite levels 
of both glucuronides 94,95, better description of EHR96, inclusion of genotypes97 and modeling of 
free MPA98.  
Examination of the population estimates for CL/F in adult Caucasian renal transplant 
recipients in various studies ranged between 13 to 33 L/h, with studies done at early post-transplant 
or with cyclosporine co-administration contributing to higher values of the CL/F 99-101.  In the same 
sub-set of population, estimates for the central V/F ranged between 12-98 L whenever a 2-
compartment model was used to describe the profile of MPA.  Considering the 20 years of POPPK 
characterization of MPA with models including early post-renal transplant data, factors that have 
repeatedly and significantly correlated with and decreased the inter-patient variability in MPA 
clearance or volume of distribution, included albumin concentration, creatinine clearance (renal 
function), cyclosporine dose and in some cases, the body weight. The most promising application 
of the developed POPPK models is the Bayesian prediction for dose optimization and monitoring 
of MPA exposure to improve the clinical outcomes.  
Exposure to MPA and outcomes in renal transplantation 
The objective of PK monitoring in clinical care is to ascertain appropriate drug exposure 
in relation to clinical endpoints or outcomes. For MPA, several studies have shown the total drug 
exposure (12 h AUC) to have a good correlation with the risk of acute rejection.   
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One of the earliest reports on association for MPA steady-state exposure to early acute 
rejection was reported in Japanese renal transplant patients 102, with lower rejection rates when 
AUC was greater than 40 µg*h/mL and higher CMV infection when AUC exceeded 90 µg*h/mL. 
Other reports after analysis of data from early pilot phase I trials 103,104 revealed a sigmoidal 
relationship of AUC0-12 h in the logistic regression analysis for the probability of decreasing the 
acute rejections. From the fitted curve, it was further determined that, with exposure of 30 
µg*h/mL, a 50% reduction in rejection could be achieved, corresponding to mean exposures after 
1 g twice daily and with an exposure of  55 µg*h/mL, a 90% reduction in rejection could be 
achieved, corresponding to mean exposures after 1.5 g twice daily. However, after consideration 
of dose related adverse events like leucopenia, diarrhea, tissue invasive CMV infections, 1 g twice 
daily dose was considered optimal, though the concentrations of MPA and MPAG were not 
different tin patients with or without adverse events. When exposures were examined, the clinical 
outcome of acute rejections in 1 g twice daily group occurred in patients with the lowest quartile 
of AUC0-12 h, that was considered an impact of interindividual variation or non-compliance82.  
Large scale retrospective analysis of studies in renal transplant patients, further confirmed the 
predictive value of MPA AUC in the risk for developing acute rejections 105. It was concluded that 
maintaining renal transplant patients on a target MPA AUC of 30-60 µg*h/mL can assure a less 
than 10% risk of acute rejections, in combination with cyclosporine and steroids106. Further, no 
gain from increasing exposure beyond 60 µg*h/mL was obtained in terms of decreasing risk for 
acute rejections, though an increase in frequency of side effects did occur. In another investigation 
of MPA exposure in 33 renal transplant patients, majority of patients with rejections had an 
exposure less than 30 µg*h/mL107. 
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In the first combination trial with tacrolimus at University of Pittsburgh, renal transplant 
patients treated with MPA/tacrolimus/steroids showed a significant reduction in the incidence of 
rejection compared with regimen without MPA (44 vs 27 %, p=0.014), when MMF was given at 
1 g twice daily108. In a multicentered, prospective, randomized fixed-dose concentration-controlled 
(FDCC) trial 109 with MMF/cyclosporine/ steroids with 150 renal transplant patients, the risk of 
acute rejection was increased in patients if MPA AUC0–12 on day 3 post-transplantation was less 
than 30 µg*h/mL. Again, exceeding exposure beyond the upper limit of ≥ 60 µg*h/mL did not 
provide a gain in efficacy but was significantly associated with increased risk of leukopenia, 
diarrhea and viral infections, CMV and BKV viremia. In another trial with 46 renal transplant 
patients, the 12 h exposure on day 5, though was not associated with rejections 110 while in 27 
patients on similar therapy and time post-transplant, the 6 h MPA exposure showed significant 
relation with acute rejections 111. Another prospective study, APOMYGRE, targeted AUC of 40 
µg*h/mL after 1 gm twice daily, using Bayesian estimation and physician dose adjustment in 
comparison to fixed dosing of 1 gm twice daily to a total of 137 renal transplant recipients112. The 
target-based dose adjustment group had a higher exposure for MPA within 3 months post-
transplant with a significantly lower incidence of BPAR (7.7 vs 24.6 % in the fixed dosing group). 
Another prospective study the fixed dose–concentration controlled (FDCC) showed significant 
associations of MPA AUC on day 3 with BPAR on first month as well as first year113. In a study 
of MMF with tacrolimus in 100 de novo renal transplant patients, Kuypers et al.72 did not find any 
significant differences in the day 7 exposure to tacrolimus (mean of 168 vs 168 ng*h/mL)  and 
MPA (mean of 56 vs 46 µg*h/mL) in patients with rejection versus rejection-free patients. 
However, a trend to increased incidence of rejections was observed in patients having a low 
exposure to both MPA and tacrolimus (26  % vs 8 % in high exposure for both, p>0.05).  
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Most of above studies confirmed relationship of MPA exposure on the risk of reducing 
acute rejections during the first 3 months post-transplant, while a study on cyclosporine withdrawal 
beyond 3 month post-transplant also showed a significantly higher risk of acute rejection in 
patients having subclinical rejections together with a lower MPA exposure (mean 43 vs 58 
µg*h/mL)114. 
In a Japanese study with 36 patients on cyclosporine or tacrolimus co-therapy, the exposure 
to MPA was significantly less in patients with rejection (mean of 34.2 vs 28.2 µg*h/mL) at 2 weeks 
post-renal transplantation115. Similar significant differences in exposure of MPA (mean 41 
µg*h/mL in rejectors vs 54 µg*h/mL in non rejectors) was observed in Chinese renal transplant 
recipients on tacrolimus or cyclosporine co-therapy and after < 1-month post-transplant 116. Several 
other studies with cyclosporine co-therapy also showed significant relationship with total MPA 
AUC and acute rejections but the free MPA AUC was related to incidence of infections/leucopenia 
117,118. 
Most of the studies showed good correlation of total MPA exposure (AUC0-12 h) with the 
risk of acute rejections, but the relationship between total exposure and adverse events, including 
leucopoenia and gastrointestinal symptoms, is less clear. In all three prospective trials, 
APOMYGRE, OPTICET and FDCC trials, no correlation was observed between MPA exposure 
and adverse events in spite of differences in exposure,  probably because of multi-causality and 
imprecise definitions for the adverse events119. However, in the absence of an upper exposure limit, 
a risk for resurgence of viral infections including CMV and BK virus can occur at higher exposures 
and lowering the dose of MMF has shown to be a viable strategy during BK infections120. Other 
reasons are also associated with MMF dose reductions though may or may not be related to 
exposure like, GI complications and hematologic abnormalities.  
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Overall, though the AUC is widely regarded as the best measure of MPA exposure, it is 
highly impractical to obtain blood samples until 12 h during routine clinical applications. Hence, 
surrogates for AUC are applied in the clinic similar to trough concentrations for tacrolimus. Similar 
strategies like single time point trough monitoring or alternatively collected 2-3 samples in a 
limited sampling design have all been attempted for MPA monitoring. 
Utility of Trough concentrations of MPA 
In an analysis of serial trough samples from 121 renal transplant patients, Borrows et al25 
reported significant association of lower median trough levels (C0) to acute rejection within 1 
month post-transplant. In the same study, median trough levels were also found to be higher in 
patients with anemia and viral infections. In the multi-centered prospective trial, the trough levels 
were significantly associated with acute rejections but less significantly in comparison to AUC, 
because of the higher variability observed in trough levels109. Pawinski et al121 had investigated 
the effect of MPA AUC versus trough on the risk of graft rejection using receiver operating 
characteristic, which was 0.85 and 0.63 for the AUC and trough, respectively. A couple of studies 
with cyclosporine coadministration had shown significant association of trough levels with acute 
rejection in 22 and 48 renal transplant patients, respectively122,123. Yet another study124 showed 
that mean MPA trough levels during the first week was significantly lower in patients who 
developed rejection (1.5 ± 0.1 vs 2.1 ± 0.1 µg/mL) and higher in those with gastrointestinal effects 
(4.1 ± 0.5 µg/mL).  The MPA trough level was also shown to be associated with formation of 
donor specific antibodies125. Further, a trough level of 1.4 µg/mL was  suggested to be 
representative of an AUC of 30 µg*h/mL that is required to prevent rejection and as well capable 
of 50 % inhibition of IMPDH125. Relationships between high MPA trough and adverse events have 
also been reported by some investigators. In a retrospective study of 30 renal transplant patients, 
 33 
the mean MPA trough was significantly higher in individuals who experienced adverse effects like 
CMV, and leukopenia compared with those who did not126.  
However, a relationship between MPA trough and acute rejection had been reported by 
many but not all studies. However, in the prospective trials including FDCC, OPTICET and 
APOMYGRE, no correlation of trough concentrations to adverse events were observed, again 
probably because of multi-causality and imprecise definitions for the adverse events119. 
The correlation between trough concentrations and total AUC show a wide range of values (r = 
0.07-0.6681) when compared amongst several studies in renal transplant patients, probably because 
of the different post-transplant periods of sample collection. Another hypothesis was that the poor 
correlation with AUC as well as rejection might be due to higher variability consequent to 
differences in enterohepatic recirculation82. Unlike early transplant, trough MPA concentrations 
may be of more utility in stable renal transplant patients, though currently, there is no 
recommended target range. Kuypers et al.72 has reported trough MPA concentrations to be poorly 
predictive of the 12 h AUC, as despite the MPA day 7 exposure being significantly different from 
exposure at 12 months, the corresponding trough concentrations did not reflect the difference.  
There has been no consensus in literature about the exposure measure that best correlated with 
adverse events or infections. In early post-transplant period, the total AUC of MPA is the most 
useful exposure measure as it shows a stronger relationship with risk of acute rejection than the 
trough concentrations. Overall in the case of rejections, single time point trough concentration has 
shown poor correlation and hence, other monitoring strategies that use limited sampling from first 
few hours and allow prediction of AUC could be more useful to improve clinical outcomes.  
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Limited sampling strategies to estimate MPA 12 h exposure  
The lack of single time points like trough or early time points like 1, 2 h samples to 
effectively predict the AUC had motivated a number of studies to examine the application of 
limited sampling strategies (LSS) (or alternatively called sparse sampling strategies), in the 
estimation of the 12 h exposure to MPA and predict clinical outcomes. Two different options have 
been presented for consideration in studies involving LSS for MPA exposure after MMF dosing. 
One is the selection of time points for blood sampling and the other option is the selection of 
methodology to estimate exposure using MPA plasma concentrations obtained at those time points. 
The more convenient option for sampling time points in the clinic would be to limit 2-3 samples 
within the first 2-4 hours post-dosing of MMF. Similarly, the easier methodology would be to use 
a simple regression equation to calculate exposure by incorporating MPA concentrations 
determined at specific time points (linear regression method – LR). The best time points for LR 
are determined from full PK profile of MPA and statistical regression-based selection of the time 
points that best describes the full exposure.  
Despite its convenience, LR is seriously limited by its practicality and thereby affecting its 
accuracy. The timing of sampling should be precise in order to reflect the original equation and 
hence it is difficult to implement in a clinical setting. A change in the covariates like cyclosporine 
or tacrolimus co-administration or the age of patients in comparison to the study from which the 
LR was derived, was shown to impair accuracy and result in poor AUC predictions 117,127. Other 
issues also include, inability to calculate AUC if a single time point is missed leading to loss or 
exclusion of the patient. 
On the other hand, the Maximum a posteriori (MAPB) bayesian estimation can estimate 
AUC from a limited number of time points but it requires complex calculations using a 
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pharmacostatistic model. The main advantage though, would be the flexibility in timing of blood 
sample as well as avoidance of patient exclusion due to loss of random samples, makes it a more 
suited methodology for clinical implementation. The MAPB method calculates the individual PK 
parameters for MPA based on previous MPA population parameters in combination with 
concentrations at the sparse time points, with other demographic or covariate information obtained 
from the individual patient and can be used for estimation of exposure or recommendation of dose 
for that patient. Hence, provision of individual information from the patients will improve the 
model from reliance on just the population parameters and move the estimations towards 
individual parameters. However, a drawback with using MAPB method for a drug with 
complicated profile like MPA, is the availability of an accurate model that can be more specific, 
like for example, to renal transplant patients at certain time periods post-transplant or with 
externally validated and clinically feasible time points for MPA as well as co-administered drugs 
like tacrolimus. 
The literature provides many examples for estimation of AUC for MPA with LSS, 
especially in adult renal transplant patients. Initial studies developed LR time points for 
abbreviated AUCs using predose, 30 or 40 min and 2 h 128,129 for cyclosporine co-therapy with r2 
versus total AUC ranging from 0.74-0.86. Few studies later included 6-8 h sampling point for 
MPA during tacrolimus co-therapy to account for the EHR130 however seriously limiting their 
clinical application. The LSS by LR method was used retrospectively to evaluate the association 
of estimated MPA exposure with clinical outcomes in several studies with cyclosporine co-
therapy.  Weber et al117 used 0, 0.5 and 2 h to estimate MPA AUC which was shown to be 
associated with the acute rejections but not the adverse events. Another retrospective study by 
Kiberd et al 131 estimated MPA AUC using 0, 1, 2 and 4 h and showed association of exposure 
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with acute rejections but not the side effects. The utility of LR was further extended for therapeutic 
monitoring in a prospective study, by estimating samples collected at predose,  40 m and 2 h for 
the estimation of MPA AUCs with cyclosporine or tacrolimus132.  The same LR estimation was 
also used for MPA with tacrolimus co-therapy in another prospective study with 100 de novo renal 
transplant patients by Kuypers et al133 and an r2 of 0.78 was reported with MPA AUC.   
Initial Bayesian model proposed by Le gullec et al 89 used 3 samples at 20 m, 1 and 3 h along with 
patient body weight to estimate MPA AUC in stable renal transplant patients beyond 6 months of 
transplantation. The estimates were compared in a different set of patients having a full AUC and 
the authors reported acceptable precision (bias 7.7 %) and precision (rmse 12.4 %). In another 
earlier study utilizing Bayesian estimation in de novo renal transplant recipients93, one 
compartment model with double gamma absorption was used with 3 samples like the earlier study. 
The authors reported higher bias (>20 %) at day 7 post-transplant which subsequently decreased 
to 10 % at month 3. Several other population models were used for Bayesian estimation in the 
clinic and accuracy was validated by comparison with full MPA exposure estimated by trapezoid 
rule. Most but not all models used 2-compartment disposition for MPA in stable and de novo renal 
transplant patients with various absorption models and using different types of mixed modeling 
software99, with some models utilizing GFR, body weight or co-therapy as covariates 89.  
A large-scale retrospective analysis had reported evidence that clinical application of 
bayesian estimation-based dosing by physicians, resulted in MPA AUCs within target range (30-
60 µg*h/mL) in comparison to routine procedures134. The analysis by authors also led to the 
suggestion that  monitoring of adult renal transplant recipients at least every 2 weeks during the 
first month post-transplant followed by every 1–3 months during the first year, for a 75% chance 
that patients are within target window for up to 1 year after the previous dose adjustment. 
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Hence, the LSS were proposed as an alternative for full AUC determination during post-transplant 
periods at recommended intervals such as day-7 post-transplant, months 1 and 2 at time of change 
in MMF dose or during rejections, infections, adverse events or suspicion of non-compliance 85. 
Pharmacodynamic monitoring – IMPDH activity in renal transplant patients 
MPA is a selective, reversible, noncompetitive inhibitor of inosine monophosphate 
dehydrogenase (IMPDH), the rate-limiting enzyme needed to produce guanosine, depleting the 
intracellular guanosine triphosphate stores. Although guanosine may be synthesized in other cells 
through a salvage pathway, T-lymphocytes don’t have that capacity and interruption of IMPDH 
enzyme activity preferentially limits lymphocyte proliferation 135 and migration to areas of 
inflammation or foreign tissue. Human IMPDH is encoded as two isoforms, type I and II, located 
on two different chromosomes with 85% of their amino acid sequence conserved, but the 
recombinant IMPDH2 was 4.8-fold more sensitive to MPA than IMPDH1. Earlier studies had 
expressed the IMPDH activity within PBMC cells as mol/gm of protein but with the availability 
of sensitive LCMS methods to determine AMP content in PBMC cells, the IMPDH activity in 
recent studies are expressed after normalization to AMP instead of the protein. 
Studies determining IMPDH enzyme activity in transplant patients were mainly performed 
to determine its utility for predicting rejections or adverse events as well as to determine utility of 
pretransplant IMPDH in accounting for differences in outcomes in patients on MMF therapy. 
Some of the earlier studies reported that, despite considerable inter-patient variability in the pre-
transplant IMPDH activity, the intra-patient variability in IMPDH activity is low. A retrospective 
study in 48 renal transplant recipients with a 3-year follow up revealed, an association between 
higher pre-transplant IMPDH activity and increased incidence of rejections, whereas a lower 
activity was associated with MMF dose reduction136. Hence determining IMPDH prior to 
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transplant could be beneficial as would be the pharmacodynamic monitoring of IMPDH activity 
along with the PK monitoring for MPA 137. The practicality of monitoring IMPDH activity is 
currently hampered by technical requirements, cost, time and tediousness involved in the 
procedure. 
The median IMPDH activity at baseline was higher in healthy individuals (74.8 
μmol/sec/M AMP) in comparison to stem cell transplant recipients on a steady state dose of MMF 
(45.2 μmol/sec/M AMP)138. The variability in transplant patients (5.3 fold) was also higher than 
healthy individuals (4 fold). The inhibition of IMPDH activity was well correlated to MPA 
exposure as reported in a serial pharmacokinetic-pharmacodynamic study in pediatric renal 
recipients done for until 6 months after transplant 139. In adult renal transplant patients, an inverse 
correlation between MPA concentration and IMPDH activity was observed, and at around 1.5 h  
post-dose of 1000 mg MMF, an average 50% peak inhibition in IMPDH activity has been 
reported140. 
In the literature, there has been limited information on the utility of quantifying inhibition 
of IMPDH activity as a biomarker to guide therapy with MPA. However various retrospective and 
prospective studies in renal transplant patients have shown the relation of MPA-IMPDH during 
MMF therapy in consideration to clinical outcomes. 
A study on the long term (15 month) follow-up of the PK and PD in 54 renal transplant 
patients showed an increasing trend in the predose IMPDH activity in rejecting as compared to the 
non-rejecting patients on chronic MMF therapy (p=0.019) 141. The authors suggested that due to 
high interpatient variability in IMPDH activity of around 42%, monitoring the trend in repeat 
predose IMPDH activity could help in prognosis of rejection.  
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In a study for intensified versus standard dose of EC-MPS, the intensified dosing regimen (days 0 
through 14: 2880 mg/day; days 15 through 42: 2160 mg/day; followed by 1440 mg/day) resulted 
in higher MPA exposure with lower IMPDH activity on day 3 of transplantation, in comparison to 
the standard dosing (1440 mg/day). The incidence of BPAR was lower (2.6%) in the intense 
regimen group as compared to standard dosing regimen (13.5%)142.  
In a 3-month follow-up study in 52 de novo renal transplant patients on EC-MPS, the 
IMPDH activity was determined by abbreviated samples at 0, 0.5, 1, 2 and 4 h, on day 7 followed 
by 1 and 3 months. A significantly lower inhibition of IMPDH was observed on day 7, in the group 
with BPAR (26.5 ± 11% vs. 56.7 ± 18%, p<0.001), however, neither the calculation method or 
time points used for determination of these values was stated. No correlation of MPA abbreviated 
AUCs or trough concentrations or the IMPDH(0-4 h) area under efficacy curve was noted with 
BPAR 143. 
The 12 h MPA exposure and IMPDH activity were determined in 66 renal transplant 
recipients on EC-MPS and cyclosporine therapy144 during a 12 week follow up. Abbreviated 
sampling was determined for both MPA and IMPDH activity and time points at predose, 1, 2, 3 
and 4 h post dose were found optimal (r2=0.8 for both MPA and IMPDH). Patients with BPAR 
showed significantly lower exposure in comparison to uneventful versus patients with infections, 
the median AUCs being 28 vs 40 vs 65 µg*h/mL, respectively. A low 12 h IMPDH AUEC was 
associated with an increased frequency of gastrointestinal side-effects (median 43 vs 75 nmol.h/mg 
protein/h). IMPDH AUEC was shown to be associated with adverse events rather than the BPAR, 
in this study. 
Due to the high variability in IMPDH activity, studies have hypothesized that inter-
individual variability may be attributed to the SNPs in genes coding for IMPDH I and II.  However, 
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results on the relationship of IMPDH genotype to pharmacokinetic and clinical outcomes are 
contradictory. A study evaluating 8 SNPs of IMPDH in de novo kidney transplant patients 
identified the SNP, 3757T>C for IMPDH II with a variant allele (C) to be associated with increased 
IMPDH activity in de-novo kidney transplant recipients145. For IMPDH I, 2 SNPs, rs2278293 and 
rs2278294, were shown to be significantly associated the incidence of BPAR within a year after 
kidney transplantation and the SNP rs2278294 SNP was shown to be associated with lower risk of 
rejection and a higher risk of leucopenia during the first post-transplant year as well146.  The 
correlations of IMPDH1 polymorphisms and MPA exposure with subclinical acute rejection 
(SCR) were investigated in 82 Japanese recipients, on day 28 post-transplantation147. It was 
reported that patients with the IMPDH1 rs2278293 G⁄G genotype tend to develop SCR, on the 
contrary the risk of SCR was found to be lower in patients with the IMPDH rs2278293 A⁄A 
genotype for whom MMF was considered more effective. 
Few studies have come around the tedious and time-consuming methods for determination 
of IMPDH activity by alternative measurement of IMPDH mRNA for type 1 and 2, using 
quantitative real-time polymerase chain reaction (RT-PCR) methods.  
In a study of 12 renal transplant recipients over 2 years, the IMPDH‐I mRNA expression 
was increased during the first 3 months following transplantation and reached maximal levels 
during acute rejection episodes, whereas type II IMPDH mRNA was stable 148. The authors 
suggested monitoring of IMPDH RNA over time may provide reliable information to predict acute 
rejection. In another cohort of 101 renal transplant patients, the IMPDH mRNA was found to be 
marginally associated with acute rejections, with higher pre-transplant expression values of type 1 
and 2 IMPDH mRNA in patients who had acute rejections 145. On the contrary, IMPDH activity 
was not correlated with acute rejections. 
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In 35 de novo renal transplant recipients followed up for 6 months, the IMPDH activity 
and mRNA expression was determined at weeks 2, 4, 12 and 24, using samples at predose and 2 h 
after MMF administration. Patients with BPAR in the first 4 weeks exhibited significantly higher 
pre-transplant expression of genes for IMPDH I and II149. The authors proposed pre-transplant 
IMPDH mRNA expression for prediction of response to MPA and cautioned to the impact of post-
transplant steroid therapy on limiting utility of post-transplant mRNA expression. 
The availability of more sensitive non-radioactive methods has facilitated MPA pharmacodynamic 
monitoring by IMPDH activity. The determination of IMPDH inhibition may provide a better 
indicator of degree of immunosuppression in comparison to the MPA plasma concentrations. Apart 
from rejections, IMPDH activity may be related to MPA dose-related toxicity and could allow 
individualizing exposure while limiting side effects. The evidence so far has not provided a 
conclusive determination of IMPDH target inhibition due to the high interpatient variability and 
suggests longitudinal patient wise monitoring.  
1.4.2.4 Indication versus protocol biopsy 
Biopsy of kidney tissue is an invasive procedure to find histological changes in the 
transplanted graft and to guide further changes in immunosuppression therapy. An indication 
biopsy is performed in response to a change in patients lab parameters like increase in serum 
creatinine or proteinuria or any change in patient’s clinical condition that may be indicative of 
allograft dysfunction including recurrent renal disease, rejections or BK nephropathy. However, 
protocol (scheduled) biopsies are obtained at predefined intervals, regardless of renal function, 
except if it is contraindicated (like in patients on anticoagulants or antiplatelet agents). Hence, 
protocol biopsies have revealed clinically inapparent rejections (subclinical) with Banff grade 1A 
or higher lesions or inflammation in the graft. Treatment of subclinical rejections identified before 
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3 months had decreased chronic tubulointerstitial score at 6 months and decreased the 2-yr serum 
creatinine in comparison to no treatment150. The exposure to immunosuppression at early post-
transplant is a likely determinant of the subclinical rejections at the 3-month protocol biopsy. It 
was also observed that patients who had inflammation in the protocol biopsy had significantly 
lower tacrolimus trough levels and higher blood creatinine levels versus those without 
inflammation in their protocol biopsy10. The biopsy is also the gold standard for diagnosing BK 
virus nephropathy. In response to this diagnosis, studies have indicated a stepwise reduction in 
MMF and tacrolimus or conversion to cyclosporine (which can also reduce MPA levels) to prevent 
risk of acute rejections precipitated by this infection 151. Due to the insensitivity of creatinine levels 
to detect subclinical rejections and in the absence of non-invasive markers to diagnose rejections, 
protocol biopsies provide information on adequacy of the immunosuppression therapy. 
1.5 HYPOTHESIS AND AIMS  
The overall goal of this research is to improve the early post-transplant graft function in 
kidney transplant recipients. Several immunological and non-immunological risk factors in renal 
transplant patients can impact early graft survival and subsequently affect the long-term outcomes. 
In this dissertation, the focus is on two of the modifiable risk factors in renal transplantation, (i) 
ischemia reperfusion injury and (ii) acute cellular rejections associated with current 
immunosuppressive therapy. 
Ischemia reperfusion injury (IR) is an inevitable process during transplantation and has 
consequences on graft survival68,152,153. The IR of kidneys is a known risk factor for delayed graft 
function (DGF) after transplant as well as acute and chronic rejection of the kidney12,13. With the 
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increased demand for transplantable kidneys, the use of extended criterion donors (age >60 yrs 
with hypertension or creatinine >1.5 mg/dL or death due to cerebrovascular causes) and donation 
after circulatory death has increased. Kidneys from such donor types may be subject to prolonged 
warm and cold ischemic times with an increase in IR injury effects, thereby leading to higher 
incidence of DGF and suboptimal kidney function154,155.  Hence, strategies for reduction in IR 
injuries will improve the graft utility, survival and decrease patient morbidity. 
Strategies like pre-treatment of donors done prior to organ retrieval are shown to reduce 
ischemia effects. However, ethical and practical issues of dealing with the donor post-mortem, is 
a major limitation. Alternatively, pharmacological treatments focused on targeting IR pathways is 
possible during preservation (static cold storage or machine perfusion) and transport of the kidney. 
If appropriate, the pharmacological treatment may also be continued during reperfusion 
(implantation as well as after transplantation), with informed consent of the patient.  Further, if 
beneficial effects are demonstrable in kidneys of pre-clinical models, the target concentration of 
ex-vivo pharmacological treatment are easily translatable for testing with human kidneys. 
Prostacyclin (PGI2), is endogenously produced by vascular endothelial and smooth muscle 
cells and has a potent vasodilator and anticoagulant effect. Treprostinil is a synthetic PGI2 analogue 
with better stability, improved potency and a longer half-life and with a pharmacological activity 
against several pathways that are known to be activated during IR. The anticipated effects of 
treprostinil as a pharmacological additive during IR include, activation of  PPAR-gamma induced 
anti-inflammatory and antioxidant effects, cAMP generation to prevent depletion of ATP levels 
apart from the vasodilatory and anti-coagulation effects. Treprostinil has been shown to attenuate 
the significant decrease in ATP content of 24 h cold preserved livers and decrease hepatic IR injury 
in an orthotopic rat liver transplant model53. Hence, overall hypothesis is that the ex-vivo addition 
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of treprostinil to cold storage solution can attenuate the IR injury and preserve the function of the 
kidney graft by its vasodilatory action on renal endothelial cells and by decreasing the reperfusion 
induced activation of inflammatory and coagulation pathways. 
The hypothesis was tested after establishing an isolated perfusion of rat kidney (IPRK) as 
a model for IR. Further, the beneficial effect of ex-vivo addition of treprostinil to storage solution 
and reperfusion, was tested by functional evaluation of cold stored renal graft using the IPRK 
model, in chapter 2. The effects of prolonged cold storage (24 vs 72 h), IR injury and treprostinil 
on the gene expression of important renal targets including renal drug transporters, metabolism 
enzymes, receptors, antioxidant enzymes and inflammatory mediators was quantitatively 
compared using a Nanostring® based analysis in chapter 3. 
The second part of dissertation evaluated baseline maintenance immunosuppression that is 
currently being followed as a standard after renal transplantation to minimize acute rejections. 
Tacrolimus, mycophenolate mofetil and steroids are usually used in renal transplant patients to 
avoid rejection of the graft. As MPA and tacrolimus have differing mechanisms of action, they 
achieve overall better efficacy when given in combination, leading to a decrease in the frequency 
of acute cellular rejection episodes156,157 and increase in graft survival at 1 year.  Despite 
standardized immunosuppression with MMF and tacrolimus, the early 3-month protocol biopsies 
have revealed histological lesions associated with inflammatory changes and presence of immune 
cells in the kidney graft even before an impact on graft function is observed. Grading of these 
lesions in protocol biopsies reveal histological changes meeting the Banff criterion for rejection 
but without any observable change in graft function (subclinical rejections). Previous reports have 
shown that the inflammation detected in 1- or 4-month biopsies to be associated with progression 
of fibrosis17 and early subclinical inflammation is a risk factor for progression of chronic interstitial 
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damage158. It has previously been shown that baseline immunosuppression (cyclosporine versus 
tacrolimus) influences the degree of inflammation in early protocol biopsies and further determines 
incidence of acute clinical rejections159. A re-assessment of standardized early immunosuppression 
(MMF + tacrolimus) taking histological findings (clinical + subclinical rejections) in early post-
transplant biopsies into consideration is necessary to improve long term outcomes. 
In conjunction with this standardized immunosuppression regimen, the pathological analysis of 
transplanted graft is performed in a few transplant centers only, at early post-transplant time 
periods such as 3 months as well as 6- or 12-months post-transplant. These protocol (screening) 
biopsies provide an accurate diagnosis for the graft conditions in response to the standard 
immunosuppression therapy and are also done to confirm the presence or absence of acute cellular 
rejections. 
The current immunosuppression protocol includes regular therapeutic drug monitoring 
(TDM) of tacrolimus and adjustment of dosing regimen to maintain a therapeutic range in order to 
minimize rejection and toxicity. MPA however is administered at a fixed dose and no TDM is 
performed. Further, there has been limited information on the utility of quantifying IMPDH 
activity inhibition as a biomarker to guide therapy with MPA, though several studies in renal 
transplant patients have shown the relation of MPA-IMPDH in consideration to clinical outcomes. 
Our hypotheses are: (a) relationship of tacrolimus exposure and outcome (clinical/subclinical 
rejections) will be influenced by genotype of the MDR1 gene expressed on the lymphocytes 
(PBMC)  (b) it is important to personalize MMF dosing based on exposure (abbreviated area under 
the curve (AUC) and/or inhibition of IMPDH activity. 
First, exposure to tacrolimus was determined by sparse sampling during early post-
transplant week-1-2 and followed up during the 3-month biopsy on week-13. Patients with same 
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blood levels might differ in target site concentrations within the peripheral blood mononuclear 
cells (PBMCs), due to efflux by P-glycoprotein expressed on PBMCs.  Hence, the genotyping of 
patients for P-glycoprotein along with estimation of total exposure to tacrolimus by maximum a 
posteriori (MAP) bayesian method was performed (in chapter 4). Next, concentrations of MPA 
along with inhibition of IMPDH activity was determined at the same sparse sampling points as for 
tacrolimus and patients were also genotyped for UDP, IMPDH I and II enzymes. The individual 
exposures to total MPA was determined by MAP estimation and individual inhibition of IMPDH 
activity was determined, in chapter 5. The associations of individual and combined exposures to 
MPA, tacrolimus and inhibition of IMPDH activity with histological lesions were analyzed by 
univariate and multivariate logistic regression in chapter 6. The summary of work, limitations and 
recommended future directions are discussed in chapter 7. 
Overall, we anticipate that the study findings can (a) extend utility of treprostinil to improve the 
preservation of renal grafts and decrease reperfusion associated post-transplant morbidities and (b) 
can suggest the utility of pharmacological measures obtained during early post-transplant in 
optimizing the maintenance immunosuppression with an impact on long term outcomes in renal 
transplant patients. 
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2.0   EVALUATION OF TREPROSTINIL IN AMELIORATING RENAL GRAFT INJURY 
FOLLOWING REPERFUSION OF COLD STORED RAT KIDNEYS 
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2.1 ABSTRACT 
Ischemia reperfusion injury after renal transplantation impairs graft function and the post-
transplant recovery of the recipient.  Treprostinil, a prostacyclin (PGI2) analogue has shown 
promising effects by attenuating ischemia reperfusion after orthotopic liver transplantation in rats. 
The aim of this study was to examine the ischemia reperfusion injury in the rat kidneys and to 
evaluate the effects of treprostinil addition either to preservation (storage) solution or preservation 
as well as during reperfusion in an ex vivo kidney perfusion model. Kidneys cold preserved (CS) 
for 24 h (4°C) were functionally evaluated using an isolated kidney system under perfusion with 
oxygenated buffer. Perfusate flow and renal functions including glomerular filtration rate (GFR 
by inulin clearance), tubular secretion (clearance of PAH, metformin) were measured during 2 h 
perfusion. Tissues at the end of preservation or perfusion were subjected to histological and mRNA 
expression analysis for oat1/mrp4 and oct2/mate1 transporters. Following reperfusion CS kidneys 
showed a significant loss in recovery of renal function as assessed by the fall in GFR, reabsorption 
of sodium and glucose and tubular secretion, to less than 10% of control values. Although a trend 
in improvement of renal function was observed with treprostinil addition to storage (CS-20 and 
CS-50), the effects were not statistically different from CS. Significant upregulation of oct2/mate1 
during storage, and oat1 during reperfusion of CS kidneys, were attenuated by CS-50 and CS-50-
R (treprostinil to both storage and reperfusion). Treprostinil addition to CS improved some 
parameters like urine flow and altered mRNA expression, but failed to improve renal function and 
histological damage by CS during this ex vivo evaluation. A longer follow up of renal function 
recovery using in vivo transplant model might provide a more conclusive evidence on the 
beneficial effects of treprostinil. 
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2.2 INTRODUCTION 
Deceased donor transplant in US contributes to more than 60% of the kidneys that are 
transplanted every year160. The deceased donor kidneys are flushed out of blood and stored in cold 
storage solution, until transplantation. The logistic demands of transplant necessitate varied 
duration of cold storage, but all kidneys are invariably exposed to reperfusion with warm recipient 
blood, thus cold storage and warm reperfusion are inevitable sequential events in every cadaveric 
kidney transplant. During cold storage, the metabolic demands of the kidneys are lowered with 
hypothermic state (4°C) but there is also oxygen deprivation and a decrease in ATP production, 
setting the stage for ensuing damages initiated during warm reperfusion161. During reperfusion in 
the recipient, sub-optimal renal ATP levels, a sudden exposure to reactive oxygen radicals and 
activation of inflammatory mediators can lead to cellular dysfunction, acute tubular necrosis 
(ATN) and delayed graft function (DGF)162,163. Clinically, the cold ischemia reperfusion (IR) 
mediated injury can be a significant contributor for ATN and DGF after renal transplant, which in 
turn can prolong the post-transplant patient recovery, delay adjustment to optimal 
immunosuppression as well as impact graft outcomes42. 
The pathophysiology of IR injury has offered a plethora of pharmacological interventional 
studies using vasodilators, anti-inflammatory agents, antioxidants, mitochondrial protectors and 
colloids, to name a few. The pharmacological intervention by simple addition to cold storage 
solution offers an easy prophylactic approach which if required, can also be extended to treat 
patients post-transplantation. 
Prostacyclin analogues are known to act on endothelial cells and platelets with potent 
vasodilatory, anti-thrombotic  and  anti-inflammatory effects which may be of benefit in targeting 
ischemic reperfusion mediated injury. Treprostinil is a potent PGI2 analogue with improved 
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chemical stability and a longer half-life. Previous study in rat liver transplant model showed that 
pretreatment of donor and recipient rats with treprostinil protected the grafts from early reperfusion 
mediated injuries. Treprostinil treated rats showed decreased mRNA expression of inflammatory 
mediators like TNF-alpha, IFN-gamma, ICAM-1 and in addition improved the hepatic tissue levels 
of cAMP, ATP, ADP, AMP and total adenine nucleotides in comparison to the placebo treated 
rats53. The potential for treprostinil to minimize cold ischemia reperfusion of renal grafts has not 
been demonstrated yet. Treprostinil is FDA approved for treatment of pulmonary arterial 
hypertension and can be considered as safe for addition to the cold storage solution during kidney 
preservation. It is hypothesized that addition of treprostinil either to preservation solution only or 
additionally during reperfusion, can improve the viability of the kidney graft by promoting cAMP 
mediated intracellular ion homeostasis, prevention of ATP loss and thereby improve the functional 
recovery of graft during reperfusion. 
Our objective in this study is to establish a model for renal ischemia reperfusion injury and 
examine the effect of treprostinil addition during cold storage and warm reperfusion, on the 
functional recovery of rat kidneys. The kidneys preserved in University of Wisconsin solution at 
4° C were reperfused in an isolated rat kidney perfusion system for simultaneous evaluation of 
glomerular and tubular functions. 
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2.3 MATERIALS 
2.3.1 Chemicals 
Remodulin® vials containing 20 mL of 1mg/mL was kindly provided by the manufacturer, 
United Therapeutics Corporation (Silver Spring, MD). The University of Wisconsin (UW) solution 
(CoStorSol™) was obtained from Preservation solutions Inc. (Elkhorn, WI). Lactated Ringer’s 
solution was obtained from Baxter healthcare (IL, USA). The components of Krebs-Henseleit 
buffer and sodium bicarbonate were of analytical grade and obtained from Sigma Aldrich, US. A 
kit containing 21 L-amino acids was obtained from Supelco, Millipore Sigma, US. Inulin (from 
Dahlia tubers), P-Aminohippuric acid, metformin and dextran (from Leuconostoc spp). was 
obtained from Millipore Sigma, US. Bovine serum albumin (protease-free) was obtained from 
Fisher BioReagents, US. 
2.3.2 Perfusate solution 
The perfusate (300 mL) was prepared fresh, a couple of hours before the perfusion of the 
kidney. The perfusate consisted of Krebs-Henseleit buffer with sodium bicarbonate (KHSB), 
containing BSA (40 g/L) with dextran (16.5 g/L) as oncotic agents and a mixture of 20 Amino 
acids164 to improve the stability and function of the perfused kidney165,166. The oncotic agents were 
dissolved in 150 mL of Milli-Q water under constant stirring for at least 30 minutes until complete 
solubility without any cloudiness was observed. KHSB was prepared separately and mixed with 
the oncotic fluid, followed by the amino acid mixture. The pH was adjusted to 7 with HCl and 
passed through 0.11 µ filter. The perfusate was equilibrated through the recirculating perfusion 
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system for at least 30 minutes for adequate oxygenation and the final pH was 7.4 prior to 
connecting the kidney. 
2.3.3 Perfusion system 
Kidneys were reperfused with the acellular perfusate prepared earlier, in a recirculation 
mode using the perfusion system (Radnoti LLC, CA). The system comprised of a peristaltic pump, 
a thermostatic controlled water jacket and an oxygenator to maintain perfusate flow, temperature 
(37°C) as well as to enrich perfusate with carbogen (95%O2/ 5%CO2), respectively. The total 
pressure within the perfusion system was monitored with an inline sphygmomanometer and an 
inline syringe filter (37 mm Acrodisc, Pall life sciences) was used to avoid any particulates and 
tissue debris from entering the renal vasculature during perfusion. The perfusion system was 
equilibrated with perfusate for 30 min to ensure adequate oxygenation, the baseline pressure was 
set to zero and the system was verified for absence of bubbles or pressure fluctuations, prior to 
connecting the kidney. 
2.4 METHODS 
2.4.1 Animals and grouping 
Adult male Sprague Dawley rats were used in this study, performed with the approval of 
the Institutional animal usage and care committee at the University of Pittsburgh. All rats were 
housed under standard conditions (light, temperature, humidity, diet and free access to food and 
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water) for a period of at least 3 days prior to the experiment. A total of 20 rats (weight range 250–
280 g) were divided into 5 groups, each consisting of four animals. Two groups were used for 
determination of baseline values, a control group with no preservation and a CS group with 24 
hours of cold preservation. Three additional groups were evaluated after 24 hours cold preservation 
with treprostinil added at final concentrations of 20, 50 ng/mL and 50 ng/mL plus an additional 10 
ng/mL during reperfusion, denoted as CS-20, CS-50 and CS-50-R, respectively. 
2.4.2 Isolation and cold storage of kidneys 
Briefly, rats were anesthetized with a mixture of isoflurane/oxygen and ventilated on a 
table top research anesthesia machine (Parkland Scientific, FL) with 1 liter/min O2 in air, until 
isolation of both kidneys. The procedures for surgery and perfusion was performed according to 
methods described in Taft et al.164. A midline abdominal incision was made to expose the right 
kidney. The intestine was gently moved aside and wrapped in a gauze, soaked with saline. The 
right ureter was identified for cannulation with a polyethylene cannula (PE-10), prefilled with 
saline and the urine flow was verified, before proceeding further. In few instances, urine flow was 
initiated by gentle suction within PE-10 via a tuberculin syringe. Next, the superior mesenteric 
artery at the branching of aorta was isolated and used for accessing the right renal artery with a 
20G cannula. The branching to the adrenal artery was ligated and cannula was secured at both 
renal artery and the superior mesenteric artery. The right kidney was flushed with 15 mL of cold 
saline to remove blood via the incised renal vein, followed by perfusion with 15 mL of cold UW 
solution. The renal vein was clamped, the cannula locked, and kidney was gently isolated along 
with the ureter to be placed into 30 mL of cold UW solution at 4 °C for 24 h. A whole-body 
perfusion was then performed for 3 minutes with cold UW solution via cannulation of the left 
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ventricle and flushing out of blood via an incision at the inferior vena cava. The left kidney was 
then isolated, cleared of adhering tissues and stored together with the right kidney. At the end of 
24 hours, the right kidneys were perfused for functional evaluation and left kidneys were stored 
for mRNA expression and histology, as described below. Freshly isolated kidneys of the control 
group were not subjected to cold storage prior to perfusion or storage for mRNA and histology. 
2.4.3 Reperfusion of the isolated rat kidney (IPRK) 
Only control rat kidneys were perfused immediately after isolation, whereas kidneys from 
all other groups were reperfused after 24 h of CS. In the case of control kidneys, cannulation of 
renal artery was performed under 20 mL/min of perfusate flow to avoid uninterrupted renal 
perfusion. After the cannula was secured in the renal artery and superior mesenteric artery, the 
kidney was quickly excised and mounted onto the perfusion chamber. On the other hand, CS 
kidneys were slowly perfused for 10 minutes with 10 mL of cold (4°C) lactated ringer solution to 
wash out all the UW solution, connected to a 10 mL/min perfusate flow and immediately mounted 
onto the perfusion chamber. The venous outflow was directed back into the perfusion reservoir to 
complete the recirculation. During the initial 15 minutes of equilibration, perfusate flow was 
adjusted to maintain a stable renal perfusion pressure at 100 mm Hg. 
2.4.4 Functional evaluation during IPRK 
Following equilibration, marker compounds namely inulin, PAH and metformin, were 
added to the perfusate at final circulating concentrations of 750, 100 and 5 µg/mL, respectively. 
The perfusate of CS50-R group, evaluating the effect of treprostinil during reperfusion, contained 
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10 ng/mL of the drug in perfusate, in addition. Following an additional equilibration of 5 minutes, 
the kidneys were perfused for 120 minutes, for functional evaluation by calculated renal clearance 
of marker compounds, described later. Urine flow was collected into pre-weighed 1.5 mL 
Eppendorf tubes for immediate determination of pH and gravimetry based volume. The urine was 
collected at 20 min time intervals and perfusate was sampled with replacement, at the midpoint of 
every urine collection time interval. At the end of perfusion, kidney was removed and weighed. A 
small section of kidney was stored in formalin and the rest was flash frozen in liquid nitrogen and 
stored in -80 °C, for mRNA analysis. Aliquots of the perfusate and urine samples were frozen in -
20°C until further analysis. 
2.4.5 Bioanalysis of marker compounds 
a) Colorimetric assay for Inulin: Inulin in perfusate and urine samples was quantified with 
a colorimetric assay167 published earlier, with few modifications for accommodating analysis of 
urine samples. Urine samples (50 µls) were diluted to 250 µls with Milli-Q water prior to analysis. 
Briefly, perfusate (100 µls) or diluted urine (250 µls) were mixed with 50 mM of indole acetic 
acid and incubated at 37 °C for 1 h in presence of 2 mL of 12 N HCl. After cooling for 10 min at 
RT, the incubates were transferred to 96-well plate and OD readings were obtained at 530 nm. 
Blank perfusate and blank urine from IPRK were used for preparation of standard and quality 
control (qc) concentrations. The standards in perfusate ranged from 0.2 – 2 mg/mL with 0.3 and 
0.9 mg/mL as qcs. The standards in urine ranged from 0.2-8 mg/mL with 0.3, 0.9 and 5 mg/mL as 
qcs. 
b) Analysis of glucose and sodium: Perfusate and urine samples were analyzed for glucose 
and sodium ion, by using hexokinase method and ion selective electrode, respectively. 
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c) HPLC assay for PAH: The perfusate and urine levels of PAH were measured using 
previously published HPLC methods, with minor modifications168,169. Briefly, 20 µls of perfusate 
or urine sample was diluted 5 times with blank matrix and precipitated with 10 µls of 10% (w/v) 
trichloroacetic acid (TCA). This mixture was shaken in a vortex for 2 min, centrifuged at 13,000 
rpm for 6 min at RT and 40 µls of supernatant was injected on to a Symmetry C18 column (5 µm, 
250 mm × 4.6 mm i.d.) (Waters Corp., Milford, MA, USA) attached with a guard column Zorbax 
SBC18 (5 µm, 12.5 mm × 4.6 mm i.d.). The mobile phase consisted of 1 M acetic acid (pH 3.2) 
and ACN in a gradient mode at a constant flow rate of 0.7 mL/min and effluent was monitored at 
270 nm. Standards for PAH ranged between 10-250 µg/mL in both matrices, as shown in Figure 
2.1.  
 
Figure 2.1. HPLC chromatogram and calibration curve of para-amino  
hippuric acid in perfusate and urine. 
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d) HPLC assay for metformin: HPLC analysis of metformin perfusate and urine was based 
on previously published method170, with some modifications. 100 µls of perfusate or 50 µls of 
urine was mixed with 20 µls of 10% (w/v) TCA and shaken in a vortex for 30 secs, centrifuged at 
13,000 rpm for 6 min at RT and 50 µls of supernatant was injected on to a Suplecosil LC-CN 
column (5 µm, 250 mm × 4.6 mm i.d.; Millipore Sigma, USA) maintained at 40 °C. An isocratic 
mobile phase comprising of 70 % (v/v) of 10 mM KH2PO4 with 1 mM sodium lauryl sulfate (pH 
6.5) and 30 % (v/v) methanol was used at 1 mL/min. Standards ranged between 0.5-25 µg/mL in 
both matrices, as shown in Figure 2.2. 
 
Figure 2.2. HPLC chromatogram and calibration curve of metformin in perfusate and urine 
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2.4.6 mRNA expression 
The extraction was performed as per the instructions of the manufacturer and described 
briefly as follow: on ice, 25 mg or less of frozen kidney tissue was mixed with RNeasy RLT buffer 
(600 uL) and homogenized on ice with a conventional rotor–stator homogenizer. Lysate was 
transferred to QIA shredder column for removing tissue debris and further purified with a RNeasy 
column (Qiagen sciences, MD, US). The purity of isolated mRNA was assessed using a 
NanoDrop™ 2000c spectrophotometer. 
2.4.7 Real time qPCR 
Superscript IV reverse transcriptase (ThermoFisher scientific, US) was used to generate 
cDNA from purified mRNA samples. Samples had varying concentrations of mRNA, but all 
samples were diluted to 25 ng/µl starting concentration, using DPEC water.  250 ng of mRNA (10 
µls) was used per reaction, in accordance to the Superscript IV protocol to obtain cDNA and final 
volume was adjusted to 20 µls with RNase free water. 
RT-qPCR was performed in 96 well plates. Each well was loaded with 4 μL of cDNA, 1μL of 
TaqMan primer mix, 10 μls of TaqMan master mix, and 5 µls of RNase free water. TaqMan 
primers (assay ID) for rat slc22a6 (oat1) (4331182-Rn00568143_m1), slc22a2 (oct2) (4331182-
Rn00580893_m1), slc47a1 (mate1) (4331182-Rn01460731_m1) and abcc4 (mrp4) (4331182-
Rn01465702_m1) gene targets and actb (β-Actin) (431182-Rn00667869_m1), gapdh (431182-
Rn99999916_s1) as housekeeping genes, were procured from Life Technologies (Carlsbad, CA, 
USA). Applied Biosystems® 7500 Real-Time PCR System was used to amplify and detect targeted 
genes. PCR amplification was performed in 40 cycles of 94°C for 15 s, then 50°C for  30 s, and 
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68°C for 60 s. The final elongation step was 68°C for 10 min. All samples were plated in duplicates 
to account for variability associated with technical errors and each target was restricted to a single 
96 well plate to avoid inter-plate variability. 
2.4.8 Histopathology 
Kidney sections taken for histology were fixed in 10% formalin in phosphate buffered 
saline, embedded in paraffin and stained with hematoxylin-eosin. A pathologist unaware of the 
experimental conditions (blinded), reviewed the stained sections under light microscopy and 
provided a qualitative assessment for presence of lesions and other changes like interstitial edema, 
tubular dilatation, cell detachment for the CS and reperfused kidneys. 
2.4.9 Calculations 
The renal clearance (CL) of inulin, PAH and metformin were used as markers for 
glomerular filtration (GFR), anionic and cationic tubular secretion capacity of the kidney, 
respectively. Urine flow rate (UFR) was calculated from the ratio of volume of urine collected and 
corresponding duration. 
Renal CL of inulin = GFR = [Urine]inulin x [UFR] 
         
                                                 [Perfusate]inulin 
where [Urine] and [Perfusate] are concentrations of Inulin in urine and perfusate, respectively. 
Renal CL was calculated for each of the six collection periods (20 min) and mean CL was 
calculated for each perfused kidney. The filtration fraction (FF) was estimated from the ratio of 
GFR to the perfusate flow, both of which were normalized per gm of kidney weight. 
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Filtration fraction = [GFR (per g of kidney)/Perfusate flow (per g of kidney)] 
In addition, the renal clearance of sodium and glucose using perfusate and urinary concentrations 
were estimated, in a pilot trial and calculated as above to determine viability (% TR = tubular 
reabsorption) of the perfused kidney. 
% TR =    1 - [R CL]    X 100 
                                      [GFR] 
where [RCL] is renal clearance determined for glucose or sodium, as applicable. 
Renal CL of other markers PAH and metformin were determined as above, from their respective 
urinary and perfusate concentrations for each of six collection periods. In addition, their tubular 
secretory CL was determined from the difference of their renal CL and GFR. 
Tubular CL = [R CL – GFR] 
where [RCL] is renal clearance determined for PAH or metformin, as applicable. 
The relative levels of mRNA expression of target genes were normalized with the copy number of 
housekeeping genes (β–actin and gapdh). The relative levels of mRNA fold changes of all genes 
were quantified using the 2-ΔΔCT method171,172. 
2.4.10 Statistical methods 
Analysis of variance (ANOVA) was used for comparison of mean parameters between 
treatment groups. Tukey HSD was used for post hoc analysis of variance between two groups. 
Comparison of parameters between treatment groups at different time points (repeated measures) 
was done by mixed model analysis.  Statistical significance of p<0.05 was considered. ANOVA, 
mixed model analysis and plots were done using graph pad prism version 8 (GraphPad software, 
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CA, US) or SPSS® version 25 (IBM corporation, US).  Gene expression results of groups were 
compared to controls utilizing analysis of variance (ANOVA) and Bonferroni post-hoc test. All 
data were expressed as mean ± standard deviation (SD). 
2.5 RESULTS 
2.5.1 Functional evaluation -filtration and viability 
The donor parameters are presented in Table 2.1. There was no significant difference 
between the treatment groups in donor parameters. Though the larger right kidneys were perfused, 
and left kidneys were stored, an increase in kidney weights was observed after perfusion. The 
kidneys from control rats were not subject to cold storage and perfused immediately following 
isolation of kidney. The parameters obtained during isolated perfusion of kidneys are compared in 
Table 2.2. After 24 hours of CS, there was a significant loss of glomerular filtration and urine flow 
in reperfused CS kidneys, in comparison to control kidneys. CS-20 kidneys showed a significant 
(p<0.01) increase in urine flow compared to other CS kidneys. 
Table 2.1. Parameters of donor rats used in IPRK 
 Body weight (g) CS kidney weights (g) 
Perfused kidney 
weights(g) 
Control 253 (24) No CS 1.5 (0.1) 
CS 287 (26) 1.1 (0.1) 1.5 (0.3) 
CS-20 296 (34) 1.2 (0.1) 1.7 (0.4) 
CS-50 312 (74) 1.2 (0.3) 1.8 (0.5) 
CS-50-R 347 (54) 1.3 (0.1) 2.0 (0.1) 
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Data represented as Mean (SD) of n=4 rats per treatment group; CS- Cold Storage (24 h) in 30 mL of University of 
Wisconsin solution 
 
However, the trend in improvement of GFR with CS-20 was not statistically different from other 
CS kidneys. 
 
Table 2.2. Functional and viability parameters in IPRK  
 
 
Control CS CS-20 CS-50 CS-50-R 
GFR 
(mL/min/g) 
0.26 *** 
(0.1) 
0.03 
(0.01) 
0.05  
(0.02) 
0.04 
(0.03) 
0.01 
(0.004) 
Urine flow rate 
(mL/min/g) 
0.04 *** 
(0.01) 
0.02 
(0.01) 
0.03 ** 
(0.02) 
0.01 
(0.01) 
0.01 
(0.001) 
Urine pH 
6.1 *** 
(0.5) 
7.6 
(0.1) 
7.4# 
(0.2) 
7.3# 
(0.2) 
7.7 
(0.1) 
Perfusate flow rate 
(mL/min/g) 
19.5 *** 
(1.1) 
17.1# 
(1.6) 
11.2 ¥ 
(2.5) 
14.5 
(1.4) 
14.4 
(2.9) 
Filtration fraction 
0.013 *** 
(0.005) 
0.002 
(0.001) 
0.005 ** 
(0.004) 
0.003** 
(0.002) 
0.001 
(0.0003) 
Data reported as mean (S.D.) collected from n=4 perfusions per treatment group; CS- Cold Storage (24 h) in 30 mL 
of University of Wisconsin solution;  
Statistically significant difference with (p< 0.001) represented by ***, #, ¥ and  (p<0.01) represented by** in comparison 
to all other groups except control group; Tukey HSD post-hoc testing was used  
 
Table 2.3 compares the tubular reabsorption capacity for glucose and sodium ion (viability), which 
were also significantly reduced during reperfusion of CS kidneys. No improvement in viability of 
CS kidneys in presence of treprostinil (5 ng/mL) was observed. 
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Table 2.3. Fractional reabsorption in IPRK (pilot trial)  
 
 
 
 
FR-Fractional reabsorption of glucose or sodium by kidney; Pilot trial with n=2 perfusions in each group; CS-Cold 
storage for 72 h and Treprostinil 5 ng/mL added to CS solution;  *Significantly different (p< 0.001) from other groups 
 
Under identical perfusion conditions, the urine from control kidneys were more acidic and 
showed a further drop in pH with increase in duration of perfusion, as shown in Figure 2.3. 
 
Figure 2.3. Urine pH at different timepoints during IPRK  
The perfusate flow (normalized to kidney weight) was significantly higher in the control 
group kidneys than the CS and CS with treprostinil kidneys. Further, the kidney weight normalized 
perfusate flow during reperfusion, was less in kidneys after addition of treprostinil during CS (CS-
20, CS-50) or both CS and reperfusion (CS-50-R). However, treprostinil addition to CS (CS-20, 
CS-50) significantly improved the filtration fraction than the CS kidneys. 
 Control* CS CS-5 
FR glucose 98.2 7.4 6.8 
FR Na 91.0 6.3 5.0 
 64 
2.5.2 Functional evaluation- tubular secretion 
 
Figure 2.4. Renal Clearance of PAH at different timepoints during IPRK (µg/mL/g) 
The clearance of PAH and metformin were used as markers for comparison of the tubular 
secretion by kidneys. Figures 2.4 and 2.6 compare the renal clearance, estimated at 20-minute 
intervals for PAH and metformin, respectively.  The mean (SD) renal clearance is also summarized 
in Figures 2.5 and 2.7 for PAH and metformin, respectively. 
 
Figure 2.5. Anionic secretion based on renal excretion parameters of PAH 
There was no drastic change in the tubular secretion capacity, which remained constant in 
all kidneys during the 2-hour perfusion period. Hence the mean values of the six individual 
clearance estimations (normalized to kidney weight) were used for further comparison and 
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interpretations. Like inulin clearance (GFR), the tubular secretion capacity of the CS kidneys 
dropped to less than 10% of control values. 
 
Figure 2.6. Renal Clearance of Metformin at different 
timepoints during IPRK (µg/mL/g) 
There was no drastic change in the tubular secretion capacity, which remained constant in 
all kidneys during the 2-hour perfusion period. Hence the mean values of the six individual 
clearance estimations (normalized to kidney weight) were used for further comparison and 
interpretations. Like inulin clearance (GFR), the tubular secretion capacity of the CS kidneys 
dropped to less than 10% of control values. 
 
Figure 2.7. Cationic secretion based on renal excretion  
parameters of Metformin  
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Like GFR, a trend in improvement was observed with CS-20 kidneys for both anionic and cationic 
secretion and with CS-50 kidneys for cationic secretion only, however the effect was not 
statistically different in comparison to other CS kidneys. 
2.5.3 mRNA expression  
Gene expression for oat1/mrp4 and oct2/mate1, representing an anionic and cationic 
transporter system pair, respectively are compared in Figures 2.8 and 2.9. CS kidneys showed a 
significant  increase (p<0.05) in oat1 after reperfusion, which was attenuated in CS-50 as well as 
CS-50-R (with 10 ng/mL added at reperfusion) kidneys, resulting in their post-reperfusion oat1 
expression that was comparable to control kidneys (no CS). As shown in Figure 2.9, a significant 
increase in mRNA expression of oct2 and mate1 was observed due to 24 h CS, which was 
attenuated by both CS-20 or CS-50 and by CS-50, respectively. 
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Cold stored only (left kidneys) – mRNA expression studied in groups: control (no cold storage), CS (24 
h cold storage), CS-20 (24 h cold storage + 20 ng/mL treprostinil), CS-50 (24 h cold storage + 50 ng/mL 
treprostinil);  
Reperfused after CS (right kidneys) – mRNA expression studied after 2 h of reperfusion in groups: 
control (no cold storage), CS (24 h cold storage), CS-50 (24 h cold storage + 50 ng/mL treprostinil), CS-
50-R (24 h cold storage + 50 ng/mL treprostinil) + 10 ng/mL treprostinil added during reperfusion 
Figure 2.8. Expression of anionic transporters oat1 and mrp4 after cold storage or reperfusion after cold 
storage 
 68 
 
Cold stored only (left kidneys) – mRNA expression studied in groups: control (no cold storage), CS (24 
h cold storage), CS-20 (24 h cold storage + 20 ng/mL treprostinil), CS-50 (24 h cold storage + 50 ng/mL 
treprostinil);  
Reperfused after CS (right kidneys) – mRNA expression studied after 2 h of reperfusion in groups: 
control (no cold storage), CS (24 h cold storage), CS-50 (24 h cold storage + 50 ng/mL treprostinil), CS-
50-R (24 h cold storage + 50 ng/mL treprostinil) + 10 ng/mL treprostinil added during reperfusion 
Figure 2.9. Expression of cationic transporters oct2 and mate1 after cold storage or reperfusion after cold 
storage 
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2.5.4 Histopathology 
 
Figure 2.10. Sectional images of renal tissue representative of population after hematoxylin and eosin 
staining 
(from Left to right- CS only, CS + reperfusion and CS-20 + reperfusion groups) 
 
Histological evaluation revealed no damage with 24 h CS as well as CS-20 addition and 
they were both like fresh isolated kidneys. On the contrary, reperfusion of CS kidneys caused 
noticeable changes like tubular dilatation, epithelial blubs, sloughing, casts which was not 
prevented in CS-20 kidneys, as shown in Figure 2.10. 
2.6 DISCUSSION 
In this study, the protective effects of treprostinil on kidneys exposed to cold ischemia and 
reperfusion was evaluated using an isolated rat kidney perfusion system along with histology and 
analysis of selected transporter genes. The isolated kidney model is well established to study 
glomerular filtration, tubular secretion or the reabsorption function of kidneys, using various 
substrate compounds or under various experimental conditions. In our model, the cold stored 
kidneys were rewarmed by acellular perfusion under constant pressure which enabled easy urine 
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collection and simultaneous estimation of renal clearance for inulin, PAH and metformin, that 
represented filtration, anionic and cationic tubular secretion functions, respectively. 
Results from the perfusion of fresh control kidneys for 2 hours, indicated stable renal function with 
good clearance of inulin (glomerular filtration) or PAH and metformin (tubular function) in 
addition to a stable urine flow, for the entire study duration. The values for tubular reabsorption of 
glucose and sodium indicated good viability of the control kidneys. Further the tubular secretion 
of marker compounds, PAH and metformin was also measured. 
In contrast, a sub-optimal renal function was observed in 24 h cold stored kidneys that were 
re-perfused, under conditions identical to control kidneys. The constant pressure perfusion resulted 
in significantly lower perfusate flow for all the cold stored kidneys, indicative of a higher resistance 
within the renal system. A 10-40 % range in drop of perfusate flow however resulted in a greater 
than 80% drop in the glomerular filtration of CS kidneys, thereby decreasing their ratio (the 
filtration fraction). Cold storage and reperfusion are in fact sub-divided into four components, 
namely, ischemia with hypothermia in earlier part  followed by rewarming with reperfusion 
(acellular), as described earlier173.  Cold storage per se with hypoxia of kidney has been shown to 
induce the release of vasoconstrictors like angiotensin II and thromboxane174,175 in addition to 
mechanical constriction of the peritubular capillaries and the vasa recta176. These factors could 
result in an increase of vascular resistance during reperfusion resulting in a drop of GFR, but it is 
further decreased on reperfusion, due to the tubular glomerular feedback activated by high Na+ 
delivery to the macula densa176,177. 
Apart from the GFR, the tubular function of CS kidneys also showed a severe compromise 
in reabsorption of sodium and glucose as well as a decrease in tubular secretion of PAH and 
metformin.  The decrease in energy-dependent tubular ion transporter functions are indicative of 
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deficiency in the availability and synthesis of ATP178. Cold storage can perturbate osmotic balance 
and aerobic metabolism resulting in many downstream effects on kidney. In particular, the 
disturbance of ATPase dependent ion homeostasis during cold ischemia have been linked to 
intracellular calcium and iron overload163,179,180, leading to opening of permeability transition pore 
and mitochondrial swelling163,173. Reperfusion of CS kidneys has been shown to result in a rapid 
loss of adenine nucleotide content combined with loss in ATP re-synthesis due to mitochondrial 
swelling181. 
Histology of CS kidneys did not indicate lack of viability or injury, however the reperfused 
kidneys showed significant histological damages. These observations could be indicative of the 
damaging effects by reperfusion that are exacerbated after 24 hours of cold storage. Even in the 
absence of leukocytes during acellular reperfusion, oxygen free radicals can be produced from 
endothelial cells in kidney vessels176,182 . The oxygen radicals can mediate cytotoxic actions 
including lipid peroxidation, protein oxidation, DNA damage,  apoptosis, mediate inflammatory 
pathways and cause changes in expression and function of renal drug transporters183. mRNA 
expression of selected transporter pairs was evaluated at end of 24 hours CS as well as 2 h 
reperfusion, respectively. Oat1/mrp4 for anion transport and oct2/mate1 for cationic transport were 
selected as they are involved in transport of marker compounds PAH and metformin, respectively.  
Cold storage alone showed significant upregulation in mRNA expression of oct2/mate1, as 
highlighted in an earlier study161. The reperfusion however, caused a significant increase in 
expression of oat1 transporter in CS kidneys. Though mRNA data represents increased expression 
values for oat1 at the end of 2-hour perfusion, it was observed that the same kidneys showed 
severely impaired transport of PAH, during functional evaluation. Hence, the increased expression 
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of oat1 could be indicative of the regulatory response to mitigate the cold ischemia reperfusion 
mediated damage in CS kidneys. 
Addition of treprostinil to storage solution at 20 ng/mL (CS-20) was associated with a 
modest but statistically insignificant improvement in GFR but a significant increase in urine flow 
compared to CS kidneys without addition of drug or CS kidneys exposed to higher concentrations 
of the drug. Notably CS-20 also increased the filtration fraction compared to all other treated or 
untreated CS kidneys, because CS-20 kidneys had the highest GFR in presence of lower perfusate 
flow per gram of kidney. A corresponding trend was also observed in the improvement of anionic 
and cationic tubular secretion with an increased renal clearance for PAH and metformin by the re-
perfused CS-20 kidneys. The renal medulla can produce both thromboxane and prostacyclin, 
however during reperfusion and hypoxia, the former is favored resulting in increased 
vasoconstriction176. Treprostinil, a PGI2 analogue can mimic endothelium derived prostacyclins 
in producing cAMP mediated vasodilation and restore the balance in these eicosanoids during 
reperfusion. Further, by promoting cAMP mediated efflux of Ca2+ during ischemia reperfusion, 
treprostinil may ameliorate disruption in ion homeostasis and prevent ATP depletion53,184.  
Reperfusion induced increase in oat1 expression of CS kidneys was significantly prevented by 
both treprostinil addition to CS only and CS plus reperfusion. Even the CS induced increase in 
oct2/mate1 transporter expression was significantly reduced in kidneys stored with treprostinil. 
Even with addition of treprostinil to storage solution, a modest but statistically insignificant 
improvement was evident in functional evaluations when compared to kidneys stored without 
drug. Further, storage with treprostinil also negates cold ischemia reperfusion induced changes in 
the examined transporters.  Addition of treprostinil to reperfusion and storage showed similar 
beneficial effects on mRNA expression, however it drastically affected glomerular and tubular 
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function without any impact on perfusate flow. This observation might be linked to a previous 
report showing a decrease in filtration coefficient of kidneys (kf) by direct infusion of PGI2. This 
decrease in kf was shown to be mediated by Angiotensin II induced mesangial cell contraction 
leading to a decrease in filtration fraction and GFR185. Direct PGI2 infusion to kidneys can also 
stimulate release of renin that leads to angiotensin II mediated decrease in GFR186.  In this ex vivo 
setting, a higher exposure to treprostinil by addition to both storage and reperfusion in isolated 
kidney perfusion was counterintuitive by failing to show any advantage and points towards the 
need to select and optimize the time of addition as well as the concentration. 
Though the isolated perfused kidney with cell free oxygenated medium supports kidney function, 
it failed to revive the cold stored kidneys, as unlike an in vivo setting, this model does not use 
blood for reperfusion. Hence, long-term evaluation of potential improvements associated with 
changes in protein expression or activity with treprostinil treatment, is also not possible using this 
ex-vivo model. Further examination of efficacy in a syngeneic renal transplant model might permit 
a longer follow-up and provide a more conclusive evidence on beneficial effects of treprostinil. 
Results of this study indicated the impact of 24 h CS and reperfusion on kidneys and treprostinil 
addition to CS improved filtration fraction as well as urine flow and a trend to improve the anionic 
and cationic tubular secretion as well as a protective effect on the mRNA expression of selected 
drug transporters. An extension of these observations using mRNA expression was conducted by 
investigating a comprehensive panel of genes and including a prolonged duration of CS for 72 h 
and will be presented in chapter 3.0. 
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3.0  ALTERATIONS IN GENE EXPRESSION OF ISOLATED RAT KIDNEYS 
FOLLOWING COLD ISCHEMIA AND WARM REPERFUSION INJURY 
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3.1 ABSTRACT 
Ischemia-reperfusion (IR) is an inevitable consequence of renal transplantation. Prolonged 
duration of cold storage (CS) and warm reperfusion can be detrimental to post-transplant graft 
function and may also have unique effects on gene expression of kidneys. The purpose of this 
study was twofold: a) to determine alterations in the expression of  important gene targets in kidney 
following 24 and 72 h of CS and after reperfusion following 24 h CS and b) to determine if 
treprostinil addition to cold storage (50 ng/mL) and reperfusion (10 ng/mL) could mitigate any of 
the unfavorable changes in gene expression associated with cold ischemia and warm reperfusion 
injury.  Gene expression in cold stored or reperfused rat kidneys were quantified with a custom 
codeset of 52 selected gene targets using Nanostring ncounter® gene expression platform. 
Differential expression versus respective blank control kidneys were reported after statistical 
significance using t-test with FDR (p<0.05). CS for 72 h significantly upregulated cox-2 
expression that was attenuated by addition of treprostinil. Perfused blank kidneys as well as the 
reperfused 24 h CS kidneys, all showed a significant upregulation in the expression of genes for 
Nfk-beta, Tnf-alpha, Il-1beta, Cxcl-10, Il-6, Il-8, Mcp-1, kim-1 and cox-2.  The differentially 
expressed genes in reperfused 24 h CS kidneys were the transporter nhe3, MnSOD, Vitamin D 
receptor, which were downregulated, and ischemia reperfusion inducible protein (irip) that was 
upregulated, indicating IR induced injury. Treprostinil added to both storage and reperfusion 
attenuated the differential expression (DE) in all the four genes while addition to storage alone 
attenuated the DE of nhe3 and irip genes only. Results showed no major effect of CS until 72 h 
CS on the expression of selected genes whereas warm reperfusion for 2 h induced pronounced 
changes in gene expression of isolated kidneys. Treprostinil addition to storage and reperfusion 
showed protection against IR induced changes in select gene expression.   
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3.2 INTRODUCTION 
Renal transplantation involves a set of procedures in transfer of the kidney from the donor 
to the recipient, resulting in an ischemic phase (cold ischemia and warm reperfusion injury). To 
minimize and prevent any deterioration due to warm ischemia, kidneys are mostly stored on ice 
(cold ischemia) until surgical implantation into the recipient. Warm reperfusion of the kidney with 
recipient blood results in the ischemia-reperfusion (IR) effects, which has been inevitable in every 
transplanted kidney. The IR effect on grafts is of much research interest and therapeutic importance 
as it could impact the post-transplant function of the kidney. During organ transplant, 
reoxygenation initiates production of reactive oxygen species in the hypoxic, ATP depleted kidney 
and activates a profound inflammatory response39. The nuclear transcription factors such as NF-
κB are expressed in the resident renal cells including endothelium and tubular cells. During IR,  
NF-κB  can activate the nucleus to produce and sustain a variety of inflammatory mediators such 
as chemokines, cytokines and further signal the migration of immune cells such as macrophages 
and neutrophils. The infiltrating immune cells can have immediate direct cytotoxic effects on the 
renal tissue but over a long term,  probably play a major role in tissue repair187. The renal tubular 
cells are most sensitive to oxidative and inflammatory changes with a consequent downregulation 
of several transport proteins after IR38,188. Hence the net effect of IR on renal filtration as well as 
tubular secretion function has been associated with clinical consequences such as primary non 
function or delayed graft function, acute rejection and interstitial fibrosis of the graft38.  Though 
renal injury after IR is an additive effect due to warm, cold ischemia and reperfusion, the individual 
cellular events during each are shown to differ40, with unique opportunities for therapeutic 
interventions. The effects of IR have been widely studied, but clinically the contribution by cold 
storage or reperfusion is difficult to be isolated and has been rarely addressed. Previous reports 
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suggest a prolonged cold storage time to increase incidence of delayed graft function189,190, 
presence of interstitial fibrosis and tubular atrophy190. During the seemingly quiescent phase of 
cold storage on ice (4°C), a slow metabolism and utilization of ATP is still ongoing at 
approximately 5% of the baseline191, leading to a gradual depletion. The mitochondrial injury 
during CS and compromised electron transport are speculated to produce reactive oxygen species. 
Studies have revealed alteration in the expression of individual genes like endothelin-1192 and 
icam-1193 during CS, that are further hypothesized to increase vasoconstriction or immune cell 
migration during reperfusion. Apart from the scarce reports on individual genes, a systematic 
expression analysis of multiple genes, that may indicate transcriptional changes during prolonged 
duration of CS of kidney, is lacking.  We proposed to utilize the quantitative determination of gene 
expression for comparative analysis of normal versus kidney tissue exposed to individual events 
of CS or perfusion or reperfusion after CS. Treprostinil, a stable PGI2 analogue was also evaluated 
by addition during cold storage or both during storage and reperfusion. Treprostinil had previously 
improved outcomes in hepatic rat transplant models53 and has favorable pharmacology like 
endothelium relaxing effects, anti-inflammatory effects194 and ability to activate PPAR-gamma 
receptors 195,196. Consequent to lack of renal functional improvement by treprostinil in the short-
term ex-vivo model, molecular effects of the drug are examined to guide a change in concentration 
or evaluation with an in vivo transplant model. Herein, it is hypothesized that prolonged cold 
storage and reperfusion may alter the expression of renal enzymes and transporters and 
pharmacologic manipulation by addition of treprostinil can show benefit against the storage or 
reperfusion induced alterations in gene expression. The relation between duration of cold storage, 
reperfusion and expression of multiple genes associated with renal function after cold 
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ischemia/reperfusion, such as mediators of inflammation and repair, receptors, enzymes and 
transporters were examined with a Nanostring assay. 
3.3 MATERIALS  
3.3.1 Chemicals 
QIAshredder and RNeasy Plus mini kits were purchased from QIAGEN (Hilden, 
Germany). Custom codeset for nCounter® assays and nCounter Master Kit was purchased from 
NanoString Technologies (Seattle, WA, USA). Qubit RNA BR assay kit, RNAse free reagents and 
plastic were purchased from Invitrogen of ThermoFischer Scientific (Waltham, MA, USA). β-
Mercaptoethanol was purchased from Millipore sigma (MO, USA). Remodulin® vials containing 
20 mL of 1mg/mL was kindly provided by the manufacturer, United Therapeutics Corporation 
(Silver Spring, MD). 
3.4 METHODS  
3.4.1 Animals and grouping 
Kidneys were isolated from male Sprague Dawley rats and were either cold stored (CS) or 
perfused for 2 h after cold storage, as described previously in Chapter 2. In addition, three groups 
of male rats (n=4 each) were assigned to a prolonged duration of cold storage (4° C for 72 h), with 
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or without addition of treprostinil and the third group served as naïve control. The experimental 
design is elaborated below. 
3.4.2 Experimental design 
3.4.2.1 Cold storage followed with reperfusion 
In brief, right kidneys were cannulated, flushed with cold UW solution and isolated along 
with the ureter for storage in 30 mL of cold (4°C) University of Wisconsin (UW) solution. The 
cannula was used for reperfusion of kidney after CS. The reperfusion was at 37°C for 2 h using an 
oxygenated acellular buffer solution, as described earlier in chapter 2. The right kidneys of control 
group were perfused immediately without any CS. At the end of perfusion, kidneys were 
immediately flash frozen in liquid N2 and stored at -80°C, until extraction of mRNA. 
3.4.2.2 Cold storage only 
The left kidneys were not cannulated but only flushed to remove blood followed by 
flushing with cold UW solution and then stored alongside the corresponding right kidneys. At the 
end of designated cold storage time, kidneys were flash frozen in liquid N2 and stored at -80°C, 
until extraction of mRNA. The left kidneys of control group (fresh blank controls) were flushed 
with saline to remove blood, immediately flash frozen in liquid N2 and stored at -80°C, until 
extraction of mRNA. 
A total of 47 kidneys were assigned to 10 different groups as below: 
CS only: (n=5 each) 
Group 1:  Control -no CS – blank controls 
Group 2:  24 h CS 
Group 3:  24 h CS with treprostinil (50 ng/mL) 
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CS with reperfusion: (n=5 each) 
Group 4:  Control- no CS only 2 h perfusion – perfused controls 
Group 5:  24 h CS followed by 2 h perfusion 
Group 6:  24 h CS with treprostinil (50 ng/mL) followed by 2 h perfusion 
Group 7:  24 h CS with treprostinil (50 ng/mL) followed by 2 h perfusion with treprostinil (10 
ng/mL) 
 
CS only (longer duration): (n=4 each) 
Group 8:  Control -no CS – blank controls 
Group 9:  72 h CS  
Group 10:  72 h CS with treprostinil (50 ng/mL) 
 
3.4.3 Extraction of mRNA 
The extraction and purification of mRNA was performed as per the manufacturer’s 
protocol. Briefly, a section of frozen kidney tissue (approximately 30 mg) was placed on ice 
without thawing. About 600 µl of Buffer RLT (with β-Mercaptoethanol) was added to the solid 
tissue in a clean tube followed by tissue disruption using a rotor stator homogenizer. The lysate 
was transferred to a QIA shredder tube and debris free tissue homogenate was obtained after 
centrifugation at maximum speed for 2 minutes. The kidney homogenate was mixed with an equal 
volume of 70% v/v ethanol and transferred to a RNeasy spin column and centrifuged for 15 
seconds at > 10,000 rpm. Further 3 steps were followed as below, to purify the RNA that was now 
bound to the spin column. 1. Addition of 700 µl RW1 buffer (15 seconds at >10,000 rpm) 2. 
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Addition of 500μL RPE buffer (15 seconds at >10,000 rpm) and 3. Addition of 500μL RPE buffer 
(2 minutes at >10,000 rpm). mRNA was eluted by addition of 30 µl of RNase-free water, 
equilibration for 1 minute followed by centrifugation (1 minute at >10,000 rpm). The yield of 
mRNA was obtained by quantification of 1 µl of solution with a NanoDrop™ 2000c 
Spectrophotometer (ThermoFisher, US). Further confirmation of yield with purity was verified 
with Qubit® RNA BR assay kit in a Qubit® 2.0 fluorometer (Life technologies, ThermoFisher, US). 
3.4.4 Design of custom codeset (Nanostring) 
A custom nCounter® assay codeset (Nanostring Technologies, WA, US) was initially 
designed with gene targets that were preidentified for quantitative assessment of expression in rat 
kidneys. These nCounter® assays are custom designed to provide a sensitive, reproducible, and 
direct method for detection of up to 800 gene targets in a single sample well, using molecular 
barcodes without the need for amplification of mRNA by reverse transcription. Some of the 
advantages of nCounter® technology include the ability to detect expression of gene targets in very 
low mRNA concentrations (0.1fM per copy per cell)197, as well as ability to quantify expression 
despite significant degradation198,199. The custom codeset was developed with 48-wells each 
containing 57 preidentified gene targets that included 5 housekeeping genes (for correcting sample 
to sample variability in amount of mRNA used and for different degradation states), as listed in 
Table 3.1. The gene targets included important basolateral and luminal drug transporters, cyp, ugt 
enzymes and prostacyclin receptors that are endogenously expressed in rat kidney, along with 
targets like chemokines, cytokines and mediators of inflammation that show increased expression 
during ischemia and reperfusion. 
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Table 3.1. Details of target genes included in the Nanostring® custom codeset 
Target class Description 
HUGO 
gene 
name 
Accession 
(position) 
Tm 
CP 
Tm 
RP 
Total 
Isofor
ms 
# 
Not 
Hit 
Anti-oxidant 
superoxide dismutase 1 (CuSOD) Sod1 NM_017050.1 (191-290) 82 79 1 0 
superoxide dismutase 2 (MnSOD) Sod2 NM_017051.2 (1566-1665) 82 81 1 0 
superoxide dismutase 3 (extracellular sod3) Sod3 NM_012880.1 (191-290) 83 83 2 0 
BL 
Transporters  
ATPase Na+/K+ transporting subunit alpha 1 
(Nakatpase) Atp1a1 
NM_012504.1 
(1886-1985) 82 80 1 0 
solute carrier family 13 member 3 (nadc3) Slc13a3 NM_022866.2 (2186-2285) 83 79 1 0 
solute carrier family 22 member 2 (oct2) Slc22a2 NM_031584.1 (746-845) 79 83 1 0 
solute carrier family 22 member 6 (oat1) Slc22a6 NM_017224.2 (785-884) 79 82 2 0 
solute carrier family 22 member 8 (oat3) Slc22a8 NM_031332.1 (1175-1274) 78 82 2 0 
solute carrier family 2 member 2 (Glut-2) Slc2a2 NM_012879.2 (101-200) 79 80 2 0 
solute carrier family 9 member A3 (nhe3) Slc9a3 NM_012654.1 (3871-3970) 83 81 2 0 
Chemokines  
C-C motif chemokine ligand 2 (MCP-1) Ccl2 NM_031530.1 (191-290) 82 79 1 0 
C-X-C motif chemokine ligand 1 (IL8) Cxcl1 NM_030845.1 (606-705) 83 80 1 0 
interleukin 12B (IL12) Il12b NM_022611.1 (365-464) 83 83 2 0 
Cytokines 
C-X-C motif chemokine ligand 10 (CXCL-10) Cxcl10 NM_139089.1 (586-685) 82 81 1 0 
interferon gamma (IFN-gamma) Ifng NM_138880.2 (187-286) 80 82 1 0 
interleukin 10 (IL10) Il10 NM_012854.2 (186-285) 81 79 3 0 
interleukin 1 beta (IL-1-beta) Il1b NM_031512.1 (441-540) 80 81 1 0 
interleukin 2 (IL2) Il2 NM_053836.1 (6-105) 83 81 1 0 
interleukin 6 (IL6) Il6 NM_012589.1 (56-155) 79 83 1 0 
nuclear factor kappa B subunit 1 (NFK-beta) Nfkb1 XM_342346.3 (3561-3660) 83 82 3 0 
Tumor necrosis factor (TNF-alpha) Tnf NM_012675.2 (306-405) 82 79 1 0 
Enzymes 
(UGT) 
UDP glucuronosyltransferase family 1 member 
A1 (ugt-1a1) Ugt1a1 
NM_012683.2 
(795-894) 79 82 1 0 
UDP glucuronosyltransferase family 1 member 
A6 (ugt-1a6) Ugt1a6 
NM_001039691.1 
(791-890) 80 82 2 0 
UDP glucuronosyltransferase 2 family, 
polypeptide B1 (ugt-2b1) Ugt2b1 
NM_173295.1 
(1504-1603) 76 78 1 0 
Enzymes 
(Vitamin D) 
cytochrome P450, family 24, subfamily a, 
polypeptide 1 (cyp24) Cyp24a1 
NM_201635.2 
(817-916) 82 82 1 0 
cytochrome P450, family 27, subfamily b, 
polypeptide 1 (cyp27b1) Cyp27b1 
NM_053763.1 
(2149-2248) 79 79 2 0 
Housekeeping 
actin, beta (Actin B) Actb NM_031144.2 (20-119) 83 83 1 0 
glyceraldehyde-3-phosphate dehydrogenase 
(gapd) Gapdh 
NM_017008.2 
(851-950) 82 82 2 0 
mitogen activated protein kinase 14 (mapk14) Mapk14 NM_031020.2 (738-837) 84 85 3 0 
Phosphoglycerate kinase 1 (pgk1) Pgk1 NM_053291.3 (1566-1665) 80 81 1 0 
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Target class Description 
HUGO 
gene 
name 
Accession 
(position) 
Tm 
CP 
Tm 
RP 
Total 
Isofor
ms 
# 
Not 
Hit 
Ring finger protein 1 (ring1) Ring1 NM_212549.2 (345-444) 82 84 2 0 
Luminal 
Transporters  
ATP binding cassette subfamily C member 4 
(mrp4) Abcc4 
NM_133411.1 
(2626-2725) 78 83 2 0 
ATP binding cassette subfamily G member 2 
(bcrp) Abcg2 
NM_181381.2 
(1027-1126) 83 79 7 0 
Multidrug resistance protein 1 (mdr1a) Abcb1 NM_001169152.1 (1971-2070) 79 83 1 0 
solute carrier family 13 member 2 (nadc1) Slc13a2 NM_031746.1 (1641-1740) 82 81 3 0 
solute carrier family 15 member 1 (pept1) Slc15a1 NM_001079838.1 (343-442) 82 78 3 0 
solute carrier family 15 member 2 (pept2) Slc15a2 NM_031672.1 (931-1030) 83 79 1 0 
solute carrier family 16 member 1 (mct1) Slc16a1 NM_012716.1 (1096-1195) 81 79 2 0 
solute carrier family 22 member 12 (urat1) Slc22a12 NM_001034943.1 (1277-1376) 82 83 3 0 
solute carrier family 47 member 1 (mate1) Slc47a1 NM_001014118.2 (1643-1742) 79 84 2 0 
solute carrier family 47 member 2 (mate-2k) Slc47a2 NM_001191920.1 (1115-1214) 81 78 2 1
#  
Solute carrier family 5 member 2 (SGLT-2) Slc5a2 NM_022590.2 (605-704) 81 83 1 0 
Inflammation 
angiotensinogen (agt) Agt NM_134432.2 (874-973) 85 85 2 0 
hepatitis A virus cellular receptor 1 (kim-1) Havcr1 NM_173149.1 (1186-1285) 82 81 5 0 
matrix metallopeptidase 2 (mmp-2) Mmp2 NM_031054.2 (2436-2535) 83 83 1 0 
matrix metallopeptidase 9 (mmp-9) Mmp9 NM_031055.1 (2566-2665) 79 78 1 0 
prostaglandin-endoperoxide synthase 1 (cox-1) Ptgs1 NM_017043.3 (1881-1980) 81 83 2 0 
prostaglandin-endoperoxide synthase 2 (cox-2) Ptgs2 NM_017232.3 (1606-1705) 80 78 1 0 
receptors 
Peroxisome proliferator activated receptor 
alpha (PPAR-alpha) Ppara 
NM_013196.1 
(1011-1110) 80 78 9 0 
Peroxisome proliferator-activated receptor 
gamma (PPAR-gamma) Pparg 
NM_013124.1 
(1291-1390) 79 82 4 0 
Prostaglandin D2 receptor-like Ptgdr NM_001135164.1 (286-385) 86 83 1 0 
Prostaglandin E receptor 2 Ptger2 NM_031088.1 (289-388) 83 84 2 0 
Prostaglandin I2 receptor Ptgir NM_001077644.1 (719-818) 84 83 1 0 
toll-like receptor 4 Tlr4 NM_019178.1 (2146-2245) 78 79 1 0 
Vitamin D receptor Vdr NM_017058.1 (1541-1640) 82 84 1 0 
Regulator of 
transporter 
expression 
hypoxia inducible factor 1 subunit alpha (HIF-1 
alpha) Hif1a 
NM_024359.1 
(363-462) 81 79 5 0 
yrdC N(6)-threonyl carbamoyl transferase 
domain containing protein 
(Ischemic reperfusion inducible protein) 
Yrdc 
(irip) NM_175604.2 (711-810) 
83 83 1 0 
# XM_017597448.1 
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3.4.5 Nanostring nCounter® assay 
nCounter® Master kit was used to process, and load 100 ng of RNA obtained from kidney 
tissues (n=47) onto the custom codeset using manufacturer's instructions. nCounter® assays were 
processed on a fully automated PrepStation and data was collected and tabulated by the nCounter® 
Digital Analyzer at the Genomics Research Core, University of Pittsburgh, Pittsburgh, PA. 
3.4.6 Internal and external controls 
The technical performance of gene expression assay for each sample (each well) was 
assessed by the controls developed and tested by the External RNA Control Consortium (ERCC). 
The reporter probes designed against these ERCC transcript sequences are pre-mixed into every 
well of the codeset. Hence, each sample (well) has 14 internal controls tested by ERCC, that 
include 6 positive internal controls at varying concentrations (128 fM, 32 fM, 8 fM, 2 fM, 0.5 fM, 
and 0.125 fM ) and 8 negative internal controls200. The range of internal concentrations 
corresponds to the expression levels of most mRNAs of interest present in 100 ng of total 
RNA200,201. Apart from the internal control, each well in this custom codeset was designed with 5 
external controls (internal reference genes) that are otherwise called housekeeping genes (pgk1, 
ring1, actinβ, gapd and mapk14). The expression of five housekeeping genes that were chosen in 
this assay were used as internal reference for every sample, to adjust for the differences arising 
from amount and quality of mRNA across the samples. Normalization of target gene counts with 
the combined geometric means of these internal reference gene counts, permit comparison of 
observed gene expression levels when starting amounts for mRNA is not the same for samples and 
(or) even between samples with intact versus degraded mRNA. 
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3.4.7 Data Analysis 
The nsolver® software (NanoString Technologies) was used for stepwise processing and 
data analysis of the results from nanostring ncounter® assays. The RCC files containing results are 
imported into nsovler and individual samples were visually inspected for any quality control flags. 
All samples selected for further data analysis were subjected to the nsolver® software-guided steps 
and described as follows. Expression counts of negative internal controls in each well were 
subtracted from the raw counts for each gene target in the corresponding sample lane to eliminate 
the non-specific background. Variability unrelated to the samples was eliminated by normalizing 
expression counts from each lane with the geometric mean of expression counts for the 
corresponding internal positive controls. Variability related to samples was minimized by 
calculating the average geometric means of housekeeping genes across all lanes and dividing this 
average by the geometric mean in each sample lane to get a lane-specific normalization factor. The 
normalized gene expression counts for each sample were finally obtained by multiplying the count 
of each gene by the lane (sample) specific factor. The nsolver® software was further used to build 
ratios in expression of every target gene across different treatment groups by using the normalized 
counts for that gene.  
Group 1 versus group 2 = ratio =      geometric mean of normalized gene count in group 1  
geometric mean of normalized gene count in group 2 
The differential expression of gene was finally expressed in fold-changes with 95% confidence 
interval, where a ratio >1 corresponds to the fold-change whereas, fold-change = (-1/ratio) when 
ratio <1.  The positive and negative fold-changes were considered as relative over-expression and 
under-expression of the target gene, respectively. 
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Statistical testing was done on normalized log2 counts of each gene (log2 counts have 
normal distribution) by nsolver® using an in-built t-test with false discovery rate (FDR). nSolver 
performs a two-tailed t-test on the normalized log2 counts that assumes unequal variance and 
provides a p value. nSolver uses the Benjamini-Yekutieli procedure to calculate the FDR from the 
p-values returned by the t-test200. The 95 % CI for fold-change is also estimated from the 
distribution of the t-statistic calculated using the Welch-Satterthwaite equation. A p-value of <0.05 
was considered as statistically significant difference in expression of target gene and the gene was 
reported to be differentially expressed between the compared groups. 
3.5 RESULTS  
3.5.1 Quality controls 
The positive controls across all the 47 sample lanes, showed linear and consistent response 
without significant variability. As summarized in Figure 3.1, the approximately 1000-fold range 
(0.125 -128 fM) in positive control concentrations produced a matching linear response 
corresponding to a range of 10 units on the log2 scale. A positive control normalization flag was 
not observed in any of sample lane and was indicative of satisfactory assay efficiency across all 
sample lanes. The response of the lowest positive control was considered below the limit of 
detection of the system. Hence, response for eight negative controls across all sample lanes were 
below the limit of detection, as shown in Figure 3.1. This indicated that negative controls did not 
hybridize to any of targets within all samples, thus conclusively ruling out any non-specific binding 
of probes in the analyzed samples. 
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*n=47 
Figure 3.1. Assay performance for positive and negative controls 
3.5.2 Internal reference genes 
All the five housekeeping genes were adequately detectable and showed a relatively stable 
expression across all the samples. As shown in Figure 3.2, the expression of housekeeping genes 
was separable as either high (actin beta, gapd), medium (pgk1) or low expression (mapk14, ring1) 
categories. Hence, the chosen housekeeping genes were satisfactory candidates for adequate 
minimization of sample variability, as they were representative of all genes in this assay, across 
the low to high expression range.  
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Figure 3.2. Expression of housekeeping genes (n=47 samples) 
3.5.3 Expression of select gene targets in control (blank) rat kidneys 
Blank frozen kidneys were used as controls for evaluating effects of 24 and 72 h cold 
storage on gene expression of selected targets. Results from blank tissues are shown as violin plots 
of normalized log 2 counts and are representative of the median and distribution in basal expression 
levels for the selected gene targets in 8-week-old Sprague Dawley rat kidneys. 
a) Renal drug transporters: 
Figure 3.3 shows the pattern in renal gene expression for seven basolateral and eleven 
apical (luminal) transporters. The Na/K-ATPase and glut-2 showed the highest and lowest relative 
expressions, respectively while oat-3 showed a higher range in expression count values when 
compared with other basolateral transporters. On the luminal side, mate1 and mate2k showed the 
highest and lowest relative expression. Pept1 and pgp had lower relative expression compared to 
other transporters that were evaluated, with the former showing a wide distribution in expression 
while the latter showed a very precise range for expression. 
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b) Renal cyp, antioxidant and ugt enzymes: 
Figure 3.4 shows comparative expression levels in log2 counts for the chosen enzyme 
targets. Ugt2b1 had relatively poor expression in comparison to ugt1a1 and ugt1a6. Similarly, 
cyp27b1 had very low expression compared to cyp 24, while all the three antioxidant superoxide 
dismutase enzymes showed a relatively higher expression.  
c) Cytokines, chemokines, markers of injury and inflammation: 
As shown in Figures 3.5 and 3.6, the naïve kidneys showed a lower expression of target 
genes that are activated prior to or following inflammation and injury to an organ. The only 
exceptions with a moderately higher expression than other targets in this category were the 
cytokine Nfk-beta and hypoxia inducible factor-1.
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Figure 3.3. Relative expression of basolateral and apical transporters in blank control rat kidneys 
 
 
Figure 3.4. Relative expression of select antioxidant and metabolic enzymes in blank control rat kidneys 
 
(normalized log2 counts) (n=8) 
 
(normalized log2 counts) (n=8) 
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Figure 3.5. Relative expression of select markers for inflammation and injury in blank control rat kidneys  
 
Figure 3.6. Relative expression of select cytokines and chemokines in blank control rat kidneys 
 
(normalized log2 counts) (n=8) 
 
(normalized log2 counts) (n=8) 
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3.5.4 Effect of CS (24 and 72 h CS- with or without treprostinil addition) on the 
expression of gene targets in rat kidneys 
Results of gene expression were compared as fold changes (with 95% CI) between groups. 
Though the significance of fold-change was evaluated with FDR p-values, consideration was also 
given to the presence of an appreciable amount of gene target (at least > 100 counts) for the fold-
change to be meaningful. Table 3.2 compares the expression between groups 1, 2 and 3 
representing blank controls, 24 h CS and 24 h CS with 50 ng/mL of treprostinil, respectively. 
Overall, 24 h CS did gnot produce a statistically significant fold-change on expression of select 
target genes. A statistically significant upregulation in expression of bcrp and ugt1a1 genes was 
observed in 24 h CS with treprostinil addition when compared to controls. 
Table 3.2. Renal gene expression after 24 h of CS (with or without treprostinil (50 ng/mL)) versus blank control 
Class of 
gene 
Gene 
name 
24h-CS vs Ctrl p-
value 
24h-CS with 
treprostinil vs Ctrl p-
value Fold change 
(95 % CI) 
Fold change 
(95 % CI) 
BL 
Transporters 
Nakatpase 1.08 (0.9 to 1.3) 0.303 1.06 (0.9 to 1.2) 0.237 
Oct2 -1.06 (-0.8 to -1.4) 0.465 1.16 ( 0.7 to 1.9) 0.318 
Glut-2 1.25 (0.2 to 6.7) 0.689 1.19 (0.3 to 5.1) 0.756 
Oat3 1.28 (0.5 to 3.7) 0.541 -1.13 ( -0.2 to -5.6) 0.822 
Oat1 1.17 (0.5 to 3) 0.630 -1.07 ( -0.4 to -3) 0.848 
Nadc3 1.01 (0.5 to 1.9) 0.981 -1.03 ( -0.5 to -2) 0.919 
Luminal 
Transporters 
Bcrp 1.29 (1 to 1.7) 0.056 1.28 ( 1 to 1.6) 0.042 
Nadc1 1.27 (0.6 to 2.8) 0.431 1.32 ( 0.6 to 3) 0.387 
Abcb1 -1.07 (-0.6 to -2) 0.687 1.03 ( 0.9 to 1.2) 0.444 
Pept2 -1.11 (-0.8 to -1.5) 0.402 1.14 ( 0.7 to 1.8) 0.457 
Sglt-2 1.18 (0.4 to 3.2) 0.670 -1.26 (-0.4 to -3.8) 0.602 
Mct1 1.28 (0.5 to 3) 0.459 1.24 ( 0.3 to 5.2) 0.656 
Pept1 1.22 (0.3 to 5) 0.720 -1.26 ( -0.1 to -11.1) 0.756 
Mate1 1.02 (0.7 to 1.6) 0.899 1.02 ( 0.7 to 1.6) 0.888 
Urat1 -1.07 (-0.6 to -1.8) 0.728 -1.02 ( -0.6 to -1.8) 0.910 
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Class of 
gene 
Gene 
name 
24h-CS vs Ctrl p-
value 
24h-CS with 
treprostinil vs Ctrl p-
value Fold change 
(95 % CI) 
Fold change 
(95 % CI) 
Mrp4 -1.03 (-0.7 to -1.5) 0.838 -1.01 ( -0.7 to -1.4) 0.934 
Mate-2k 1.08 (0.3 to 4.2) 0.878 1.03 (0.3 to 3.6) 0.955 
Nhe3 -1.02 (-0.6 to -1.7) 0.921 -1.01 ( -0.6 to -1.7) 0.962 
Regulation 
of 
transporters  
Hif-1 alpha 1.04 (0.8 to 1.4) 0.671 1.14 ( 0.9 to 1.4) 0.191 
Irip 1.02 (0.8 to 1.3) 0.791 1.02 ( 0.8 to 1.3) 0.842 
Enzymes 
(UGT) 
Ugt-1a1 1.11 (0.7 to 1.7) 0.520 1.65 (1.1 to 2.5) 0.024 
Ugt-2b1 -1.01 (-0.3 to -3.7) 0.984 1.61 (0.5 to 4.9) 0.285 
Ugt-1a6 -1 (-0.6 to -1.8) 0.997 1.08 (0.6 to 1.9) 0.720 
Enzymes 
(vitamin D) 
Cyp27b1 1.55 (0.3 to 8.8) 0.475 1.6 (0.1 to 27.7) 0.628 
Cyp24 1.66 (0.3 to 9.1) 0.407 1.24 ( 0.3 to 5.5) 0.667 
 Ifn-gamma 1.21 (0.7 to 2.1) 0.366 -1.7 ( -1 to -2.9) 0.043 Cxcl-10 1.14 (0.5 to 2.6) 0.644 1.38 (0.9 to 2.1) 0.104 
Cytokines 
Tnf-alpha 1.34 (0.2 to 8.5) 0.642 1.94 ( 0.3 to 11.6) 0.352 
Il6 1.3 (0.1 to 20.4) 0.710 2.22 (0.1 to 46.2) 0.353 
Il10 1.53 (0.7 to 3.5) 0.216 1.61 (0.4 to 7.3) 0.378 
Il-1-beta 1.25 (0.6 to 2.6) 0.436 1.19 ( 0.6 to 2.3) 0.460 
Il2 1.96 (0.3 to 11.4) 0.299 1.31 (0.3 to 5) 0.603 
Nfk-beta 1.01 (0.8 to 1.3) 0.916 -1.02 ( -0.9 to -1.2) 0.689 
Chemokines 
Mcp-1 2.07 (0.7 to 6) 0.114 2.25 (0.9 to 5.8) 0.072 
Il12 1.76 (0.5 to 5.8) 0.215 1.55 (0.5 to 5.2) 0.358 
Il8 1.39 (0.4 to 4.5) 0.443 1.44 (0.5 to 4.4) 0.369 
Antioxidant 
Cu sod 1.31 (0.7 to 2.3) 0.218 1.31 ( 0.8 to 2.3) 0.211 
extracellular sod3 1.04 (0.4 to 2.5) 0.845 -1.14 (-0.4 to -3.1) 0.643 
Mn sod -1.11 (-1 to -1.3) 0.074 -1.02 ( -0.9 to -1.1) 0.644 
Inflammation 
Cox-2 1.36 (0.9 to 2.1) 0.108 1.7 (0.8 to 3.6) 0.085 
Kim-1 1.34 (0.5 to 3.5) 0.438 1.34 ( 0.6 to 2.8) 0.330 
Mmp-9 1.52 (0.3 to 8.4) 0.495 1.8 (0.2 to 19.1) 0.362 
Agt -1.22 (-0.9 to -1.7) 0.116 1.07 ( 0.9 to 1.3) 0.476 
Cox-1 -1 (-0.3 to -3.1) 0.993 1.26 (0.3 to 4.8) 0.661 
Mmp-2 -1.08 (-0.4 to -3) 0.776 1.03 (0.7 to 1.5) 0.852 
Receptors 
 
Pg I2 receptor 1.1 (0.5 to 2.5) 0.643 1.55 (0.9 to 2.6) 0.062 
Pg E receptor 2 1.17 (0.5 to 2.9) 0.644 1.51 (0.6 to 3.9) 0.278 
Pg receptor dp1 -1.04 (-0.3 to -3.1) 0.930 1.31 (0.4 to 4.2) 0.515 
Ppar-alpha -1.17 (-0.7 to -2) 0.459 -1.12 ( -0.6 to -2.1) 0.634 
Vit D receptor -1.13 (-0.5 to -2.8) 0.605 -1.04 (-0.8 to -1.4) 0.654 
Toll-like receptor 4 1.03 (0.2 to 4.7) 0.935 -1.03 (-0.7 to -1.4) 0.836 
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Class of 
gene 
Gene 
name 
24h-CS vs Ctrl p-
value 
24h-CS with 
treprostinil vs Ctrl p-
value Fold change 
(95 % CI) 
Fold change 
(95 % CI) 
Ppar-gamma -1.8 (-0.8 to -4.2) 0.114 1.04 ( 0.5 to 2.1) 0.859 
CI- Confidence Interval; significant differences are in bold font and p<0.05 after controlling for false discovery rate; 
genes with significant differences in fold-changes are highlighted in green (upregulated) or orange (downregulated) 
but genes with counts<100 are ignored; Pg- Prostaglandin; CS- Cold Storage 
Similarly, comparison of groups 8, 9 and 10 did not indicate any major influence by 72 h 
CS, indicated by lack of significant changes in expression (fold-change), as shown in Table 3.3. 
Only 2 genes showed a statistically significant fold-change in comparison to blank control, bcrp 
was downregulated in 72 h CS with treprostinil addition and cox-2 was upregulated in the 72 h CS 
groups, respectively. Figure 3.7 shows attenuation of increased renal expression in cox-2 after 72 
h CS with addition of treprostinil. 
Table 3.3. Renal gene expression after 72 h of CS (with or without treprostinil (50 ng/mL)) versus 
blank control 
Class of gene Gene name 
72h-CS vs Ctrl p-
value 
72h-CS with 
treprostinil vs Ctrl p-
value Fold change 
(95 % CI) 
Fold change 
(95 % CI) 
BL 
Transporters 
Oat1 1.13  (0.8 to 1.6) 0.295 -1.34 (-0.9 to -2.1) 0.120 
Nadc3 1.07  (1 to 1.2) 0.082 -1.07 (-0.7 to -1.6) 0.561 
Nakatpase 1.1  (0.9 to 1.4) 0.190 1.07 (0.8 to 1.4) 0.314 
Glut-2 -1.06  (-0.3 to -3.6) 0.855 -1.24 (-0.3 to -5.6) 0.593 
Oct2 1.31  (0.8 to 2.2) 0.184 1.34 (0.8 to 2.3) 0.164 
Oat3 -1.14  (-0.7 to -1.7) 0.403 -1.08 (-0.3 to -4) 0.825 
Luminal 
Transporters 
Bcrp -1.17  (-0.8 to -1.8) 0.211 -1.81 (1 to -3.2) 0.034 
Nadc1 1.02  (0.5 to 2) 0.928 -1.79 (-0.4 to -8.3) 0.246 
Pept2 1.08  (0.7 to 1.7) 0.615 -1.08 (-0.8 to -1.6) 0.532 
Mrp4 1.08  (0.9 to 1.3) 0.173 1.33 (0.7 to 2.5) 0.178 
Mate1 1.04  (0.9 to 1.2) 0.365 -1.16 (-0.6 to -2.1) 0.403 
Mate-2k -1.21  (-0.2 to -7.1) 0.686 1.32 (0.6 to 2.7) 0.288 
Urat1 1.02  (0.6 to 1.8) 0.918 1.21 (0.8 to 1.9) 0.252 
Pept1 -1.06  (-0.3 to -4) 0.905 -1.46 (-0.4 to -4.8) 0.372 
Sglt-2 1.07  (0.5 to 2.1) 0.783 1.28 (0.6 to 2.6) 0.346 
Abcb1 1.07  (0.6 to 1.9) 0.631 -1.01 (-0.4 to -2.6) 0.976 
Mct1 -1.6  (-0.3 to -9.1) 0.350 -1.78 (-0.5 to -7.1) 0.195 
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Class of gene Gene name 
72h-CS vs Ctrl p-
value 
72h-CS with 
treprostinil vs Ctrl p-
value Fold change 
(95 % CI) 
Fold change 
(95 % CI) 
Nhe3 1.03  (0.6 to 1.7) 0.854 1.04 (0.6 to 1.9) 0.817 
Regulation of 
transporter 
Irip -1.07  (-0.7 to -1.7) 0.665 1.2 (0.8 to 1.8) 0.222 
Hif-1 alpha 1.05  (0.8 to 1.5) 0.548 1.2 (0.7 to 2.2) 0.316 
Enzymes  
(UGT) 
Ugt-1a1 -1.05  (-0.7 to -1.6) 0.758 -1.78 (-0.6 to -5.3) 0.118 
Ugt-2b1 1.21  (0.6 to 2.3) 0.332 1.16 (0.4 to 3.3) 0.591 
Ugt-1a6 -1.08  (-0.7 to -1.6) 0.566 -1.33 (-1 to -1.8) 0.050 
Enzymes  
(vitamin D) 
Cyp24 1.01  (0.2 to 4.6) 0.981 -1.32 (-0.2 to -7.1) 0.635 
Cyp27b1 -1.07  (-0.4 to -2.8) 0.827 1.68 (0.7 to 4.2) 0.158 
 
Tnf-alpha 1.22  (0.6 to 2.7) 0.360 -1.45 (-0.6 to -3.7) 0.284 
Cxcl-10 1.26  (0.6 to 2.6) 0.283 -1.25 (-0.4 to -4.3) 0.507 
Cytokines 
 
 
 
Il10 -1.28  (-0.3 to -6.3) 0.543 -1.05 (-0.3 to -3.6) 0.905 
Ifn-gamma 1.29  (0.4 to 3.9) 0.423 1.8 (0.4 to 8.5) 0.243 
Il6 -1.12  (-0.4 to -3.2) 0.748 -1.73 (-0.1 to -33.3) 0.464 
Il2 -1.23  (-0.3 to -5.6) 0.692 -1.35 (-0.3 to -5.9) 0.479 
Il-1-beta 1.39  (0.4 to 4.7) 0.335 1.48 (0.7 to 3.3) 0.222 
Nfk-beta 1.06 (0.8 to 1.4) 0.479 1.16 (1 to 1.4) 0.056 
Chemokines 
Il12 2.03  (0.6 to 6.9) 0.158 1.15 (0.2 to 7.1) 0.758 
Mcp-1 -1.02  (-0.3 to -3.3) 0.969 -1.31 (0 to -50) 0.789 
Il8 -1.3  (-0.4 to -3.8) 0.411 -1.29 (-0.5 to -3.2) 0.351 
Anti-oxidant 
extracellular sod3 -1.23  (-0.6 to -2.5) 0.412 1.47 (0.7 to 3.2) 0.210 
Cu sod -1.27  (-0.8 to -2) 0.175 -1.7 (-0.5 to -6.3) 0.197 
Mn sod -1.13  (-0.9 to -1.4) 0.139 -1.08 (-0.9 to -1.3) 0.269 
Inflammation 
agt 1.09  (0.7 to 1.8) 0.598 -1.26 (-0.8 to -1.9) 0.160 
Mmp-9 1.34  (0.4 to 4.8) 0.504 -1.45 (-0.4 to -5.3) 0.298 
Cox-2 1.96  (1.1 to 3.6) 0.028 1.03 (0.3 to 3.9) 0.923 
Cox-1 1.57  (0.6 to 3.9) 0.208 -1.06 (-0.5 to -2.3) 0.812 
Kim-1 1.74  (0.5 to 6) 0.175 -1.32 (-0.2 to -8.3) 0.660 
Mmp-2 1.05  (0.7 to 1.6) 0.642 1.04 (0.7 to 1.6) 0.807 
Receptors 
Ppar-alpha -1.05  (-0.8 to -1.4) 0.631 1.07 (0.8 to 1.4) 0.480 
Pg E receptor 2 2.28  (0.2 to 24) 0.262 1.28 (0.1 to 16.5) 0.771 
Ppar-gamma 1.23  (0.8 to 2) 0.230 1.11 (0.7 to 1.8) 0.408 
Pg receptor dp1 1.27  (0.2 to 6.9) 0.598 1.44 (0.2 to 9.1) 0.459 
Pg I2 receptor 1.26  (0.4 to 4.6) 0.497 -1.03 (-0.1 to -7.1) 0.953 
Toll-like receptor 4 -1.13  (-0.7 to -1.9) 0.398 -1.11 (-0.4 to -3) 0.698 
Vit D receptor 1.04  (0.6 to 1.8) 0.809 1.03 (0.3 to 3.2) 0.914 
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CI- Confidence Interval; significant differences are in bold font and p<0.05 after controlling for false discovery rate; 
genes with significant differences in fold-changes are highlighted in green (upregulated) or orange (downregulated); 
Pg- Prostaglandin; CS- Cold Storage 
 
 
Figure 3.7. Cox-2 expression in rat kidneys after 72 h cold preservation  
Control- no cold storage; 72 h CS- cold storage for 72 h in UW solution; 72 h CS (Treprostinil)- cold storage for 72 
h in UW solution with 50 ng/mL treprostinil  (n=4/group) 
3.5.5 Effect of CS with reperfusion (24 h CS and 2 h reperfusion) on the expression of 
gene targets in rat kidneys 
In contrast to CS only, CS with reperfusion for 2 hours, showed higher fold-changes in 
expression of several target genes. The control group was perfused for 2 hours immediately after 
isolation and without any cold storage. Figure 3.8 illustrates only the most differentially expressed 
genes in perfused control group versus blank kidneys and is highlighted by a several-fold change 
in expression for cytokines like Cxcl-10, Nfk-beta, Il-6, Il-1-beta, Tnf-alpha, chemokines like 
Mcp-1 and Il-8 and injury markers like kim-1 and cox-2. An equivalent fold-increase in expression 
of these genes was also observed in kidneys reperfused after CS, except for Cxcl-10 and kim-1, 
 97 
that showed a significantly higher expression in the control perfusion group. Expression fold-
changes for additional genes in kidneys reperfused after 24 h CS (groups 5, 6 and 7) are compared 
against the control perfused kidneys in Table 3.4 and significant differences are summarized in 
Figure 3.9. In reperfused kidneys, there was a significant decrease in expression of nhe3, MnSOD 
and Vit D receptor and an increase in expression of the gene for ischemia reperfusion injury protein 
(Irip). Treprostinil during CS was found to significantly attenuate the increase in Irip and the 
decrease in nhe3 expression. Similar effects were observed with addition of treprostinil to both CS 
and reperfusion in addition to preventing the decrease in anti-oxidant MnSOD, Vdr and an increase 
in urat1 transporter expression. 
 
Figure 3.8. Differential expression of genes after isolated perfusion of fresh control rat kidneys (2 hours)
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Table 3.4. Renal gene expression following 2-hour reperfusion after 24 h of CS and with treprostinil addition to only storage or both storage and reperfusion 
versus control kidneys (perfused without CS) 
Class of gene Gene name 
24h-CS + 
Reperfusion 
 vs Ctrl perfusion 
p-
value 
24h-CS 
(treprostinil) + 
Reperfusion 
 vs Ctrl perfusion 
p-
value 
24h-CS + 
Reperfusion (both 
treprostinil) 
 vs Ctrl perfusion 
p-
value 
Fold change (CI) Fold change (CI) Fold change (CI) 
BL 
Transporters 
 
Glut-2 1.04 (0.4 to 2.7) 0.913 1.21 (0.5 to 3) 0.540 1.01 (0.4 to 2.8) 0.979 
Nadc3 -1.1 (-0.7 to -1.7) 0.566 -1.06 (-0.8 to -1.4) 0.652 -1.09 (-0.5 to -2.6) 0.685 
Nakatpase -1.35 (-0.7 to -2.5) 0.200 -1.1 (-0.8 to -1.5) 0.357 -1.11 (-0.8 to -1.6) 0.315 
Oat1 1 (0.5 to 2) 0.997 1.04 (0.6 to 2) 0.864 -1.2 (-0.4 to -3.6) 0.625 
Oat3 1.07 (0.5 to 2.4) 0.838 1.01 (0.6 to 1.6) 0.947 -1.15 (-0.5 to -2.6) 0.626 
Oct2 1.18 (0.7 to 2) 0.412 1.05 (0.5 to 2.3) 0.860 1.25 (0.8 to 1.9) 0.117 
Bcrp 1.61 (0.4 to 7) 0.411 1.65 (0.5 to 5.2) 0.250 1.45 (0.5 to 4.6) 0.374 
Luminal 
Transporters 
Mate-2k -1.31 (-0.3 to -6.3) 0.603 -1.93 (-0.5 to -8.3) 0.262 -1.02 (-0.1 to -7.1) 0.972 
Mate1 1.03 (0.5 to 2) 0.907 -1.04 (-0.7 to -1.6) 0.790 1.03 (0.6 to 1.7) 0.875 
Mct1 1.31 (0.5 to 3.3) 0.464 1.16 (0.4 to 3.2) 0.711 1.15 (0.4 to 3.6) 0.652 
Mrp4 -1.49 (-0.9 to -2.6) 0.104 -1.18 (-0.8 to -1.7) 0.254 -1.07 (-0.8 to -1.4) 0.516 
Nadc1 -1.32 (-0.3 to -5.3) 0.612 1.18 (0.3 to 4.3) 0.710 -1.18 (-0.2 to -5.9) 0.763 
Nhe3 -1.65 (0.9 to -2.4) 0.014 -1.13 (-0.7 to -1.7) 0.455 -1.54 (-0.6 to -3.8) 0.145 
Pept1 -1.05 (-0.5 to -2.4) 0.876 -1.36 (-0.6 to -3.1) 0.358 -1.44 (-0.4 to -4.8) 0.398 
Pept2 1.22 (0.6 to 2.4) 0.409 1.18 (0.5 to 2.8) 0.570 1.35 (0.9 to 2.1) 0.090 
Abcb1 -1.26 (-0.9 to -1.7) 0.079 -1.06 (-0.9 to -1.2) 0.379 -1.04 (-0.6 to -1.8) 0.783 
Sglt-2 -1.15 (-0.6 to -2.2) 0.539 -1.17 (-0.7 to -1.9) 0.350 -1.2 (-0.6 to -2.3) 0.343 
Urat1 1.22 (0.5 to 2.8) 0.493 1.14 (0.6 to 2.2) 0.557 1.56 (1.2 to 2.1) 0.013 
Regulation of 
transporter 
Hif-1alpha -1.04 (-0.7 to -1.6) 0.793 -1.27 (0.9 to -1.4) 0.004 -1.13 (-0.8 to -1.6) 0.265 
Irip 1.45 (1 to 2.2) 
 
0.046 1.13 (0.9 to 1.5) 0.276 1.2 (0.9 to 1.6) 0.129 
Cyp24 -1.9 (-0.5 to -6.7) 0.220 -1.27 (-0.5 to -3.6) 0.511 -1.21 (-0.3 to -4.8) 0.595 
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Class of gene Gene name 
24h-CS + 
Reperfusion 
 vs Ctrl perfusion 
p-
value 
24h-CS 
(treprostinil) + 
Reperfusion 
 vs Ctrl perfusion 
p-
value 
24h-CS + 
Reperfusion (both 
treprostinil) 
 vs Ctrl perfusion 
p-
value 
Fold change (CI) Fold change (CI) Fold change (CI) 
Enzymes 
(vitamin D) Cyp27b1 1.1 (0.8 to 1.5) 0.416 -1.13 (-0.8 to -1.5) 0.334 1.12 (0.7 to 1.9) 0.521 
Enzymes  
(UGT) 
Ugt-1a1 -1.06 (-0.5 to -2.1) 0.808 1.27 (0.7 to 2.4) 0.356 -1.02 (-0.4 to -2.4) 0.940 
Ugt-1a6 -1.17 (-0.4 to -3.3) 0.668 1.03 (0.3 to 3.5) 0.927 1.02 (0.3 to 3.4) 0.948 
Ugt-2b1 -1.36 (-0.6 to -3.2) 0.239 -1.3 (-0.6 to -2.9) 0.412 -1.79 (-0.7 to -4.8) 0.132 
Cytokines 
Cxcl-10 -5.8 (0.3 to -9.1) 0.000 -4.92 (0.5 to -11.1) 0.005 -2.65 (-0.4 to -16.7) 0.140 
Ifn-gamma -5.46 (0.8 to -25) 0.028 -8.91 (0.3 to -25) 0.003 -5.35 (-0.4 to -100) 0.105 
Il-1-beta 1.31 (0.8 to 2.2) 0.186 1.28 (0.6 to 2.9) 0.409 1.33 (0.5 to 3.4) 0.328 
Il10 1.52 (0.4 to 5.7) 0.368 1.38 (0.8 to 2.4) 0.152 1.49 (0.7 to 3.1) 0.163 
Il2 1.76 (0.3 to 9.6) 0.398 1.26 (0.4 to 4.2) 0.621 1.89 (0.4 to 9.7) 0.287 
Il6 1.29 (0.5 to 3.4) 0.449 -1.21 (-0.5 to -3.2) 0.580 1.46 (0.3 to 7.4) 0.404 
Nfk-beta -1.87 (0.9 to -3.1) 0.025 -1.66 (-0.8 to -3.4) 0.093 -1.33 (-0.6 to -2.9) 0.221 
Tnf-alpha 1.65 (0.4 to 6.3) 0.318 1.05 (0.3 to 3.3) 0.892 -1.08 (-0.7 to -1.7) 0.490 
Chemokines 
Il12 -2.36 (0.6 to -3) 0.001 -2 (0.8 to -3) 0.009 -1.38 (-0.6 to -3.3) 0.244 
Il8 -1.04 (-0.4 to -2.8) 0.915 -1.39 (-0.6 to -3.3) 0.308 1.05 (0.3 to 3.3) 0.871 
Mcp-1 -1.07 (-0.2 to -5) 0.896 -1.39 (-0.6 to -3.1) 0.317 -1.2 (-0.4 to -3.6) 0.640 
Anti-oxidant 
Cu sod 1.41 (0.5 to 3.8) 0.379 1.29 (0.6 to 2.9) 0.370 1.02 (0.4 to 2.8) 0.950 
extracellular sod3 1.21 (0.6 to 2.3) 0.457 -1.01 (-0.5 to -1.9) 0.972 1.37 (0.7 to 2.5) 0.203 
Mn sod -1.75 (1 to -3) 0.043 -1.64 (0.8 to -2.3) 0.013 -1.34 (-0.7 to -2.6) 0.191 
Inflammation 
Agt -1.2 (-0.6 to -2.4) 0.499 -1.09 (-0.5 to -2.4) 0.786 -1.21 (-0.6 to -2.3) 0.392 
Cox-1 -1.1 (-0.3 to -3.6) 0.811 -1.32 (-0.5 to -3.3) 0.395 -1.53 (-0.9 to -2.5) 0.063 
Cox-2 -1.48 (-0.6 to -3.6) 0.233 -1.06 (-0.6 to -1.8) 0.778 1.09 (0.4 to 2.8) 0.714 
Kim-1 -4.22 (0.4 to -6.7) 0.000 -4.5 (-1 to -20) 0.045 -3.22 (-0.5 to -20) 0.091 
Mmp-2 -2.58 (-0.4 to -14.3) 0.168 -1.15 (-0.5 to -2.5) 0.598 -1.04 (-0.5 to -2.4) 0.886 
Mmp-9 -2.44 (-0.3 to -25) 0.199 -1.74 (-0.3 to -10) 0.387 -1.18 (-0.2 to -6.7) 0.786 
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Class of gene Gene name 
24h-CS + 
Reperfusion 
 vs Ctrl perfusion 
p-
value 
24h-CS 
(treprostinil) + 
Reperfusion 
 vs Ctrl perfusion 
p-
value 
24h-CS + 
Reperfusion (both 
treprostinil) 
 vs Ctrl perfusion 
p-
value 
Fold change (CI) Fold change (CI) Fold change (CI) 
Receptors 
Ppar-alpha -1.3 (-0.8 to -2) 0.153 -1.33 (-0.9 to -2) 0.135 -1.27 (-0.7 to -2.3) 0.257 
Ppar-gamma 1.03 (0.2 to 4.5) 0.928 1.05 (0.3 to 4.1) 0.896 -1.36 (-0.5 to -4.2) 0.439 
Pg E receptor 2 1.51 (0.5 to 4.2) 0.316 1.22 (0.4 to 3.7) 0.637 1.71 (0.6 to 4.6) 0.167 
Pg I2 receptor -2.28 (-0.6 to -8.3) 0.144 -1.56 (-0.6 to -4.2) 0.158 -1.36 (-0.5 to -3.8) 0.393 
Pg receptor dp1 1.54 (0.4 to 5.7) 0.403 1.71 (0.7 to 4.5) 0.185 1.91 (0.8 to 4.7) 0.087 
Toll-like receptor 4 -1.35 (-0.5 to -3.4) 0.423 -1.17 (-0.4 to -3.6) 0.599 -1.07 (-0.4 to -3) 0.852 
Vit D receptor -2.39 (0.9 to -5) 0.028 -2.04 (0.6 to -2.6) 0.0003 -1.51 (-0.8 to -3) 0.104 
CI- Confidence Interval; significant differences are in bold font and p<0.05 after controlling for false discovery rate; genes with significant differences are 
highlighted in green (upregulated) or orange (downregulated), but genes with counts<100 are ignored; Pg- Prostaglandin 
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Figure 3.9. Differential gene expression and effect of treprostinil on kidneys  
reperfused after 24 h CS 
3.6 DISCUSSION  
Renal transplantation associated ischemia reperfusion (IR) not only originates from 
different cells of the renal, vascular or immune systems like endothelial, tubular or immune cells, 
but also results in activation of different injury mechanisms like inflammation or oxidative stress. 
In this ex-vivo model for IR during renal transplantation, gene expression changes in kidney were 
individually examined either after cold ischemia or following warm reperfusion. The panel of gene 
targets of renal importance were chosen in the context of IR injury such as mediators of 
inflammation, injury, antioxidants, enzymes and transporters. Simultaneous quantitative 
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comparison of expression in genes for various mechanisms was examined by application of 
nanostring assay. The nanostring® designed custom codeset for rat kidney contained target-specific 
oligonucleotide probes, capable of hybridizing directly to the single stranded RNA and are 
quantified after hybridizing with fluorescent tagsets . The nanostring based assay is also less 
stringent than PCR based method by using an enzyme free chemistry for quantification and is 
typically not affected by variability in degradation of mRNA between samples. In the current study 
design, left and right kidneys of same rat were utilized for separate evaluation of cold ischemia 
and warm reperfusion. A set of left kidneys were frozen immediately after isolation and right 
kidneys were frozen after 2 hours of perfusion and served as controls for the cold storage and 
reperfusion groups, respectively.  
Results for the selected genes in blank controls are presented as comparison of absolute 
expression values in Sprague Dawley rat kidneys for the first time, using this technology.  The 
results obtained in naïve kidneys are in concordance with that previously reported for drug 
transporter and enzyme expression in the SD rats202. Accordingly, a higher abundance was 
obtained for genes like oat1, oat 3, oct2 in comparison to others known to have lesser renal 
expression like pept-1. Further, as can be assumed during baseline condition, the expression of 
genes such as antioxidant enzymes was higher than those only activated during inflammation or 
injury such as interleukins, interferon gamma and Kim-1. For cold stored kidneys, the increasing 
duration of storage was hypothesized to be associated with transcriptional activations leading to a 
higher reperfusion mediated injury. The fold-change in gene expression was evaluated in kidneys 
that were cold stored for 24 and 72 hours to determine effect of cold storage and its duration on 
the organ, prior to reperfusion. Previous reports are limited to individual genes in rat kidney such 
as endothelin 1 and icam-1, that were shown to have increased expression with duration of cold 
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storage (ranging from 4- 72 h)192,193. An increased expression of the gene for antioxidant enzyme 
MnSOD was also observed following cold storage of human tubular cells203, attributed to the 
production of free radicals in the mitochondria. Such changes during cold storage were 
hypothesized to be associated with greater damage during reperfusion leading to clinical effects 
such as delayed graft function due to enhancement of vasoconstriction192, decreased antioxidant 
capacity173, enhanced attraction of leukocytes193 as well as increased allergenicity of the 
transplanted organ204. Hence, in this study we separately analyzed the effect of cold storage for 24 
and 72 h on gene expression in kidney, in the absence of reperfusion effects.  
However, among the panel of genes evaluated, there was no significant alteration in any of 
the gene at end of 24 and 72 h cold storage, except for a marginal upregulation in cox-2 at 72 h. 
Previous studies have examined upregulation of cox-2 only during reperfusion of rat kidneys or 
liver and report on protective effects of cox-2 inhibitors like indomethacin, parecoxib and 
meloxicam205-207. It is possible that cox-2 was activated during ischemia, but the increase in 
activity was more pronounced only with availability of oxygen during reperfusion208. However, in 
kidneys preserved with treprostinil (50 ng/mL), the cox-2 upregulation was not significantly 
different from controls. Overall, cold ischemia did not cause a significant fold-change in 
expression of selected genes in the kidney after 24 h storage as well as an adequately longer storage 
duration of 72 h. 
Reperfusion of kidneys was carried out in an isolated kidney perfusion system (IPRK) for 
functional evaluation of 24 h CS groups, as presented in Chapter 2. This ex-vivo model of CS 
followed by reperfusion was an attempt to mimic the exposure of transplanted kidneys to cold 
ischemia followed by warm reperfusion and to evaluate immediate functional recovery as well as 
the changes in gene expression. Fresh control kidneys as well as 24 h CS kidneys were reperfused 
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at 37°C with an oxygenated acellular perfusate and the gene expression was compared at the end 
of 2 h perfusion.  
The levels of gene expression for upstream response elements like NFK-beta, Ifn-gamma, 
Tnf-alpha, Il-1beta as well as other cytokines like cxcl-10, Il-6, Il-8, cox-2, Mcp-1 was 
significantly increased both in control as well as reperfused kidneys. Despite the presence of high 
gene expression for inflammatory cytokines, the renal function of perfused controls was superior 
and perfusate flow rate was significantly higher than  other reperfused 24 h CS kidneys, as was 
presented in chapter-2.  It is possible that the high perfusate flow rate observed in control kidneys 
during IPRK can result in vascular shear stress, endothelial detachment209,210  and result in release 
of inflammatory mediators by damaged endothelium along with an increase in kim-1 (kidney 
injury molecule) expression. The significantly increased expression of Ifn-gamma and associated 
Cxcl-10 in control kidneys, could be suggestive of an early protective response, as previous studies 
have demonstrated beneficial effects of this pathway, including prevention of necrosis and 
thrombosis during the early post-transplantation period52,211,212.  
Kim-1 is a transmembrane protein of renal tubular epithelium and is a marker of renal 
injury or repair. Kim-1 upregulation in response to acute injury has been associated with tubular 
dedifferentiation and regeneration to rebuild a functional epithelium as well as phagocytose 
apoptotic or necrotic cells out of tubular lumen and thus is essential for graft recovery213-215.  
Unlike perfused control kidneys, the early activation of Cxcl-10 and kim-1 mediated response to 
reperfusion was significantly less in all 24 h CS groups, but the expression of other inflammatory 
mediators was not different.  
However, in addition the 24 h CS kidneys also showed a significantly higher expression in 
irip gene and a lower expression of the transporter nhe3, the vitamin D receptor and the antioxidant 
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MnSOD at the end of 2 h reperfusion. The alteration in these genes in kidneys following ischemia 
reperfusion have been reported earlier and are discussed below. The function of irip is to regulate 
transporter activities 216,217 and the overexpression of irip during IR has been shown to negatively 
regulate the activities of transporters including oct1-2-3, Mate1, Oat1 and Pgp. It is interesting to 
note that irip may not affect the transcript levels of oct-1 or mate1 but the protein levels were 
downregulated after irip overexpression due to IR. Under baseline conditions low irip expression 
is thought to act on post-transcriptional level such as to decrease degradation of the transporter 
protein by proteasomes and thus increase the amounts of the functional transporter217. The apical 
Nhe3 transporter is the major isoform of Nhe  (sodium hydrogen exchanger) that mediates one 
molecule of extracellular Na in exchange for one cytosolic proton. Nhe3 is responsible for sodium 
reabsorption in proximal tubules in addition to the indirect control of reabsorption for chloride, 
bicarbonate, amino acids, proteins and citrate218.  
Studies in rat model, have established severe reduction in mRNA and protein of nhe3 
following IR and is associated with the natriuresis, acidosis and volume depletion following IR 
injury. Apart from the hypoperfusion during renal ischemia, the proinflammatory cytokines like 
TNF-alpha, IL-1-beta were established to mediate the nhe3 downregulation219,220. The IR can also 
lead to an increased production of reactive oxygen species that can overwhelm the antioxidant 
capacity leading to decrease in expression or activity of the antioxidant enzymes like SOD.  Of the 
3 isoforms, SOD2 (MnSOD) is located in the mitochondria, the organelle that has shown to be a 
main endogenous source of ROS during reperfusion221. Paradoxically, the ROS can trigger 
production of MnSOD by the mitochondria, however function of mitochondria also depends on 
ATP. Hence, during IR, the optimum expression of MnSOD could be indicative of preserved 
mitochondrial function and capacity to scavenge the ROS. Intravenous SOD has also been 
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clinically beneficial to prevent and treat kidney IR during transplantation222. Expression of Vitamin 
D receptor (Vit D) has also been shown to be downregulated following IR in a rat model223. 
Evidence points to the anti-inflammatory effect of Vitamin D to be mediated via the Vdr binding 
to p65 subunit of Nfk-beta and thereby disable its nuclear interaction and gene transcription224. In 
addition, paricalcitol, a vitamin D analogue has been shown to have protective effects in renal IR 
by increasing the expression of Vdr in a rat model223.  
Unlike the 24 h CS kidneys, 24 h CS kidneys with treprositnil (added to both storage and 
reperfusion) did not show any significant change in the expression of irip, nhe3, MnSOD or the 
Vdr in comparison to controls. The 24 h CS kidneys with treprostinil (added to storage only) did 
not differ from controls in expression of irip and nhe3 whereas the downregulation in MnSOD and 
Vdr were observed, as in the untreated 24 h CS kidneys. Taken together, the effects on expression 
of irip, nhe3, MnSOD, Vit D in kidneys after exposure to treprostinil indicate a decrease in IR 
effects at molecular level, either by its anti-inflammatory effects225,226 or possible anti-oxidant 
effect.  One of the limitations of this study was with the short duration of perfusion (2 h) and 
immediately following up with gene expression thereby limiting the observation changes to more 
immediate events after reperfusion and ignoring the possible downstream changes in expression. 
A longer follow up is possible with in vivo transplant model which would facilitate additional 
differentiation between CS groups based on effects on the downstream targets and/or on the 
adaptive and innate immune activation after IR. 
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3.7 CONCLUSION 
The effect of cold storage and warm reperfusion on the renal gene expression was evaluated 
using nanostring assay for multiple genes. There was no impact on the duration of CS on the renal 
gene expression, until 72 h. Warm reperfusion for 2 h after 24 h CS was associated with 
inflammatory response and downregulation in expression of genes such as nhe3, MnSod, Vdr and 
an upregulation in irip, all of which are markers for renal IR effects. Treprostinil addition to both 
24 h CS and reperfusion was able to reverse all the above expression changes due to IR, while 
treprostinil addition to storage could only reverse the expression of nhe3 and irip. Hence, even 
though renal functional improvement was not observed with treprostinil (chapter 2), changes in 
gene expression after treprostinil exposure indicate protection against the IR induced effects at a 
molecular level. The evaluation for potential beneficial effects needs to be further assessed in an 
in vivo setting of renal transplant model. 
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4.0  ESTIMATION OF 12-HOUR EXPOSURE TO TACROLIMUS DURING THE EARLY 
POST-TRANSPLANT PERIOD BY SPARSE SAMPLING 
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4.1 ABSTRACT 
Tacrolimus and mycophenolate-based immunosuppression is the standard of care in renal 
transplantation. Protocol biopsies have revealed early subclinical rejections in patients on standard 
immunosuppressive therapy. The overall objective of this study was to evaluate the effect of early 
post-transplant exposure and response to mycophenolate and tacrolimus therapy on subclinical 
inflammation and acute rejections in the grafts of renal transplant patients. The specific objective 
in this chapter is to evaluate tacrolimus exposure during early post-transplant period (week-
1=period I) and follow-up study on the day of the 3-month protocol biopsy (week-13=period II). 
Sparse samples were obtained at 1.5 and 3.5 h in addition to routine trough blood samples in 42 
and 23 patients, during early and follow-up periods, respectively. AUC0-12 h was estimated from a 
prior population model by maximum a posteriori bayesian estimation. The bias and imprecision of 
predictions were low and within acceptable limits. The predicted tacrolimus AUC0-12 h ranged 
between 39-294 ng*h/mL and 101-302 ng*h/mL during periods I and II, respectively. The 
apparent CL/F of tacrolimus showed a trend to decrease from an average of 28.7 to 24.8 L/h from 
period I to II, associated with an increase in average hematocrit by 30%. CL/F was more than 2-
fold higher in CYP3A5 expressers during period I, however none of the MDR1 genotypes (3435, 
2677, 1236, 1199) showed significant differences. Trough concentrations were higher than 8 
ng/mL in 30 % and 80 % of patients at period I and II, respectively and showed a good correlation 
with predicted AUC (r= 0.795 (0.679-0.872)).  Only 55 and 60 % of the patients had exposure 
above the recommended 150 ng*h/mL during periods I and II, respectively. Hence, in conjunction 
with regular monitoring of trough levels, the more informative and ideal measure of exposure 
(AUC0-12 h) could be estimated by sparse sampling in an outpatient setting during early and stable 
post-transplant periods, for further improvements in outcomes. 
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4.2 INTRODUCTION 
Renal transplantation is the treatment of choice for end stage renal diseases and has greatly 
improved the survival and quality of life in these patients. The current immunosuppressive regimen 
of tacrolimus along with the antimetabolite mycophenolate and glucocorticoids, has offered the 
best short-term outcomes in terms of decrease in acute kidney rejection episodes and a > 90 % 
allograft survival within the first-year post-transplant. Chronic rejection, however, causes late 
allograft failure in about 10-20 % of renal allograft recipients227 and the presence of interstitial 
fibrosis with tubular atrophy (clinical and subclinical rejections SCR), remains the major factor in 
late allograft failure. Longitudinal analysis have also shown SCR to originate very early after 
transplantation and contribute to chronic damage of the kidney228,229, irrespective of any immediate 
drop in renal function. As the rejection associated histological inflammation in graft is 
immunological in origin, the broad study objective was to determine the association of rejections 
(both clinical and subclinical) to immunosuppressant drug exposure and efficacy with the current 
standardized regimen of mycophenolate and tacrolimus during the early post-transplant period. 
Tacrolimus is therapeutically monitored after transplantation to maintain therapeutic blood 
concentrations as well as to avoid the side effects due to overexposure. The target tacrolimus 
concentrations vary with time post-transplant and at this center, tacrolimus trough concentration 
(C0) of 8-12 ng/mL is targeted during the initial 3-month study period. The use of trough (C0)  
blood concentrations to adjust tacrolimus dose is based on observations on the association between 
a target C0 and clinical outcome of acute rejections. With mycophenolate, steroids and anti-IL-2 
induction therapy,  a target C0 between 5-10 ng/mL during the first year could be considered as a 
therapeutic range for tacrolimus62,66.  In an early investigative trial for C0 of tacrolimus, decreasing 
rejection was observed with increasing C0 while increasing toxicity occurred beyond a limit, 
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thereby a range of 5-15 ng/mL was proposed during the first 7 weeks post-renal transplant64. 
Another study67 derived an effective target C0 of 9.3 ng/mL on the day 5 post-renal transplantation 
and C0 values below the cut-off were associated with a shorter graft survival. In general, the target 
C0 associated with avoiding rejections were comparatively lower in some studies performed at later 
post-transplant periods, with the lack of steroid co-therapy (after tapering of steroids). In contrast 
few other studies have failed to show any association of C0 with rejection 69,70. 
In the case of tacrolimus, C0 are considered as surrogates for the AUC (area under the 
curve), which is the most reliable marker for drug exposure. However, the correlation of C0 with 
AUC has been shown to be variable and questionable with a better relation during the first month 
post-transplant period than at later time periods 62,63.  
The relationship of tacrolimus exposure to clinical outcome has also been investigated in 
several studies. It has been shown that patients experiencing rejections have lower tacrolimus AUC 
during the early post-transplant period 75. An AUC exceeding 200 ng*h/mL was suggested for 
tacrolimus during the early post-transplant period for avoiding the risk of acute rejections75,76. 
Another study had shown exposures of 210 ng*h/mL and 125 ng*h/mL as optimal limit for 
tacrolimus, until the first 6- and 52-weeks post-transplant, respectively 73. Recent consensus report 
suggests a post-transplant target exposure of 150 ng*h/mL to avoid rejections in recipients of 
kidney230. 
In addition to whole blood exposure, the tacrolimus intracellular concentrations were 
shown to be associated with histological rejections in renal transplant patients 231. Further, the 
authors found polymorphisms in ABCB1 transporters may impact tacrolimus intracellular 
concentrations and association with rejections231.   
 112 
The importance of adequate tacrolimus exposure cannot be more emphasized as the current 
clinical needs are to minimize the exposure to tacrolimus but at the same time to prevent acute 
rejections, due to sub-optimal AUC (exposure). Further, expert panel discussions have recognized 
and pointed out the lack of controlled trials for determination of an appropriate tacrolimus target 
AUC62,232 for a specific transplant population and hence target exposure values are based on 
observational studies in various patients at different post-transplant times. Hence, the purpose of 
this chapter is to determine individual patient exposures to tacrolimus on two separate occasions, 
during an early period and at 3-month follow-up after renal transplantation, in order to examine its 
association with occurrence of clinical and SCR. Determination of AUC by a sparse sampling 
procedure with bayesian estimation was utilized to determine 12 h exposure along with the 
genotyping of patients for ABCB1 transporter, as a surrogate for efflux of tacrolimus from its 
target site of action. 
4.3 MATERIALS 
Tacrolimus and internal standard (Ascomycin) were purchased from LC Laboratories 
(Woburn, Mass, US) and Calbiochem (San Diego, Calif, US), respectively. Ammonium acetate, 
formic acid, acetonitrile (Optima®), methanol and water were obtained from Fisher Scientific (Fair 
Lawn, NJ, USA). All other chemicals used for LCMS sample processing were purchased from 
Fisher Scientific (Fair Lawn, NJ). The QIAamp® DNA blood mini kit (cat no. 51104) was 
purchased from Qiagen (Qiagen Inc., MD, US). TaqPath ProAmp Master mix was purchased from 
ThermoFisher scientific Inc. (MA, US). The assays for genotyping of the selected target single 
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nucleotide polymorphisms were identified and purchased from TaqMan® (Applied Biosystems, 
CA, USA). 
4.4 METHODS  
4.4.1 Study approval 
A review of the proposed study was conducted by the Institutional Review Board (IRB) at 
the University of Pittsburgh. The study was approved by IRB under the category of minimal risk 
to patients (titled “Exposure to Mycophenolic acid/Tacrolimus and outcomes in renal transplant 
recipients”, Approval No. PRO16050030, dated 20 Oct 2016). 
4.4.2 Screening 
Potential renal transplantation candidates were screened with following inclusion and 
exclusion criterion. 
Inclusion: 
• Recipients of cadaveric or living donor kidney with proposed immunosuppressive 
regimen of MMF and immediate release tacrolimus 
• Completed at least 2 days of therapy with same dose of tacrolimus and MMF 
• Adults (18-70 years)  
Exclusion: 
• Combined renal-pancreas transplantation 
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• On pre-existing therapy with MMF or similar acting drugs like azathioprine  
• On clopidogrel or heparin based anti-coagulant therapy (biopsy not anticipated) 
• Therapy with enteric coated mycophenolate therapy 
• Hemoglobin less than 8 g/dL 
• Therapy with drugs that could interact with MMF like cholestyramine, 
metronidazole or ciprofloxacin 
• Abnormal liver function tests with > 3 times of upper limit for enzymes ALT, AST 
or bilirubin. 
4.4.3 Enrollment in study 
As a part of the informed consenting procedure, patients that were deemed suitable for 
inclusion, were met by investigators and the study protocol was explained in detail. A printed copy 
of study procedures was also provided to the patients. Patients were informed that the participation 
in the study was voluntary and that they could withdraw their consent from study participation at 
any time.  Once patients provided their signed consent, they were enrolled into the study. 
4.4.4 Study design- sampling periods and time points 
This was a prospective study design and the enrolled patients were to be studied on two 
separate occasions (periods) during their post-transplant follow-up visits (Figure 4.1). The period-
I was scheduled to be completed within 14 days post-transplant and period-II was scheduled along 
with the 3-month protocol biopsy. In addition, a baseline blood sample was obtained prior to 
transplant surgery in all enrolled patients. This pre-transplant baseline sample was used for 
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genotyping as well as characterization of individual IMPDH enzyme activities in the absence of 
any immunosuppression. 
During each study period, a limited sampling (LS) method (3.5 h) was proposed, with 3 
blood samples obtained at trough (pre-dose), and at 1.5 and 3.5 h after combined dosing of MMF 
and tacrolimus. These LS time points were chosen for compatibility with the anticipated duration 
of outpatient visits (~4 h) as well as based on a previous study that identified the 1.5 and 3.5 h 
post-dosing time points using D-optimality criterion, to be the most informative for combined 
bayesian estimation of exposure to both tacrolimus and MPA233. 
4.4.5 Study conduct and sampling 
Blood samples (approximately 10 mL) were drawn from a peripheral vein catheter at or 
around the designated time points into lithium heparin tubes and mixed well. The morning trough 
blood sample was initially obtained and the times of previous and current dosing for MMF and 
tacrolimus were individually documented. Following the morning dose of MMF and tacrolimus, 
patients were restricted to have water, juice or crackers until the first time point (1.5 h). The post-
dose samples were obtained at or around 1.5 and 3.5 h. An aliquot of whole blood (~200 µls) was 
transferred into tubes coated with dried EDTA (2 % (w/v)) and stored at 4° C for not more than 2 
weeks prior to quantification of tacrolimus by LCMS/MS. 
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Figure 4.1. Cohort diagram  
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4.4.6 Processing of blood samples and quantification of tacrolimus 
Tacrolimus concentrations in whole blood (ng/mL) were measured using a previously 
validated liquid chromatography tandem mass spectrometry method (LCMS/MS) in a Waters® 
Quattro micro API mass spectrometer. Processing of blood samples was done as follows: Fifty 
microliters of whole blood sample was mixed with two microliters of zinc sulfate heptahydrate 
(ZnSO4∙7H2O) to precipitate the proteins. Acetonitrile (500 µls) spiked with internal standard 
(Ascomycin at concentration of 15 ng/ml) was then added and the mixture was vortexed for 1 min 
followed by centrifugation at 2000 g for 3 minutes. The supernatant was transferred into LCMS 
vials and 20 µls was injected on to a Nova-Pak® C18 2.1 x 10 mm cartridge (Waters # 186003523) 
maintained at 55° C. Analytes were effectively separated using a gradient elution consisting of an 
aqueous mobile phase (95% water / 5% methanol) with an organic mobile phase (100% methanol), 
at a flow rate of 0.6 mL/min. Both mobile phases also contained 0.1 % v/v formic acid and 2 mM 
ammonium acetate, in order to optimize ionization and chromatographic resolution. The MS/MS 
based multiple reaction monitoring was done in positive ion mode with m/z transition pairs of 
821.5 → 768.5, 809.5 → 756.5 and retention times of 1.02, 1.01 min, both respectively for 
tacrolimus and ascomycin (Figure 4.2a). The validated method showed linearity over the assay 
range of 2 – 40 ng/mL (Figure 4.2b). Further, during each batch of analysis quality controls were 
verified at concentrations of 4, 16 and 25 ng/mL of tacrolimus in whole blood. 
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Figure 4.2. (a) Representative chromatogram of tacrolimus and internal standard (ascomycin)  
(b) Standard curve for tacrolimus (range: 2-40 ng/mL) 
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4.4.7 Data Analysis 
4.4.7.1 Prediction of individual concentrations 
Tacrolimus clearance in individual patients were determined by nonlinear mixed effect 
modeling of NONMEM® (version 7.4, Icon, Ireland) by using a maximum a posteriori (MAP) 
bayesian method with first order estimation. The MAP method utilized a prior population 
pharmacokinetic model for tacrolimus with parameters that were fixed to the median values under 
the subroutine ADVAN4 TRANS4. The individual blood concentrations from LS time points 
(obtained at trough, followed by 1.5 and 3.5 h post dosing), the exact clock timings and dosing 
history (mg dose and clock timings) of tacrolimus were available as prior information in every 
patient, that was subsequently used to estimate the apparent clearance (CL/F) of tacrolimus in each 
patient. The estimated individual parameters (such as CL/F, V/F) were output by specification of 
“posthoc”. The maxeval=0 option was used to predict concentrations of tacrolimus at additional 
time points such as 0.25, 0.5, 1, 2, 3, 5, 8, 10 and until the next dose (12 h) on the day of study. 
For comparison, the total exposure (12 h) was also calculated from linear regression based equation 
by inputting the observed concentrations at 1.5 and 3.5 h into the published233 equation 24.3 + (5.9 
x C1.5) + (12.2 x C3.5), as ~90 % of sampling time points were within 10 minutes of 1.5 and 3.5 h.    
4.4.7.2 Predictive performance 
The predictive performance of the population model used for obtaining individual 
predicted concentrations were verified with diagnostic plots of the observed versus predicted (DV 
versus IPRED), weighted residuals (WRES) and normalized distribution of prediction errors 
(NPDE), using pirana® (Certara, NJ, US) and RStudio (version 1.1.453). Visual predictive check 
(prediction and variance corrected) was performed using pirana® and RStudio after 1000 
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simulations to derive replicates of model predicted concentrations. The median and 90 % 
prediction intervals (5th and 95th percentile) of model predicted concentrations were then compared 
against the corresponding distribution of observed values. 
The bias in the predicted concentrations were estimated using mean prediction error (MPE) 
and the precision was estimated by median absolute prediction error (MDAPE) and by median 
percentage in absolute prediction error relative to the observed concentrations (%MDAPPE). 
 
 
 
 
4.4.7.3 Non-compartmental pharmacokinetic analysis 
The total exposures (predicted AUC 0-12 h) were calculated from the predicted 
concentrations and corresponding time points using non-compartmental analysis (NCA) by 
Phoenix WinNonlin (Certara, NJ, US). In addition, the cumulative exposure (AUC 0-90 days) from 
start of tacrolimus dosing until day 90 (representing 3-month protocol biopsy) was also calculated 
from trough blood concentrations obtained during therapeutic monitoring and corresponding day 
of blood sample, using NCA by Phoenix WinNonlin. 
4.4.8 Genotyping 
Whole blood samples (stored in -80°C) were used to genotype patients for select 
polymorphisms in enzymes CYP3A4, CYP3A5 and the transporter ABCB1, which could impact 
metabolism and availability of tacrolimus into the lymphocyte compartment, respectively. The 
MPE =1  Individual predicted concentration – Observed concentration 
                                 N 
 
MDAPE = Median Abs [Individual predicted concentration – Observed concentration] 
 
 
% MDAPPE = Median  Abs [Individual predicted concentration – Observed concentration] x100 
                                                                       Observed concentration 
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genomic DNA was extracted and purified from whole blood using the QIAamp® DNA blood mini 
kit. The genotypes for CYP3A4 (6 C>T), CYP3A5 (6986A>G) and ABCB1 (C3435T, G2677T/A, 
C1236T and G1199A) were determined by the allelic discrimination assays of Taqman® (Applied 
Biosystems, CA, US) and assays were performed according to manufacturer instructions.  The 
genotypic variants and reaction details are presented in Table 4.1.  In brief, 20 ng of genomic DNA 
was mixed with 1xTaqPath proamp master mix and 1xTaqman® allelic discrimination assay mix 
for the loci of interest.  Following enzyme activation at 95 °C for 10 min, reactions were processed 
with forty cycles of 15 s at 95°C and 1 min at 60 °C.  Data was collected in Realtime as well as 
with an endpoint read of fluorescent intensities. Genotypes were determined from the cluster 
analysis of the endpoint reads and further verification of cluster identification was done with 
Realtime data obtained using Taqman® method (7900 fast real time PCR system, Applied 
Biosystems, CA, USA). 
 
Table 4.1. Assay details for identifying SNPs in select enzymes and transporters associated with tacrolimus 
disposition in patients 
gene SNP name rs number Assay ID 
(Taqman®) 
CYP3A4 6 C>T (*22) rs35599367 C__59013445_10 
CYP3A5 6986A>G (*1, *3) rs776746 C__26201809_30 
ABCB1 C3435T rs1045642 C___7586657_20 
ABCB1 C1236T rs1128503 C___7586662_10 
ABCB1 G2677T/A rs2032582 
(assay 1/2) 
C_11711720D_40/ 
C_11711720C_30 
ABCB1 G1199A rs2229109 C__15951365_20 
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4.4.9 Statistical analysis 
The demographic and clinical variables in patients during both study periods were 
compared using Wilcoxon signed rank tests or paired t-test, as appropriate. The abbreviated, total 
exposure, dose normalized trough concentrations were statistically compared between the two 
occasions using paired t-test, for data from patients that participated in both periods. An 
independent t-test was used for statistical comparison of exposure and dose normalized trough 
concentrations among different genotype pairs. Statistical tests as well as correlation analysis were 
done with SPSS® version 25 (IBM corporation, US) and plotted using R software. 
4.5 RESULTS  
The demographic and clinical variables obtained during periods I and II of the study are 
summarized in Table 4.2. Median days corresponding to periods I and II were on 6th and 91st day 
post- transplant. The median age of patients was around 51 years with majority of patients being 
white (~75%) and recipients of cadaveric organs (~65-70%). All patients received thymoglobulin 
induction therapy and were started on 1000 mg dose (twice daily) of MMF from the day of surgery. 
Tacrolimus was usually started around the 48 h after transplant. The target trough levels for 
tacrolimus was 8- 12 ng/mL during the first 3 months followed by 6-10 ng/mL thereafter. 
The liver function related values in Table 4.2 such as ALT, AST and bilirubin, indicate a stable 
hepatic function in the study population. After renal transplantation, an improvement in renal as 
well as hematological (hematocrit and hemoglobin) parameters are observed from period I to 
period II. With improved renal function, the significant drop in serum creatinine values and a 
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corresponding significant increase in the estimated glomerular filtration rate (calculated by the 
Chronic Kidney Disease Epidemiology Collaboration-CKD-EPI equation) are also evident, as in 
Table 4.2. The correlations between clinical and demographic variables are represented in Figure 
4.3. 
Table 4.2.  Demographic and clinical characteristics of study population (Median (range)) 
Patient 
characteristic 
All patients Only patients that completed both periods 
Period I 
n=42 
Period I 
n=23 
Period II 
n=23 p value
* 
Days post-
transplant 
6.00 
[3.00, 9.00] 
6.00 
[4.00, 9.00] 
91.0 
[81.0, 117] NA 
Gender 
(male/female) 
24/18 12/11 12/11 NA 
Race 
(Caucasian/Afro-
American 
/Others) 
32/7/3 17/5/1 17/5/1 NA 
Age 
51.0 
[23.0, 69.0] 
50.0 
[23.0, 66.0] 
50.0 
[23.0, 66.0] 
NA 
Cadaveric/ 
Living donor 
29/13 15/8 15/8 
NA 
Weight 
(Kgs) 
93 
[52, 139] 
97 
[58, 136] 
91 
[58, 130] <0.001 
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Patient 
characteristic 
All patients Only patients that completed both periods 
Period I 
n=42 
Period I 
n=23 
Period II 
n=23 p value
* 
Albumin 
(g/dL) 
3.80 
[2.60, 4.70] 
4.00 
[2.60, 4.60] 
4.10 
[3.40, 4.60] NS 
ALT 
(IU/L) 
14.0 
[3.00, 375] 
14.0 
[3.00, 375] 
16.5 
[9.00, 68.0] NS 
AST 
(IU/L) 
14.0 
[7.00, 227] 
13.0 
[7.00, 227] 
16.5 
[9.00, 33.0] NS 
Total bilirubin 
(mg/dL) 
0.5 
[0.2, 1.4] 
0.5 
[0.2, 1.4] 
0.4 
[0.3, 0.9] NS 
Serum creatinine 
(mg/dL) 
3.30 
[0.700, 14.3] 
3.30 
[0.700, 13.0] 
1.50 
[0.900, 3.70] < 0.001 
eGFR 
(mL/min/1.73m2) 
22.0 
[4.00, 100] 
22.0 
[4.00, 100] 
51.0 
[18.0, 90.0] <0.001 
Hematocrit 
(%) 
27.5 
[20.3, 38.3] 
27.3 
[20.3, 38.3] 
35.0 
[24.2, 47.2] <0.001 
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Patient 
characteristic 
All patients Only patients that completed both periods 
Period I 
n=42 
Period I 
n=23 
Period II 
n=23 p value
* 
Hemoglobin 
(g/dL) 
9.15 
[6.70, 13.0] 
9.10 
[6.70, 13.0] 
11.5 
[8.00, 15.5] <0.001 
*Wilcoxon signed rank test comparison in patients that completed both periods; NS- No 
significance (p ≥ 0.5) 
 
Figure 4.3. Evaluation of correlation between clinical and demographic parameters (Periods I & II) 
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The population parameter estimates233 used for maximum a posteriori Bayesian prediction 
of tacrolimus blood concentrations is shown in Table 4.3.  The 2-compartment model with 
absorption lag time was used without fixing F (bioavailability) and hence clearance and volume 
terms are presented as apparent values (CL/F, Q/F and V1/F, V2/F).  
The maximum a posteriori Bayesian estimation (MAP) showed superior predictions for AUC0-12h 
in comparison to linear regression (LR) equation-based estimation. As shown in Figure 4.4, there 
was a better correlation of MAP estimations with observed tacrolimus trough levels (r=0.71) 
compared to LR (r=0.48). Further, despite good correlation with MAP (r=0.85), a systematic 
overestimation in exposure occurred with LR method (slope = 1.34) compared to MAP  estimation.  
The quality of Bayesian estimation from model were assessed from the bias and precision values 
that are shown in Table 4.4. The mean of prediction error with 95% CI was -0.09 (-0.30-0.12) 
ng/mL and was not significantly different from zero (p=0.38).  
Table 4.3. Prior population parameters for tacrolimus in renal transplant recipients during early post-
transplant period 
* Exponential model used for all IIV terms; εprop (proportional term on residual 
error) was 0.01% CV; εadd (additive term on residual error) was 0.97 ng/mL 
PARAMETERS  
(2 compartment)233 
THETAS OMEGAS 
Description Units Estimate IIV –(% CV) * 
Oral clearance (CL/F) L/h 3.85 185 
Central volume (V1/F) L 221 133 
Distributional Clearance (Q/F) L/h 21.9 - 
Peripheral volume (V2/F) L 520.8 144 
Absorption Rate (KA) h-1 1.68 199 
Absorption Lag (TLAG) h 0.045 350 
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Linear_regression = 1.337*(Bayesian_estimation) + 52.79 
 
 
Figure 4.4. Correlation between tacrolimus exposure determined by Bayesian estimation, linear regression 
and trough blood levels  
The scatter plot matrix shows individual panels examining correlation between tacrolimus exposure 
determined by two different methods (ng*h/mL) and correlation with the observed tacrolimus trough blood 
concentrations (ng/mL). Corresponding r values for correlations are in the diagonally opposite panel 
The imprecision was 0.47 (0.36-0.59) ng/mL, which was satisfactory and low in 
comparison to average trough concentrations (6-10 ng/mL). The median absolute percentage 
prediction error was 4.15 % (2.3-5.5) and was within acceptable limits. The model predictions 
were also visually evaluated for comparison with observed blood concentrations and are presented 
in panels a-d of Figure 4.5. As shown in figure 4.5a, the individual predicted concentrations agreed 
well with observed concentrations. The weighted residuals (after first order estimation) had values 
less than 3 units and both WRES and prediction errors showed an approximate normal distribution, 
as seen in panels b and c of Figure 4.5, respectively. The prediction and variability-corrected visual 
predictive check (pvcVPC) is presented in panel d of Figure 4.5. The pvc was done to correct for 
tacrolimus concentrations observed in patients taking different daily doses. The median as well as 
the 5th and 95th percentile of the prediction and variability-corrected observations overlapped with 
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the distribution of the simulated concentrations and indicated suitability of the model to predict 
tacrolimus concentrations in the study population. 
 
Table 4.4.  Predictive performance of Bayesian estimation for tacrolimus concentrations  
at sparse sampling time points 
Measure 
Estimate  
(95 % CI) 
Mean prediction error 
(MPE, ng/mL) 
-0.09  
(-0.30 – 0.12) 
Median absolute prediction error  
(MDAPE, ng/mL) 
0.47 
(0.36 – 0.59) 
Median absolute percentage prediction 
error  
(MDAPPE, %)  
4.15 
(2.30 – 5.50) 
 
The observed trough concentrations and predicted exposures (AUC0-12 h) are summarized in Table 
4.5. The average dose was similar across both periods, suggesting absence of major dose changes 
after the PK study during period I. Though the mean trough concentrations during period I were 
slightly below the target 8 -12 ng/mL and significantly increased during period II, the mean 
predicted total exposures were close to the recommended 150 ng*h/mL and did not significantly 
differ between both periods (Table 4.5). However, only 55 % and 60 % of the patients had exposure 
exceeding 150 ng*h/mL during periods I and II, respectively.  
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a  b  
c  d  
a) Observed versus individual predictions (ng/mL) b) Histogram plot for weighted residuals (first order estimation) c) 
Plot of normalized prediction distribution errors (NPDE) d) pvc-VPC plot where blue dots represent the prediction 
and variance corrected observations, the solid and broken lines represent median and 90% prediction intervals. The 
shaded areas around lines represent 99% confidence intervals for median, 5th and 95th prediction intervals obtained 
from the simulations with IIV of V2/F and CL/F fixed at 80 and 125%, respectively 
 
Figure 4.5. Evaluation of observations versus predictions with the tacrolimus population model 
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Table 4.5. Summary of observed and predicted pharmacokinetic parameters for tacrolimus 
Mean ± SD 
Median 
(Min, max) 
All patients Only patients that completed both periods 
Period I 
(n=40) 
Period I 
(n=23) 
Period II 
(n=23) p value* 
Dose 
(mg, bid) 
 
4.0 
[2.0, 6.0] 
4.0 
[2.0, 6.0] 
4.0 
[2.0, 10.0] NS 
Trough blood 
concentration 
(ng/mL) 
7.0 ± 3.7 6.6 ± 3.4 9.9 ± 3.7 0.02 
Dose-normalized 
trough 
(ng/mL/mg) 
1.9 ± 1.2 1.8 ± 1.0 2.6 ± 1.3 0.009 
Predicted AUC(0-12 h) 
(ng*h/mL) 
153.2 ± 69.5 
142.3 
[39, 294] 
149.1 ± 63.8 
143.1 
[39, 264] 
179.3 ± 55.9 
165.3 
[101, 302] 
NS 
Dose-normalized 
predicted AUC(0-12 h) 
(ng*h/mL/mg) 
40.8 ± 20.0 38.6 ± 16.7 47.4 ± 20.5 NS 
Predicted CL/F 
(L/h) 28.7 ± 11.9 28.2 ± 9.9 24.8 ± 9.9 NS 
*paired t-test comparison in patients that completed both periods; NS- No significance (p ≥ 0.05) 
A good correlation of tacrolimus trough concentrations to predicted AUC0-12 h was 
observed with value for correlation coefficient r=0.795 (0.679-0.872), as shown in Figure 4.6. For 
fixed values of trough concentration, a range of corresponding predicted AUCs were observed. 
Figure 4.7 compares the change in apparent clearance of tacrolimus in relevance to that of 
hematocrit during periods I and II. An overall 12% decrease in CL/F was observed during the 
corresponding time period when hematocrit had increased in patients by a median of 28%.  
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Figure 4.6. Correlation of observed trough blood concentration (ng/mL)  and predicted 12 h AUC 
(ng*h/mL) for tacrolimus 
 
Figure 4.7. Comparison of hematocrit and tacrolimus Cl/F during early and intermediate post-transplant 
periods (I and II) 
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Figure 4.8. Cumulative exposure of tacrolimus (AUC 0-90 days) during the first 90 days post renal 
transplantation 
The distribution of cumulative exposure of tacrolimus calculated using periodic trough 
blood concentrations until 90th day post-transplant is represented in Figure 4.8.  A 2-fold range of 
cumulative exposure was observed between the extreme values in patients and an average exposure 
of 820 ng.day/mL was observed.  
The distribution of CYP 3A5, MDR1 genotypes in study population is shown as 
frequencies of alleles in Table 4.6. The frequencies for alleles were comparable to typical values 
reported for Caucasian population. The effect of genotypes on the tacrolimus dose normalized 
trough blood levels and predicted dose normalized AUC0-12 h are presented in Figures 4.9- 4.10. 
The heterozygous CYP 3A5 expressers (*1/*3) and homozygous (*1/*1) were pooled for this 
analysis due to small sample size.  
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Table 4.6. Frequency (%) of the SNP variants for CYP 3A5 and MDR1 genes 
N=37; difference in total for each genotype is due to genotype being “undeterminable” in few 
cases 
As seen in Figure 4.9, expressers of CYP3A5 showed a significantly lower dose normalized trough 
and predicted dose normalized exposure for tacrolimus, during the early post-transplant period. 
The period I values for mean dose normalized trough and predicted AUC0-12 h in CYP3A5 
expressers were (0.9 ± 0.4 vs 2.3 ± 1.2) ng/mL/mg, p<0.05 and (25.8 ± 16.7 vs 50.4 ± 25.7) 
ng*h/ml/mg, p< 0.001, respectively. The mean CL/F for tacrolimus during period I, observed in 
CYP3A5 expressors (*1/*1/*3) was more than 2-fold higher than non-expressors (51.5 ± 27.6 vs 
23.7 ± 7.3) L/h. The differences between CYP3A5 genotypes in blood exposure of tacrolimus 
during period II were not significant, however the study sample sizes were also lower. In contrast 
to CYP3A5, the MDR1did not affect dose normalized trough blood levels or predicted AUC0-12h, 
when the different genotypes were compared among patients, as shown in Figure 4.10. 
SNP Gene 
Homozygous 
(wild type) 
Heterozygous 
variant 
Homozygous 
variant 
rs776746 
 
CYP3A5 
6986A>G 
3 
(8.1) 
5 
(13.5) 
28 
(75.7) 
rs1128503 
MDR1 
C1236T 
12 
(32.4) 
22 
(59.5) 
3 
(8.1) 
rs2032582 
MDR1 
G2677T/A 
13 
(35.1) 
21 
(56.7) 
3 
(8.1) 
rs1045642 
MDR1 
C3435T 
6 
(16.2) 
24 
(64.9) 
7 
(18.9) 
rs2229109 
MDR1 
G1199A 
34 
(91.9) 
3 
(8.1) 
0 
(0) 
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Figure 4.9. Tacrolimus dose normalized trough concentration (ng/mL) and predicted dose 
normalized AUC0-12 h (ng*h/mL) according to CYP3A5 genotypic variants in Period I and II 
The heterozygous (*1/*3) and homozygous (*1/*1)  CYP3A5  expressers were pooled for this analysis 
due to smaller frequency of the alleles and are indicated by (*1/*1/*3).  (*3/*3) variants are considered 
as non-expressors of CYP3A5;  Independent sample t-test used for  statistical comparisons between 
genotypes with p<0.05 considered as significant difference
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Figure 4.10.  Tacrolimus predicted dose normalized AUC0-12 h (ng*h/mL) according to MDR1 genotypic variants in Period I and II 
Alleles with reported increase or decrease in MDR1 (p-glycoprotein) efflux activity were pooled together for comparisons; The variants with 
reported higher activity were CC for C1236T as well as C3435T and TT/TA for G2677T/A genotypes. G1199A was not compared due to absence 
of homozygous variant GG in study cohort;  Independent sample t-test used for  statistical comparisons between genotypes in each period, with 
p<0.05 considered as significant difference 
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4.6 DISCUSSION  
Tacrolimus with mycophenolate therapy has been the preferred immunosuppressive 
regimen to avoid acute and chronic rejections after renal transplantation. Despite substantial 
reductions in acute clinical rejection rates, the presence of subclinical rejections (SCR) with 
clinical rejections (ACR) has been observed at 3 months after transplantation in our center, in 
patients on standard immunosuppression protocol with tacrolimus and mycophenolate42,227,229.  
Subclinical rejection is observed as tubulointerstitial infiltrates in the renal allograft without any 
functional deterioration but has been associated with progressive functional changes leading to 
long term graft loss158. Though not routinely performed at all transplant centers, the serial protocol 
biopsies obtained at 3 months and 12 months after kidney transplant enables monitoring of the 
early allograft inflammation and damage along with any detectable decline in the renal function. 
The causal relationship of SCR with the early post-transplant exposure to tacrolimus and 
mycophenolate-based immunosuppression remains unclear. Hence, the objective of the study in 
this chapter was to determine the exposure to tacrolimus at two separate occasions, one during the 
first few days after transplantation (1 week, early post-transplant) and one along with the 3-month 
protocol biopsy, for further comparison of association with outcomes. 
After transplantation, mycophenolate therapy was administered as a fixed dose regimen 
(1000 mg of MMF twice daily) in the absence of TDM. For tacrolimus however, due to the high 
interpatient variability, TDM based dose adjustment was done using trough blood concentrations 
to avoid toxicity as well as minimize rejection. Though trough blood concentrations (C0) of 
tacrolimus are routinely used in TDM for clinical practicality, the association of C0 with the true 
 137 
exposure (AUC0-12 h) as well as the clinical outcomes has been a matter of debate62,63,73,74. 
Tacrolimus trough targeting can also represent high variability in exposure as a fixed trough 
concentration can be associated with a 2-3-fold difference in corresponding 12 h exposure234,235.  
Historically, the evolution of tacrolimus target trough concentrations has slowly seen a shift from 
higher concentrations of around 20 ng/mL in earlier years of use to lower concentrations during 
recent times mainly after co-administration with mycophenolic acid71.  However, incidences of 
toxicity and rejection are shown to occur in patients despite trough levels within acceptable 
therapeutic range232, as  patients might differ in AUC0-12 h with under or over-exposures, despite 
the same observed C0 in addition to the differences in exposures of co-administered MPA therapy. 
Further, lack of monitoring for MPA or trough based monitoring for tacrolimus, cannot account 
for the impact of high ADME changes are known to occur during periods such as early after 
transplant236, on their respective total exposures. Hence, the determination of AUC0-12 h is the best 
measure for exposure for the further study of relationship with clinical outcomes. 
In routine clinical care, however, the determination of the full 12 h AUC is challenging due 
to patient burden and clinical feasibility, however obtaining sparse samples in outpatient clinic 
followed by bayesian estimation of the 12 h exposure to both tacrolimus and MPA, provides a 
flexible and more realistic alternative to the full AUC.  Abbreviated AUCs or limited or sparse 
sampling (LS) followed by maximum a posteriori bayesian estimation (MAP) of exposure are not 
routinely employed in the clinic, as they require additional time from patients and clinical staff, 
increasing the cost of care. In addition, MAP bayesian estimation requires trained personal to 
implement or develop a population model with parameter estimates having adequate precision, in 
comparison to linear regression based (LR) based LS method. If resources can support MAP, 
determination of AUC from limited sampling followed by MAP estimation, has shown good 
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correlation with CNI inhibitor in prior studies in renal transplant patients237. Further, for 
tacrolimus, LS done at times 0, 1 and 3 h post-dose have shown bias and imprecision values of 
less than 15 % 77. 
The LS followed by MAP estimation was chosen for its practicality in clinical usage, as it 
permits more variability around the blood sampling times and in addition, loss of a single time 
point will not invalidate the patient data, as it uses additional information obtained from individual 
patients, unlike the regression equation-based LS methods234. Using optimality criterion, a 
previous study had also shown the 1.5 and 3.5 h post dosing time points to be the most informative 
for combined bayesian estimation of exposure to both tacrolimus and MPA233.  Further a less than 
4- hour total study time is required to obtain patient compliance in the outpatient setting as well as 
to ensure minimal burden on routine clinical activities. 
The LS protocol was implemented by obtaining two additional samples at 1.5 and 3.5 h 
post-dosing of immediate release tacrolimus and MMF, in addition to the trough samples collected 
during the clinical visits on two occasions, period-I and II around days 6 and 90 post-renal 
transplant, respectively. The post-dose LS sampling time points were obtained at 63 instances on 
an average of 1.57 ± 0.17 h and 3.47 ± 0.24 h, indicating the feasibility of LS in routine clinic and 
were well within the 30 min limit of deviation allowed for accurate bayesian estimation. The 
comparison of results from estimation by MAP Bayesian and LR, showed a systematic 
overprediction with LR and inability to calculate exposure in patients with missing time points. 
Further, as around 10 % of sampling time points had a deviation greater than 10 min from ideal 
sparse sampling time points, it could have impacted the accuracy of prediction by LR based 
calculations. 
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A two-compartment model with fixed absorption rate and time lag was used to describe 
the time profile after single dose of immediate release tacrolimus.  Though the evaluated predictive 
performance for individual estimates were satisfactory, the higher values of estimates for 
interindividual variability of tacrolimus during the early post-transplant period resulted in a wide 
prediction interval around the median of the observed values, when applied to current study with 
smaller sample size. The MAP predicted AUC0-12 h ranged from 39 – 294 ng*h/mL with median 
of 142.3 ng*h/mL during period I (day-6) and 101-302 ng*h/mL with median of 165.3 ng*h/mL 
on period II (day-90), though the median dose was around 4 mg on both occasions. The combined 
trough concentrations of both periods showed a good correlation with the predicted AUC0-12 h as 
previously shown for tacrolimus73,238. However, it cannot be used for accurate estimation of 
exposure, as shown in the Figure 4.5, and in line with previous reports, a fixed trough concentration 
can sometimes have a 2-3-fold difference in corresponding 12 h exposure234. The predicted 
exposures during the two occasions were comparable with earlier observations in renal transplant 
patients. Previously, during initial 6 weeks of post-renal transplant period with basiliximab 
induction and MPA co-administration, a tacrolimus target of 210 ng*h/mL was suggested to be an 
ideal 12 h exposure which can be subsequently decreased to 150 ng*h/mL73. Recent consensus 
report identified 150 ng*h/mL to be an ideal target exposure during early post-transplant period in 
renal transplant recipients230.   
In comparison with desired target exposure, a less than optimal mean exposure was 
observed in our study patients, especially during the early post-transplant period around day-6 with 
only 55 % of patients having total exposure above 150 ng*h/mL. On period-II (day-90) around 
60% of patients had exposure above 150 ng*h/mL.  Trough concentrations were higher than the 
target (8 ng/mL) in 30 % and 80 % of patients at period I and II, respectively. The trough as well 
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as estimated exposure for tacrolimus were comparatively increased on continual therapy and hence 
the mean estimated exposure values in period II  was within acceptable therapeutic range. This 
observation of a steady increase in tacrolimus exposure has been reported in earlier longitudinal 
studies with renal transplant patients on tacrolimus therapy73,235,239. Unlike earlier studies however, 
this study examines exposure in relevance to clinical and subclinical rejections.  
The mean value of estimated apparent oral clearance was around 28 and 24 L/h 
respectively, during periods I and II. In fact, the trend in increase of estimated AUC0-12h, should 
be due to the change in CL/F, as there was an absence of significant dose change. Tacrolimus has 
a highly variable oral bioavailability (F) mainly due to the first pass metabolism/efflux due to 
combined effect of CYP 3A enzymes and P-gp in the gut and liver55. In renal transplant patients 
on steroid tapering like our study population, the CL/F can be initially higher due to the induction 
effect of steroids on the CYP enzymes or P-glycoprotein in the gut and liver. It is also shown that 
the mean hematocrit and hemoglobin values in our study patients at period II were approximately 
higher by 30%, due to the normal post-transplant recovery. As tacrolimus shows high binding to 
RBCs, lower hematocrit during early post-transplant can increase the metabolism of unbound 
tacrolimus in the liver, leading to a higher CL/F during that time period. Previous studies and 
population models have also shown hematocrit to be a significant covariate that could determine 
CL and whole blood concentrations of tacrolimus239. The change in albumin however was 
marginal with time and hence its impact on CL/F due to changes in the binding of tacrolimus to 
plasma proteins could have been obscured.  
CYP3A5 is the single most influential covariate known to directly influence the dose 
requirement and blood concentrations of tacrolimus, as CYP3A5 has higher efficiency to 
metabolize  tacrolimus when compared to CYP3A4240. Almost 76% of study patients were 
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CYP3A5 non-expressors and comparable to earlier reported range of 75 – 85 % in white 
population62. CYP3A5 is present in majority of the Caucasians as the homozygous *3/*3 genotype 
also called as non-expressers, due to the inherent loss of CYP3A5 expression due to *3 allele while 
those with *1 allele are called expressers.  In our study patients, it was observed that the estimated 
AUC0-12h was halved and CL was more than doubled in CYP expressers having one *1 or both 
*1/*1 (homozygous) alleles. This effect has been widely reported in earlier studies associated with 
estimates of increased dose requirement by at least 50% in patients with *1 allele or even more so 
in homozygous expressers241,242. Hence, the Clinical Pharmacogenomic Implementation 
Consortium (CPIC) also recommends a 1.5 to 2-fold increase in starting dose of tacrolimus in 
CYP3A5 expressers57. Due to the lower sample size during period II, the comparison of estimated 
exposure between CYP3A5 genotypes was not statistically different. 
Unlike CYP3A5, the blood exposure or dose of tacrolimus did not differ among patients 
with various MDR1 (P-gp) genotypes. However, it should also be noted that P-gp is expressed on 
lymphocytes and the genotypes can variably alter intracellular tacrolimus concentration and 
possibly be better representative of tacrolimus efficacy than the whole blood concentrations. 
Indeed an earlier study had shown higher dose adjusted tacrolimus concentration within PBMCs 
in carriers of 1199A and 3435T variants, both of which correspond to the lower activity of the 
MDRI protein243. Few studies have investigated associations of MDR1 gene polymorphisms in 
association with biopsy proven rejection but have been contradictory so far. Studies have shown 
association of variant alleles with rejection243,244 in liver and kidney transplantation while another 
study reported no association245. In addition, a few practical challenges exist for the direct 
estimation of intracellular tacrolimus levels, such as the possible efflux of tacrolimus during 
PBMC isolation, requirement of sensitive LC-MS/MS method and obtaining adequate cell counts 
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during early post-transplant when other efficacy markers like IMPDH activity are also evaluated. 
Hence, the genotypic variants of MDR1 are currently treated as surrogates for intracellular 
tacrolimus concentrations and examined for association with biopsy proven outcomes (chapter 6). 
However, it is also acknowledged that a direct genotype-phenotype correlation of P-gp activity 
may be confounded by other non-genetic factors, such as changes in unbound tacrolimus caused 
by binding to alpha acid glycoprotein (AAG), as AAG can be induced during the immediate post-
transplant periods246.  
In conclusion, the estimation of tacrolimus exposure from limited sampling was carried out 
at early post-transplant and followed up around day-90 along with routine monitoring of trough 
blood levels. The individual exposures to tacrolimus along as well as other influential covariates 
like hematocrit and genotypes of CYP3A5 and MDR1 genotypes were obtained.  Genotyping 
revealed that the estimated exposure (AUC0-12h)was halved and CL was more than doubled in CYP 
expressers having one *1 or both *1/*1 (homozygous) alleles while the blood exposure or dose of 
tacrolimus did not differ among patients with various MDR1 (P-gp) genotypes. The MAP 
Bayesian based approach was found to be better for estimation of exposure from limited sampling. 
The parameters for tacrolimus will be examined further by analysis along with efficacy and 
exposure to MPA, to determine cut-off values related to the occurrence of clinical/subclinical 
rejections and infections, in renal transplant patients. 
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5.0  ESTIMATION OF THE EXPOSURE TO MYCOPHENOLIC ACID AND ITS 
RELATIONSHIP TO INOSINE MONOPHOSPHATE DEHYDROGENASE ACTIVITY USING 
SPARSE SAMPLING IN RENAL TRANSPLANT PATIENTS  
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5.1 ABSTRACT 
Mycophenolic acid and tacrolimus-based immunosuppression is the standard of care in 
renal transplant patients. Protocol biopsies have revealed early subclinical rejections in patients on 
standard immunosuppression therapy. The overall objective of this study was to determine the 
effect of early post-transplant exposure and response to therapy with mycophenolate and 
tacrolimus, on the evolution of biopsy proven acute rejections (clinical + subclinical) or episodes 
of infections in renal transplant patients. The specific objective of the study presented in this 
chapter is to evaluate individual exposure to MPA along with its effect on the inhibition of its 
target (IMPDH) during early post-transplant period (week-1=period I) and during follow up at the 
time of 3-month protocol biopsy (week-13=period II). Sparse samples for plasma and PBMC were 
obtained at predose, 1.5 and 3.5 h during the early and the follow-up periods, from 42 and 23 renal 
transplant patients, respectively. AUC0-12 h was estimated from a prior population model by 
maximum a posteriori bayesian estimation. The mean MPA exposure (predicted AUC0-12 h) was 
comparable between Period I to Period II (48.3 ± 21.4 vs 58.2 ± 32.8, NS) with only 47 and 50 % 
of patients falling within the 30-60 µg*h/mL exposure window, respectively. The dose normalized 
exposure however showed an increase during Period II (0.05 ± 0.02 vs 0.07 ± 0.03 µg*h/mL/mg, 
p=0.002), while there was no change in the dose normalized free exposure (0.97 ± 0.78 vs 0.71 ± 
0.36 ng*h/mL/mg, NS). IMPDH activity was significantly higher at early posttransplant with 
median values for predose (54.8 vs 36.3 µM XMP/M AMP/sec, p =0.04) and Rmin (26.1 vs 19.0 
µM XMP/M AMP/sec, p=0.01), during period I vs II, respectively. The IMPDH Rmin was 
significantly higher while the predose activity tended to be higher in patients with the lowest MPA 
exposures (< 30 µg*h/mL). The individual estimates of exposure and IMPDH activity indicated 
time-dependent changes in MPA exposure and response during early post-transplant and the need 
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for post-transplant time-based assessments for MPA PK and PD, which could be enabled by sparse 
sampling in an outpatient setting. 
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5.2 INTRODUCTION 
Mycophenolic acid (MPA), the active metabolite of the prodrug mycophenolate mofetil 
(MMF) is an immunosuppressant used in combination with tacrolimus for maintenance therapy in 
renal as well as other solid organ (liver, heart and lung) and hematopoietic stem cell transplant 
patients. Mycophenolic acid is a reversible inhibitor of the enzyme inosine monophosphate 
dehydrogenase [IMPDH] and the immunosuppression results due to the selective reduction in 
guanine nucleotide synthesis in lymphocytes, that depend on this de novo pathway247. Studies in 
renal transplant patients with MMF dosing have shown a significant inverse relationship between 
exposure or Area under the curve (AUC0-12 h) for MPA and biopsy proven rejection 
(BPAR)72,109,131. On the other hand, associations of trough (C0) MPA levels are weak and 
inconsistent both with AUC0-12 h248-250 as well as BPAR72,109,118,131.  Hence, for the prevention of  
acute rejection in combination with tacrolimus, a MPA AUC0-12 h of 30-60 µg*h/mL has been 
recommended 132,251.   
Significant inter-patient variability in the pharmacokinetics of MPA is known252 and with 
a fixed dosing of MMF, many patients do not reach or fall outside the intended 30-60 µg*h/mL 
target range90,105,113,131 for MPA. Several patient covariates can impact pharmacokinetics of MPA 
leading to the between-patient variability in total exposure. MPA free fraction and clearance can 
decrease significantly with increasing albumin concentrations88,253. MPA clearance and variability 
are affected by plasma protein binding changes in presence of high concentrations of the metabolite 
MPAG or the uremic toxins, consequent to poor or delayed graft function. Hence, patients with  
creatinine clearance less than 25 mL/min showed a significantly higher mean MPA clearance on 
days 3, 7 and 21 post-transplantation90. A positive correlation between the clearance of MPA and 
body weight has also been shown in renal transplant patients89.  Hence, the variability in MPA 
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pharmacokinetics are associated with changes in covariates following renal transplant (both within 
patient as well as between patients) and these are more profound and significant during early post-
transplant period. Further, apart from MPA exposures, corresponding changes in biological effects 
of MPA (inhibition of IMPDH activity) may be an additional factor that needs to be taken into 
consideration.  
The association of early post-transplant exposure of MPA as well as response to MPA with 
the diagnosis of acute rejection (clinical + subclinical) observed during early protocol biopsy in 
renal transplant patients on standard immunosuppression therapy, is not clear. Hence, the broad 
study objective was to determine the contributory role of individual exposures to MPA (along with 
efficacy) and tacrolimus during early post-transplant period, in renal transplant patients with 
diagnosis of biopsy proven rejections (clinical + subclinical) or infection (BK virus or CMV). 
However, as determination of full exposures (AUC0-12 h) is not clinically practical, estimation of 
AUC using sparse sampling provided a viable alternative. Population pharmacokinetic models 
with maximum a posteriori bayesian (MAP) estimation of AUC0-12 h from sparse sample 
concentrations, are used in some clinics to predict dose as well as confirm exposures for MMF and 
MPA, respectively134. Hence, the objective of the study presented in this chapter is to determine 
individual patient exposures to MPA along with its association to  IMPDH activity by application 
of sparse sampling on 2 occasions, once during early post-transplant (1-2 weeks) and  followed up 
at 3rd month, in renal transplant patients with protocol biopsies performed at 3 months. 
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5.3 MATERIALS  
Methanol (UPLC MS grade), acetonitrile and water (MS grade) were purchased from 
Fisher Scientific (Fair lawn, NJ, US). Formic acid and ammonium acetate were purchased from 
Sigma-Aldrich (St. Louis, MO). MMF Cat No: M831450, mycophenolic acid (MPA) Cat No: 
M831500, deuterated mycophenolic acid (d3-MPA) Cat No: M831502 and MPAG Cat No: 
M831520, were purchased from Toronto Research Chemicals (ON, Canada).  Blank plasma was 
obtained from central reference testing laboratory, Pittsburgh. The centrifree ultrafiltration device 
Cat No. 4104 MI was purchased from Fisher Scientific. 
IMP, AMP, 8-bromoadenosine 5-monophosphate (Br-AMP) and Dulbecco’s Phosphate 
Buffered saline without calcium were purchased from Sigma Aldrich. XMP was purchased from 
Toronto Research Chemicals, Ficoll-Paque solution was from GE Healthcare (QC, Canada) and 
Sepmate50® tubes were purchased from stem cell technologies (BC, Canada). Sodium dihydrogen 
phosphate, potassium chloride, ammonium acetate, potassium hydroxide was from Fisher 
Scientific. The details of kits and reagents related to genotyping were presented in chapter 4. 
5.4 METHODS  
5.4.1 Study approval and Screening 
The study protocol was approved by IRB (Approval No. PRO16050030, dated 20 Oct 
2016, titled “Exposure to Mycophenolic acid/Tacrolimus and outcomes in renal transplant 
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recipients”). The details of inclusion exclusion criterion, screening of patients, enrollment, study 
design and time points were as provided in chapter 4. 
5.4.2 Blood sampling 
The conduct of the study and blood sampling are as described in chapter 4.  A baseline 
blood sample was obtained prior to transplant, for characterization of individual IMPDH enzyme 
activities in the absence of immunosuppression. On the study day, three blood samples of 
approximately 7-8 mL each were obtained from all subjects. The first morning tough blood sample 
was obtained on arrival of patient to the clinic. Following the oral dose of MMF with tacrolimus, 
two additional samples were drawn at around 1.5 and 3.5 h into lithium heparin tubes. The exact 
clock times of previous and current dosing and sampling were individually documented. An 
aliquot of 2 mL blood sample was centrifuged at 4°C for 4 min at 1500 x g. The supernatant plasma 
was then transferred to cryovials, labeled and stored as duplicates at −80°C, until analysis of MPA 
and MPAG concentrations by LCMS/MS. The remaining blood used for PBMC isolation. 
5.4.3 PBMC isolation 
Blood was diluted 1:3 by using Dulbecco’s phosphate buffered saline (DPBS without 
Calcium) and layered on top of 15 mL of Ficoll reagent in a Sepmate® tube followed with 
immediate centrifugation at 1200 g for 20 min. The supernatant was decanted by quick flip over 
of tube for not more than 2 secs to avoid pouring out of the sedimented layer. The decanted 
supernatant was washed once with cold DPBS and made up to volume of 30 mL, followed by 
centrifugation at 300g for 8 min. After discarding supernatant, the pale white pellet was retained 
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along with approximately 0.5 mL of DPBS. The viable PBMC cells are counted by tryphan blue 
exclusion under 20x magnification using a hemocytometer. The PBMC cells were immediately 
lysed by adding 100 µls of ice-cold water and lysates were stored in duplicates at -80° C, until 
analysis of AMP and XMP concentrations by LCMS/MS. 
5.4.4 Protein binding 
The binding of MPA and MPAG in plasma was determined by ultrafiltration and using 
once sample for each patient per each occasion (period) of the study. Thawed plasma sample was 
incubated with mild shaking at 37° C for 30 min. Then about 250-300 µls was transferred to a 
centrifree® ultrafiltration tube, taking care to carefully add on sides of the tube to avoid formation 
of bubbles. The ultrafiltration tubes were centrifuged in a Sorvall RC-58 centrifuge at 1000 g for 
30 min at 37° C and the obtained protein-free ultrafiltrate was retained and stored at -80°C, until 
analysis of MPA and MPAG that correspond to their unbound concentrations. 
5.4.5 LCMS/MS analysis of plasma/ultrafiltrate samples 
Prior to LCMS analysis, plasma samples (50 µls) were mixed with 200 µls of Acetonitrile 
containing 50 ng of internal standard (d3-MPA) and vortexed for 30 seconds followed by 
centrifugation at 15,000 rpm for 8 min at 12°C. Supernatant (25 µls) was taken into another tube 
and mixed with 475 µls of  mixture containing water : methanol (1:1 v/v) and again centrifuged at 
15,000 rpm for 8 min at 12°C. Supernatant (400 µls) was transferred into LCMS vials and 1 µl 
was injected on to a Acquity® UPLC HSS T3 column (1.8 µm, 100 mm × 2.1 mm i.d.) (Waters 
Corp., Milford, MA, USA). The mobile phase was 2 mM ammonium acetate containing 0.1% v/v 
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of formic acid and acetonitrile in a gradient mode at a constant flow rate of 0.3 mL/min for 8 
minutes. The settings for MS were: Capillary voltage 2.5 kV, Cone voltage: 40 V, Desolvation 
temperature: 500 °C, Cone gas flow 150 l/hr and Desolvation gas flow 850 l/hr. The mass 
transitions for MMF, MPA, MPA d-3 and MPAG were 433.9>114, 320.96>206.97, 323.9>209.9 
and 518.8> 343.1, respectively. 
The assay range was linear for MPA between 0.01-25 μg/ml, while linear range for MMF 
and MPAG concentrations were from 0.1-100 μg/ml, as shown in Figure 5.1. The processing 
conditions for ultrafiltrate was similar except that 100 µls of acetonitrile was added to samples and 
2 µls was injected on to the column. For ultrafiltrate samples, water was used for calibration 
standard preparation and the assay range for MPA and MMF were between 0.002-1 μg/ml, while 
the range for MPAG concentrations was from 0.02-10 μg/ml. 
5.4.6 Incubation protocol for assessment of IMPDH activity 
The protocol for evaluation of IMPDH activity in lysates of PBMC was adapted from 
Bemer et al.254 after slight modifications, as described below. All activities were carried by 
incubation on ice. The frozen lysates were thawed and subjected to 15 secs of probe sonication for 
disrupting intact PBMC cells, if any. Next, the lysates were centrifuged for 1 minute at 1000g, to 
precipitate cellular debris. The clear supernatant lysates of PBMC were incubated in duplicate, one 
to assess XMP production from the externally added substrate IMP, and the other to assess AMP 
content as a surrogate for number of PBMCs used for incubations. For XMP incubations, 50 µls 
of lysate was mixed with 130 µls of ice-cold incubation buffer (composed of 40 mM sodium 
dihydrogen phosphate and 100 mM potassium chloride (pH 7.4) along with 1 mM of IMP and 0.25 
mM of NAD+). The incubation process was initiated by placing in a heated water bath at 37°C and 
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with gentle agitation for 180 min. In parallel, the duplicate of the lysate (50 µls) was mixed with 
130 µls of ice-cold working buffer (composed of 40 mM sodium dihydrogen phosphate and 100 
mM potassium chloride (pH 7.4) only) and incubated alongside the earlier sample, for the 
assessment of AMP content in PBMC. Unlike incubates to assess XMP production, the duplicate 
incubates for AMP estimation did not include NAD+, because NAD+ was an interference for AMP 
analysis, owing to the similarity in mass to charge ratio and retention times during LCMS/MS 
analysis. 
Incubations were terminated with 1 mL of ice-cold methanol followed with addition of 20 
µls of internal standard (10 μg/ml of Br-AMP in deionized water) and the mixture was vortexed 
for 30 seconds and centrifuged at 15,000 g for 10 min at 37° C. About 0.9 mL of supernatant was 
then transferred to 12 × 75 mm disposable culture tubes that were placed on ice and then 
evaporated to dryness under a stream of air at 30 °C. The dried samples were stored in -80°C after 
proper wrapping of the culture tubes and stored for up to 2 weeks until LCMS analysis. A 
requirement for greater than 2 weeks of storage did not arise, and no stability issues were 
encountered with up to 2 weeks of storage at -80°C. 
5.4.7 LCMS analysis (XMP/AMP) 
The dried samples were reconstituted with 100 µls of LCMS grade water, transferred into 
vials and 10 µls was injected onto a Thermo Scientific Hypercarb column (2.0mm × 100mm × 5μ, 
part no. 35005-102130; Thermo Scientific, Bellefonte, PA) for the analysis of XMP or AMP. The 
total sample run time was 10 min. 
The chromatographic separation was performed on an Agilent HPLC/MS system series 1200 with 
a thermostatically controlled autosampler (Agilent Technologies, Palo Alto, CA) maintained at 4° 
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C. The mobile phase consisted of A: acetonitrile and B: 0.1 M ammonium acetate in LCMS water, 
adjusted to pH 8.5 with ammonium hydroxide and freshly prepared every time, just before 
analysis, failing which retention times were altered.  Elution was achieved with a mobile phase 
gradient starting at 5% acetonitrile for first 0.5 min then increased to 30% at 4 min and held at 
30% till 5 min and then switched back to 5% at 5.1 min. The first 3.5 minutes of eluate as well as 
the last 3 minutes were diverted to waste. The column temperature was set to 30 °C and the flow 
rate was maintained at 0.3 mL/min. The autosampler needle was washed between injections with 
0.03 % v/v of ammonium hydroxide to avoid carryover with NAD+ or AMP. 
A SCIEX 4000 Q triple quadrupole ion trap mass spectrometer electron spray (ES) in positive ion 
mode was used. The temperature of the drying gas (nitrogen) was maintained at 350 °C at a flow 
of 11 L/min.  
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Figure 5.1. (a) Representative ion chromatograms of Adenosine monophosphate (AMP), Xanthosine 
monophosphate (XMP) and Internal standard (Br-AMP) 
 (b) Standard curve for XMP (range 5-2000 ng/mL) and AMP (5-1000 ng/mL) 
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Figure 5.2. (a) Representative ion chromatograms of mycophenolic acid glucuronide (MPAG), 
Mycophenolate mofetil (MMF), Mycophenolic acid (MPA) and Internal standard (MPA-d4) 
at retention times 1.3, 2.2, 3.4 and 3.4 mins, respectively (b) Standard curve for MPAG 
(range 0.1-100 µg/mL), MMF (0.1-100 µg/mL) and MPA (0.01- 25 µg/mL) 
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The transition ion pairs under MRM mode were m/z 365.5> 153.3, 348.4> 136.3 and 
426.1> 214.4 for XMP, AMP and Br-AMP, respectively. The typical retention times were 3.8 min 
for XMP, 5.5 min for AMP and 6.9 min for Br-AMP. As shown in Figure 5.2, the assay was linear 
for XMP and AMP in the range of 5-2000 and 5-1000 ng/mL, respectively. 
5.4.8 Calculations and data analysis 
The fraction unbound (fu) of either analyte (MPA or MPAG) was determined as ratio of unbound 
(ultrafiltrate) to total (plasma) concentrations, as below 
fu = [analyte]filtrate                               
       [analyte]plasma 
% free = fu x 100; where % free is the unbound free drug expressed in percentage. 
5.4.9 Prediction of individual concentrations and predictive performance 
Individual parameter estimates for CL were determined by nonlinear mixed effect 
modeling using NONMEM 7.4.3 (Icon, Ireland). The population values for MPA were fixed from 
a prior model 233 with subroutine ADVAN4 TRANS4 and maximum a posteriori (MAP) bayesian 
method with first order estimation was used. A two-compartment model with first order absorption 
(Ka=2.65 h-1) was used to describe the time profile of MPA after single dose of mycophenolate 
mofetil (MMF). The CL/F was fixed at 6.83 L/h, central volume V1/F at 133 L, 
intercompartmental Q/F at 28.2 L/h and V2/F at 995 L. Exponential model was used for all the 
interindividual variability terms and a combined error model was used to describe the residual 
variability. The MMF dose and MPAG concentrations were converted into MPA equivalents by 
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multiplication with 0.739 and 0.645, respectively. The dosing history and clock timings were used 
as prior information for each patient for estimation of individual parameters and were output with 
specification of “posthoc” and maxeval=0.  Individual concentrations of MPA were predicted until 
12 h after MMF dosing on the day of study and compared with observed concentrations. Predicted 
MPA concentrations at desired time points were used to estimate the individual 12 h exposures 
(AUC0-12 h) for each period, as described later. Alternatively, a linear regression based equation 
was also used to estimate exposure, by using observed concentrations at 1.5 and 3.5 h in the 
published equation233: 16.5 + (4.9 x C1.5) + (6.7 x C3.5), as ~90 % of sampling time points were 
within 10 minutes of 1.5 and 3.5 h. 
Predictive performance of the population model was verified with diagnostic plots using 
pirana® (Certara, NJ, US) and RStudio (version 1.1.453), as described in chapter 4. The bias in 
predicted concentrations were estimated using mean prediction error (MPE) and precision was 
estimated by median absolute prediction error (MDAPE) and median percentage in absolute 
prediction error relative to the observed concentrations (% MDAPPE), as described earlier in 
chapter 4. 
5.4.10 Non-compartmental analysis 
The partial exposures (AUCpartial) for MPA and MPAG were calculated until 3.5 hours (or 
the actual time of last sample) on periods I and II, by using non-compartmental analysis (NCA) of 
Phoenix® WinNonlin (Certara, NJ, US). The partial exposures of MPA and MPAG were multiplied 
by their corresponding unbound fractions to obtain unbound partial exposures (AUCp-free). The 
total exposures (predicted AUC 0-12 h) were calculated from individual predicted concentrations 
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using NCA by Phoenix® WinNonlin. The total exposure of MPA was multiplied by corresponding 
unbound fractions to obtain unbound exposure (AUCfree). 
5.4.11 IMPDH enzyme activity 
Activity of IMPDH in PBMC lysates of patients was expressed as XMP (μmol) produced 
per unit time (sec) after normalization with AMP (mol), considering AMP content as a surrogate 
for the actual number of PBMC cells that were initially present in the lysate. The estimated AMP 
content was used for normalization, in lieu of cell counts or protein content, due to better accuracy 
and sensitivity in measuring AMP in comparison to cell counting or protein estimation by 
traditional methods. 
              IMPDH activity  
(μmolof XMP/second/mol of AMP)     =  
 
[produced XMP] x 106  
--------------------------------------- 
(incubation time in secs x measured AMP)] 
 
Parameters corresponding to description of individual IMPDH enzyme activities such as 
the predose activity, Rmin and AUC_B were summarized using the drug effect module of NCA 
using Phoenix® WinNonlin. The AUC_B was the area under the IMPDH activity curve from 
baseline until the last observed time point of around 3.5 h and Rmin corresponds to response 
minimum which is the least IMPDH activity during the observation interval and is associated with 
the maximum inhibition effect by MPA. 
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5.4.12 Genotyping 
The protocol followed for exaction, purification of genomic DNA and genotyping by allelic 
discrimination assays, was as described in chapter 4. The genotypes associated with disposition of 
MPA and IMPDH activity such as UGT 1A9 (98 T>C), UGT 1A9 (275 T>A), UGT 1A9 (2152 
C>T),  IMPDH 1 (106 G>A), IMPDH 1 (125 G>A) and IMPDH 2 (3757 T>C) were considered 
for analysis, and details are as shown in Table 5.1. 
 
Table 5.1. Assay details for identifying SNPs in select enzymes and transporters associated with 
mycophenolic acid disposition and IMPDH activity in patients  
gene SNP name rs number Assay ID (Taqman®) 
UGT 1A9 98 T>C rs72551330 C__64627083_10 
UGT 1A9 275 T>A rs6714486 C__27843087_10 
UGT 1A9 2152 C>T rs17868320 C__34418857_10 
IMPDH 1 106 G>A rs2278294 C__2830834_20 
IMPDH 1 125 G>A rs2278293 C__15965182_10 
IMPDH 2 3757 T>C rs11706052 C__1842928_10 
 
5.4.13 Statistical analysis 
Statistical tests were performed using SPSS® software version 25 (IBM corporation, US) 
and Prism version 8 (GraphPad software, CA, US). A paired t-test or Wilcoxon signed rank test 
 160 
was used for comparison of values between period I and II within the same patient while overall 
comparisons between the patients in both periods were tested using unpaired t-test or Mann 
Whitney test, with significance of < 0.05. Ratio statistics of SPSS was used to obtain confidence 
interval around the median of predictive performance values. Graphical outputs were done using 
R (version 3.5), pirana® and Prism software. 
5.5 RESULTS  
A summary of the clinical variables and demographic information are described earlier 
(Table 4.2 of chapter 4). As noted earlier, a significant improvement in renal function (estimated 
glomerular filtration rate eGFR) with time was observed when comparing values from both 
periods, around the 6th and 91st day post-transplant, respectively. Though, median albumin levels 
did not differ between the 2 periods, there was a significant increase in percentage protein binding 
of MPA and MPAG in period II, in concordance with improvement in eGFR. As shown in Table 
5.2 and Figure 5.3, the percentage free drug dropped from an average of 2.5 down to 1% and from 
52 to 32% from period I to II for MPA and MPAG, respectively. The partial exposures (until 3.5 
h after dosing of MMF) obtained during both periods for MPA and MPAG are compared in Table 
5.2 and Figure 5.3. As MPAG is renally cleared, poor MPAG elimination was observed during 
period I, at around 6 days after transplantation of the graft, resulting in a significantly higher 
MPAG/MPA ratio (~ 50 vs 12, period I vs II). With time, there was a significant decrease in 
exposure to the renally eliminated MPAG, due to the improved function of the transplanted kidney, 
while the partial exposure to the hepatically cleared MPA was significantly increased from period 
I to period II. MPA  is a low clearance drug and hence as (CLtotal = fu x CLintrinsic), the CL of total 
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MPA is significantly higher when fu was higher (period I) followed by lower fu and decreased 
MPA clearance (period II).  Again, despite lower fu during period II (increased protein binding of 
MPA), partial exposure to MPAfree was unchanged, while it significantly decreased for MPAG 
(Table 5.2 and Figure 5.3). The observations for unaltered MPAfree exposure was supported by 
predicted CL/Ffree for MPA also being unaltered during the two periods (Table 5.4), as is usually 
the case with drugs having a low extraction ratio. This also indicated a normal conjugation activity 
by UGT enzymes involved in the metabolism of MPA during this post-transplant study period. 
The maximum a posteriori Bayesian estimation (MAP) showed superior predictions for AUC0-12h 
in comparison to linear regression equation-based estimation (Figure 5.4). Figure 5.4 also shows 
that despite good correlation with MAP, a systematic overestimation in exposure occurred with 
the regression method. There was a better correlation of MAP estimations with observed MPA 
trough levels (r=0.89). The results with MAP estimation were more consistent with clinically 
reported exposures after 1000 mg MMF dosing .
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Table 5.2. Protein binding and partial AUCs (total and free) of MPA and MPAG (Period I & II) 
Mean ± SD 
Median 
(Min, max) 
MPA MPAG 
All patients Only patients that completed both periods All patients 
Only patients that completed both 
periods 
Period I 
(n=42) 
Period I 
(n=23) 
Period II 
(n=23) 
p value* 
Period I 
(n=42) 
Period I 
(n=23) 
Period II 
(n=23) 
p value* 
AUCpartial 
(µg*h/mL)# 
 
13.8 ± 8.0 
11.8 
[2.5, 35] 
15.0 ± 8.6 
14.5 
[2.5, 35] 
22.4 ± 14.1 
19.8 
[5.8, 63.9] 
0.03 
432 ± 276 
372.3 
[87.2, 1234.5] 
391.7 ± 252.5 
300.5 
[92.7, 966.6] 
203 ± 62.7 
198.8 
[61.5, 334.9] 
<0.005 
fu (%) 
2.5 ± 1.9 
1.8 
[0.4, 8.9] 
2.5 ± 2.2 
1.4 
[0.4, 8.9] 
1.0 ± 0.3 
1.0 
[0.4, 1.6] 
<0.01 
49.7 ± 21.4 
52.8 
[15.5, 90.0] 
52.0 ± 24.3 
53.7 
[15.5, 90.0] 
32.4 ± 16.7 
26.5 
[10.1, 73.1] 
<0.001 
AUCpartial. free 
(µg*h/mL) 
0.28 ± 0.21 
0.23 
[0.03, 1.1] 
0.29 ± 0.2 
0.23 
[0.08, 0.9] 
0.23 ± 0.17 
0.19 
[0.06, 0.8] 
NS 
239 ± 205 
152.9 
[22.6, 697.4] 
225.5 ± 208.9 
145.1 
[30.2, 675.4] 
69.2 ± 47.3 
54.9 
[16.5, 173.3] 
<0.005 
Ratio 
(MPAG/MPA) 
49.6 ± 58 
27.4 
[3.5, 255] 
46.1 ± 64.6 
20.2 
[5.5, 255] 
12.0 ± 8.4 
10.4 
[3, 43.6] 
<0.01  NA 
 
NA 
 
NA 
 
NA 
AUCpartial = AUC0-3.5 h, * paired t-test comparison in patients that completed both periods; NS- No significance (p ≥ 0.5) 
# Correlation to predicted AUC0-12 h was r= 0.81 (0.66-0.89) and 0.98 (0.95-0.99) in period I (n=42) and II, respectively 
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Figure 5.3. Summary of partial (total and unbound) Area Under Curves and fraction unbound (fu) for MPA and MPAG (Periods I & II) 
Partial AUC of MPA or MPAG = AUC0-3.5  h
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Linear_regression = 1.215*(Bayesian_estimation) + 15.41 
 
 
 
Figure 5.4. Correlation between MPA exposure determined by Bayesian estimation, 
linear regression and trough plasma levels 
The scatter plot matrix shows individual panels examining correlation between exposure determined by two 
different methods (µg*h/mL) and correlation with the observed MPA trough plasma concentrations (µg/mL). 
Corresponding r values for correlations are in the diagonally opposite panel 
Table 5.3. Predictive performance of bayesian estimation for mycophenolic acid plasma concentrations 
Measure Estimate 
(95 % CI) 
Mean prediction error 
(MPE, µg/mL) 
0.04 
(-0.21 – 0.29) 
Median absolute prediction error 
(MDAPE, µg/mL) 
0.80 
(0.65 – 1.0) 
Median absolute percentage prediction error 
(MDAPPE, %) 
25 
(21.8 – 27.5) 
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The quality of MPA concentration predictions using a prior model with maximum a 
posteriori bayesian estimation, were assessed from the bias and precision values, as shown in Table 
5.3. The model predicted concentrations were also visually evaluated for comparison with 
observed plasma concentrations and are presented in panels a-d of Figure 5.5. The mean of 
prediction error (with 95% CI) was 0.04 (-0.21-0.29) µg/mL and was not significantly different 
from zero (p=0.733). The observed imprecision in prediction was 0.80 (0.7-1) µg/mL with an 
absolute prediction error of 25% (21.8 – 27.5). The predicted concentrations agreed well with 
observed concentrations, but the higher absolute prediction error was due to underpredictions at 
1.5 h and slight overprediction at 3.5 h, observed in less than 5 % of samples. The weighted 
residuals (after first order estimation) and prediction errors showed an approximate normal 
distribution with a mild skew towards positive values. The prediction and variability-corrected 
visual predictive check (pvcVPC) is presented in panel d of Figure 5.5. The pvc was done to correct 
for MPA concentrations after different daily doses of MMF. As shown in the Figure, the median 
as well as the 5th and 95th percentile of the prediction and variability-corrected log transformed 
observations overlapped with the distribution of the simulated concentrations and indicated model 
acceptability in predicting MPA concentrations. 
The predicted individual exposures to MPA (AUC0-12 h) in patients are summarized in 
Table 5.4 and a graphical comparison of exposure versus the desired therapeutic range is presented 
in Figure 5.6. An overall increase in MPA exposures with higher dose of MMF was observed as 
shown in Figure 5.6.  In addition, a trend to increase in mean predicted AUC0-12 h was noted with 
time after transplant (48.3 vs 58.2 µg*h/mL), which was paralleled by a significant decrease in 
predicted CL/F from period I to II, as shown in Table 5.4.   
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Table 5.4. Predicted CL/F and exposure for MPA by maximum A Posteriori bayesian estimation 
Mean ± SD 
MPA 
All patients Only patients that completed both periods 
Period I 
(n=42) 
Period I 
(n=23) 
Period II 
(n=23) 
p value* 
Predicted AUC0-12 h 
(µg*h/mL) 
43.9 ± 21.7 48.3 ± 21.4 58.2 ± 32.8 
NS 
(0.1522) 
Dose Normalized 
Predicted AUC0-12 h 
(µg*h/mL/mg) 
0.04 ± 0.02 0.05 ± 0.02 0.07 ± 0.03 0.0020 
Predicted AUC0-12 h free 
(µg*h/mL) 
0.946 ± 0.736 0.847 ± 0.490 0.537 ± 0.392 0.0203 
Dose Normalized 
Predicted AUC0-12 h free 
(ng*h/mL/mg) 
0.961 ± 0.733 0.974 ± 0.781 0.705 ± 0.362 
NS 
(0.1029) 
Predicted CL/F 
(L/h) 
28.9 ± 16.0 25.9 ± 14.6 16.6 ± 6.3 0.002 
Predicted (CL/F)free 
(L/h) 
15.8 ± 10.4 16.8 ± 11.9 18.4 ± 11.5 0.697 
*paired t-test comparison in patients that completed both periods; P<0.05 was significant 
difference; NS – not a statistically significant difference; AUCfree- unbound Area Under the 
Curve 
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a) Observed versus individual predictions (µg/mL) b) Histogram plot for weighted residuals (first order estimation) 
c) Plot of normalized prediction distribution errors (NPDE) d) pvc-VPC plot where blue dots represent the 
prediction and variance corrected natural log transformed observations, the solid and broken lines represent median 
and 90% prediction intervals. The shaded areas around lines represent 99% confidence intervals for median, 5th and 
95th prediction intervals obtained from the simulations with IIV of V2/F and CL/F fixed at 50 and 100%, 
respectively 
Figure 5.5. Evaluation of observations versus predictions with the Mycophenolic acid population model 
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Figure 5.6. Summary of predicted area under the curve (AUC) values for Mycophenolic acid  
 with MMF doses on Period I and II 
The boxes represent median and inter-quartile range in predicted total MPA exposures achieved in 
patients on different doses of MMF (mg/ twice daily); The shaded between 30-60 µg*h/mL represents 
desired range of MPA exposure based on previous studies; The number of patients on each dose from 
left to right are n = 3 and 39 for 750 and 1000 mg bid in period I and n = 6, 4 and 13 for 500, 750 and 
1000 mg bid in period II, respectively  
 
 
The dose normalized predicted exposure was significantly increased during period II, while 
the dose normalized predicted free exposure showed no change (Table 5.4). The same pattern is 
also observed when exposures after similar MMF doses, were compared across both periods.  
Higher exposures occurred in period II after similar doses (Figure 5.6). Overall, only 47 and 50% 
of patients were within the 30-60 µg*h/mL range during periods I and II, respectively. Around 33 
and 13% of patients were below and 13 and 37% of patients were above the AUC range, during 
periods I and II, respectively.  
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Figure 5.7. Summary of Mycophenolic acid concentrations versus IMPDH activity at  
  sparse sampling time points (Periods I and II) 
 
The median baseline pretransplant IMPDH activity was 93.2 (62.29, 155.2) µM XMP/M 
AMP/sec and variable between the patients. The IMPDH activity at the sparse sampling points in 
both periods along with corresponding MPA concentrations are illustrated in Figure 5.7. Overall, 
the IMPDH activity reached nadir values around 1.5 h at both periods corresponding to the peak 
values of MPA plasma concentrations. IMPDH activities at all time points in period II were lower 
than at similar time points in period I and the corresponding MPA concentrations were also higher.  
The higher inhibition of IMPDH activity in Period II was also evident on comparison of the 
pharmacodynamic parameters presented in Table 5.5. The average values of predose, Rmin were 
significantly lower while those of maximum inhibition percentage, AUC_B were significantly 
higher, indicating better inhibition in IMPDH activity during Period II. 
The pre-transplant IMPDH activity showed significant positive relationship with the predose 
activity as well as the Rmin during Period I, so patients with higher pretransplant activity tend to 
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show higher predose activity and higher Rmin during the early post-transplant period, as shown in 
Figure 5.8. 
 
Figure 5.8. Relationship of pre-transplant IMPDH activity versus post-transplant IMPDH activity during 
trough (predose) and response minimum (Rmin) (Periods I and II)  
The scatter plot matrix shows individual panels examining time-dependent correlation between parameters 
of IMPDH activity such as the Rmin (Response minimum of IMPDH activity within the sparse sampling time 
points), predose (IMPDH activity at trough time point) and activity obtained at pretransplant; all IMPDH 
activity values were in µM of XMP/mol of AMP/sec; Square root transformation of Rmin and predose values 
was done prior to evaluating correlation; Corresponding r values for correlations are in the diagonally 
opposite panel 
 
This relationship was not significant during period II, after a prolonged exposure to MPA. 
IMPDH activity showed an inverse relationship with total MPA concentrations which was better 
than with the free MPA concentrations, examined during both periods. As shown in Figure 5.9, a 
negative relationship (r = - 0.28 – -0.38) existed for the IMPDH activity versus MPA 
concentrations in both periods, while comparable value was observed for free MPA, only in period 
II. 
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Table 5.5. Summary of response (PD) parameters related to IMPDH activity and  
 corresponding exposure (PK) parameters for MPA on Periods I and II 
 Period 1 Period 1 Period II  
 
 
(n=34) 
Patients that finished both 
periods 
 
p value 
(paired 
 PD parameter    
Predose 
[µM XMP/M AMP/sec] 
 
58.4 
[7.7, 272] 
54.8 
[7.7, 272] 
36.3 
[2.1, 179] 
0.04 
Rmin 
[µM XMP/M AMP/sec] 
 
28.3 
[13.9, 44.1] 
26.1 
[15.1, 39.1] 
19.0 
[10.2, 28.4] 
0.01 
AUC_B 
[h.µM XMP/M AMP/sec] 
244.0 ± 157.0 248.6 ± 164.2 293.8 ± 166.6 0.009 
PK parameter     
AUCpartial 
(µg*h/mL) 
14.5 ± 8.5 15.6 ± 8.7 21.4 ± 14.1 NS 
AUCp-free 
(µg*h/mL) 
0.3 
[0.08, 1.0] 
0.2 
[0.08, 0.7] 
0.2 
[0.06, 0.8] 
NS 
Predicted AUC0-12 h 
(µg*h/mL) 
44.8 ± 23.5 46.6 ± 23.0 55.7 ± 33.5 NS 
Predicted CL/F 
(L/h) 
28.9 ± 16.0 25.9 ± 14.6 16.6 ± 6.3 0.002 
Values are expressed as Mean (± SD) or Median (Range) ; Pre-dose- pre-dose trough values for IMPDH activity; 
AUC_B (AUC below baseline); Rmin- Response minimum corresponds to the least IMPDH activity observed during 
the study duration; AUCpartial- partial 3.5 h AUC for MPA;  AUCp-free- partial free AUC for MPA; AUC0-12 h- 
Individual estimated 12 h AUC for MPA 
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Figure 5.9. Correlations between IMPDH activity, MPA and free MPA concentrations (Periods I and II) 
 
The overall comparison after dual monitoring of MPA and IMPDH activity, showed a 
significantly higher Rmin (IMPDH activity at peak inhibition ~ 1.5 h post MMF dose) in patients 
with lower 12 h predicted exposure to MPA (< 30 µg*h/mL) when compared to patients with 
higher exposure (Figure 5.10). A similar trend was also observed with predose (trough) versus 
exposure (not shown) as Rmin showed a good correlation with predose IMPDH activity, whereas 
the AUC_B was not significantly different between the categories of MPA exposure, as reported 
in an earlier study255.  
The distribution frequencies of UGT and IMPDH genotypes in study population are presented in 
Table 5.6. The frequencies for alleles were comparable to typical values reported for the Caucasian 
population. The effect of UGT genotypes on dose normalized exposure to MPA and MPAG are 
compared in Table 5.7 after pooling of heterozygous variants with homozygous variants, due to 
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low sample size. No significant differences were observed when MPA and MPAG exposures were 
compared between the genotype groups. Similarly, no significant differences in IMPDH activity 
and MPA exposure were observed on comparison of genotype groups for IMPDH I and II, except 
a higher pre-transplant activity with IMPDH II wild type, as in Table 5.8. 
 
Figure 5.10. IMPDH activity in relation to corresponding MPA exposure 
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Table 5.6. Frequency (%) of the SNP variants for UGT1A9 and IMPDH 1/2 genes 
N=37; difference in total for each genotype is due to genotype not determinable in random patients 
 
  
SNP Gene Homozygous (wild type) 
Heterozygous 
variant 
Homozygous 
variant 
rs72551330 UGT 1A9 98 T>C 
36 
(97.3) 
0 
(0) 
0 
(0) 
rs6714486 UGT 1A9 275 T>A 
30 
(81.1) 
6 
(16.2) 
1 
(2.7) 
rs17868320 UGT 1A9 2152 C>T 
33 
(89.2) 
3 
(8.1) 
0 
(0) 
rs2278294 IMPDH 1  106 G>A 
18 
(48.6) 
16 
(43.2) 
2 
(5.4) 
rs2278293 IMPDH 1 125 G>A 
11 
(29.7) 
18 
(48.6) 
8 
(21.6) 
rs11706052 IMPDH 2 3757 T>C 
32 
(86.5) 
4 
(10.8) 
1 
(2.7) 
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Table 5.7. Effects of SNP variants on MPA exposure 
Parameter 
(Median) 
Unit UGT1A9 275 T>A 
Period I 
UGT1A9 275 T>A 
Period II 
  Wild 
type 
  
Variant 
(n =7) 
p 
value
 
Wild 
type 
  
Variant 
(n =7) 
p 
value
 Dose normalized 
AUCpartial of MPA 
 
(µg*h/mL) 
0.020 0.010 ns 0.030 0.03 ns 
Dose normalized 
AUCpartial of MPAG 
 
0.60 0.25 ns 0.35 0.32 ns 
MPAG/MPA ratio  38.0 12.2 ns 12.3 9.8 ns 
  
UGT1A9 2152 C>T 
Period I 
UGT1A9 2152 C>T 
Period II 
  
Wild type 
(n =33) 
Variant 
(n =3) 
p 
value
 
Wild type 
(n =17) 
Variant 
(n =3) 
p 
value
 Dose normalized 
AUCpartial of MPA (µg*h/mL) 
0.020 0.030 ns 0.030 0.04 ns 
Dose normalized 
AUCpartial of MPAG 
0.56 0.24 ns 0.35 0.32 ns 
MPAG/MPA ratio  34.5 11.25 0.04 12.3 9.8 ns 
MPAG- the glucuronide conjugate metabolite of MPA; AUCpartial is partial area under the curve for 
mycophenolic acid or MPAG until approximately 3.5 h after dosing of MMF; UGT – Uridine glucuronyl 
transferase enzyme; Median data are presented, *Mann–Whitney U test, ns – not significant 
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Table 5.8. Effects of SNP variants on IMPDH activity 
Parameter Unit IMPDH 1 106 G>A p value*  
  Wild type (n =18) 
Variant carrier 
(n =18)  
Pre-transplant 
[µM XMP/M 
AMP/sec] 
 
72.1 
[62.3, 148] 
145 
[90.5, 160] 
0.088 
Pre-dose 42.6 
[18.3, 92.6] 
40.6 
[19.1, 63.1] 
0.897 
Rmin 
17.9 
[11.3, 36.3] 
25.2 
[16.9, 35.5] 
0.429 
Dose normalized 
AUCpartial of MPA  
[µg*h/mL] 0.020 
[0.01, 0.04] 
0.020 
[0.02, 0.03] 
0.713 
  IMPDH 1 125 G>A  
  Wild type (n =11) 
Variant carrier 
(n =26)  
Pre-transplant 
[µM XMP/M 
AMP/sec] 
 
109 
[63.2, 145] 
142 
[72.1, 162] 
0.239 
Pre-dose 44.0 
[23.0, 83.4] 
39.5 
[18.6, 66.5] 
0.664 
Rmin 
19.6 
[5.88, 31.4] 
25.2 
[15.5, 38.5] 
0.221 
Dose normalized 
AUCpartial of MPA  
[µg*h/mL] 0.020 
[0.01, 0.04] 
0.020 
[0.02, 0.03] 
0.706 
  IMPDH II 3757 T>C  
  Wild type (n =32) 
Variant carrier 
(n =5)  
Pre-transplant 
[µM XMP/M 
AMP/sec] 
 
142 
[77.5, 158] 
63.5 
[32.2, 66.7] 
0.015 
Pre-dose 44.0 
[22.3, 68.3] 
35.6 
[14.1, 50.3] 
0.385 
Rmin 
26.2 
[14.8, 38.5] 
11.3 
[8.7, 22.0] 
0.172 
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Dose normalized 
AUCpartial of MPA  
[µg*h/mL] 0.020 
[0.01, 0.03] 
0.030 
[0.02, 0.03] 
0.225 
AUCpartial is partial area under the curve for mycophenolic acid until approximately 3.5 h after dosing of MMF; 
IMPDH- Inosine monophosphate dehydrogenase enzyme; Rmin – Minimum activity corresponding to maximum 
inhibition by MPA; data are expressed as median (interquartile range), XMP- Xanthosine monophosphate, AMP- 
Adenosine monophosphate, *Mann–Whitney U test. 
5.6 DISCUSSION  
Renal transplant patients have a greater risk for acute rejections during the first few weeks 
after transplantation. This includes an increased incidence of subclinical rejections (similar 
histological findings as clinical rejections but with no change in kidney function) during this time 
period256. Hence, post-transplant therapy is usually begun with a higher immunosuppression target 
for drugs like tacrolimus as well as steroids, which are subsequently tapered with time. On the 
contrary, a fixed dosing strategy is adopted for mycophenolate mofetil. In addition, though 
pharmacokinetic and pharmacodynamic approaches for monitoring response to MPA have been 
developed, they are not routinely employed in the clinic. As pointed out in several studies252,257, a 
high inter-patient variability was observed for exposure of MPA after fixed dosing with MMF, 
especially during early post-transplant  and this together with a higher initial risk for rejection, 
underscores the need for ensuring optimal exposure to MPA 251, at least during the early post-
transplant period. 
The higher between as well as within subject variability in MPA PK was thought to be 
related to changes in renal function as well as a low bioavailability252, early after transplantation.  
Consequently, many patients on same starting dose of MMF do not reach the intended target MPA 
AUC of 30-60 µg*h/mL during early post-transplant period 90,105,113,131 and this indicates that early 
post-transplant monitoring of MPA could benefit renal transplant patients. Obviously, the 
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consensus guidelines of 2006132 recommended MPA monitoring at least for specified time points 
including early post-transplant period to help optimize outcomes and more so in patients at high 
risk for rejection. 
When pharmacokinetic monitoring is considered, the primary objective is to ensure 
appropriate patient exposure as total drug exposure is related with clinical endpoints or surrogate 
outcomes. In the case of MPA, the total area under the curve in a dosing interval (AUC0–12 h) has 
so far provided the most reliable measure for MPA exposure132,258. Previous studies had clearly 
established a good correlation of MPA total 12 h exposure with clinical efficacy in renal 
transplantation 251,259 and MPA exposure window, ranging between 30 to 60 µg*h/mL113,132, has 
been suggested early after transplantation, to minimize rejections. The corresponding pre-dose 
(trough) concentrations determined in these studies ranged between 1 to 3.5 µg/mL. Maintaining 
the recommended AUC targets might not only provide adequate MPA concentrations during early 
post-transplant, but will also limit the adverse reactions like leukopenia260.  
However, determining AUC0-12 h is impractical in the clinical setting and will also increase 
the cost of monitoring. Several alternatives exist to overcome full exposure measurement like 
determination of trough concentrations or abbreviated sampling strategies. But as trough (pre-
dose) concentrations are near the low end of therapeutic range, reliance on this single measurement 
has shown to give misleading results on adequacy of exposure251. Trough MPA concentrations 
also show a wider range of  % CV values in comparison to the corresponding AUCs, especially 
during the first few weeks after transplant251. C0 also displays greater within-patient variability 
than AUC0–12 h, and correlations between MPA C0 and AUC0–12h have been generally poor 248-
250,261. In addition, the MPA exposure has been shown to have better correlation to 
pharmacodynamic85,139 or clinical outcome measures72,109,118,131 than trough concentrations.  
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Abbreviated (limited or sparse sampling) strategies, on the other hand, may use between two to 
five blood samples and can estimate AUC0-12 h of MPA with better accuracy259. The samples 
preferably should be within 4 hours post-dosing, to enable determinations in outpatient clinic. If a 
regression derived equation is used for estimation of AUC from sparse sampling, there is a need 
to follow exact sampling times in clinic. Alternatively, maximum a posteriori probability (MAP) 
bayesian method can be used to estimate the MPA AUC0-12 h99 using a population based 
pharmacokinetic model (median drug clearance, volume of distribution) combined with data from 
individual patients (such as drug concentration, dose, other covariates). Advantages of MAP 
method includes, flexibility in timing of blood sampling and potential to improve estimations by 
adding more data to the model. For example, a bayesian estimation method for MPA AUC0-12 h 
allowed a 10, 15- or 30-min window for sampling at 20, 60- and 180-minutes post-dosing, 
respectively112.  However, the challenges limiting predictive performance for bayesian estimation 
of MPA during early post-transplant period include a high within and inter patient variability as 
well as aspects like food intake and co-morbidities248,262.  Further, experiences with MPA that has 
complex PK profiles and high variability between patients, have indicated a need for compromise 
between practicality and acceptable accuracy in such estimation procedures during monitoring263.   
In this chapter, exposure to MPA (AUC0-12 h) along with corresponding inhibition in the IMPDH 
activity was determined in renal transplant patients, by using sparse sampling with MAP bayesian 
estimation on two different occasions. Determination of 12 h exposure to MPA after MMF dosing 
was the chosen measure, as we predict the Area Under the Curve to relate better with histological 
outcomes (clinical + subclinical rejections) determined based on protocol biopsies. Comparison of 
12 h exposure determined using MAP and linear regression, indicated MAP estimations to be 
within clinically expected exposure limits while a systematic overprediction of exposure was noted 
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with regression equation method. Around 10% of sampling time points also had a deviation of 
greater than 10 min from ideal sparse sampling time points, that could have further impacted 
calculations with regression method. The results from MAP estimation indicated negligible bias 
and overall good agreement of predicted versus observed MPA concentrations, but with a higher 
absolute prediction error. This was predominantly due to mispredictions in ~ 5% of samples that 
was not systematic and were random across patients and time points. In the absence of systematic 
bias, values of CL/F, the primary parameter of interest, can be considered valid along with the 
estimated exposures. The mean predicted CL/F for this cohort of patients was 28.9 L/h during 
early post-transplant around day-6 and was decreased to 16.6 L/h during estimation at 3-month 
follow up. Values for CL/F were comparable to some previous studies149 that were done around 
the same time period after renal transplantation.   
PK studies with MPA have also shown that the clearance of MPA decreases during first 
year after transplantation and hence the exposure based on total MPA increases with time264, as 
was observed in this study. Previous studies with fixed MMF dosing regimen have reported an 
approximately 30-50% lower exposure during early post-transplantation than the later post-
transplantation period118, that were attributed to changes in renal function, plasma protein binding 
due to changes in albumin concentrations or changes to co-administered drugs, such as steroid 
dose tapering. As albumin levels were not different, the lower MPA exposure during period I, was 
primarily due to the higher % free MPA as well as higher levels of the metabolite MPAG during 
the period I (early post-transplant period). With suboptimal renal function during period I, 
MPAG/MPA ratio was also significantly higher, with a high between patient variability. MPA is 
displaced from plasma protein binding sites by either MPAG or by uremic toxins, both of which 
are higher in concentration during early post-transplant period.  Subsequently, with improvement 
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in renal function, MPAG levels decreased and % free MPA reached a normal range around 1% 
and hence MPA exposure was comparatively increased and MPAG/MPA ratio also decreased in 
period II.  As MPA has low extraction ratio of 0.2265, any increase in MPA free is immediately 
subjected to glucuronidation and hence, MPAfree as well as CL/Ffree of MPA was unchanged 
between the two periods, as expected for a low clearance drug. 
The concentration-effect of MPA was shown by decrease in IMPDH activity with 
corresponding increase of total MPA exposure. The relationship of MPAfree with IMPDH activity 
at the sparse time points of pre-dose, 1.5 and 3.5 h was not superior in comparison to total MPA 
versus IMPDH activity.  Hence, the total MPA was considered for further associations with 
IMPDH activity as well as for clinical outcomes, as established earlier for MPA therapy 266. The 
nadir values for IMPDH inhibition occurred at 1.5 h post-dosing of MMF and started recovering 
by 3.5 h, as reported in few other studies. Median values around 1.5 h were approximately 50% of 
median trough values after 1000 mg dose and matched with 47% inhibition around 2 hours in 
another study with 1000 mg dose140. In comparison, only 26-29% inhibition at 1.5 h was observed 
after 500 mg dose255. Good correlation between the pretransplant IMPDH activity and Rmin 
(r=0.59) and to a lesser extent with predose IMPDH activity (r=0.36) was found during the period 
I. However, during follow up at steady state the pretransplant activity was no longer correlated and 
only the relation between predose IMPDH activity and Rmin persisted (r=0.86). In comparison to 
period I (day 6), the values for IMPDH predose and Rmin were lower by an approximate 40 % after 
continuous MPA therapy, during period II (day 90) and corresponds with the higher values of 
trough as well as 12 h exposure for MPA during period II. Due to similar extent of decrease in 
Rmin and predose, they remained correlated, unlike the pre-transplant values that were collected 
once before start of MPA therapy and used the same values for comparisons during both periods. 
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The observations also suggests that the post-dose IMPDH activity corresponds with the post-
transplant time dependent change in MPA pharmacokinetics.  
Finally, a significant relation between the full 12 h exposure (PK) and IMPDH activity 
(PD) was also shown and patients with lower exposure to MPA showed a significantly higher Rmin 
corresponding to less effective inhibition as well as a trend of higher predose IMPDH activity. An 
earlier study with long term follow up of patients141, reported significantly higher predose IMPDH 
activity in patients who were rejecting the graft, though no significant differences occurred in the 
levels of immunosuppressant drugs. Therefore, our observations using sparse sampling, indicated 
both the pharmacodynamic markers, Rmin obtained at 1.5 h post-dosing or predose IMPDH activity 
were responsive to changes in estimated exposures to MPA and  the obtained values were also in 
agreement with earlier studies 141,255. 
In conclusion, a practical sparse sampling strategy was used for estimation of exposure to 
total and unbound MPA as well as the metabolite MPAG in addition to determining the activity of 
its target IMPDH enzyme at around week 1 and at 3-month follow up in renal transplant patients. 
The utility of these measures in predicting outcomes of biopsy proven rejections and infections, 
will be evaluated further in chapter 6. 
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6.0  AN INTEGRATED ASSESSMENT OF PHARMACOLOGIC MEASURES OBTAINED 
DURING EARLY POST-TRANSPLANT PERIOD IN RELATION TO 
CLINICAL/SUBCLINICAL REJECTIONS AND INFECTIONS IN RENAL TRANSPLANT 
PATIENTS 
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6.1 ABSTRACT 
The occurrence of subclinical and clinical rejections during early post-transplant period can affect 
long term graft survival in renal transplant patients. Currently, immunosuppressive therapy is 
individualized only for tacrolimus with routine TDM. Additional monitoring of patients on 
tacrolimus and MMF therapy, can provide a more reliable way to minimize clinical and subclinical 
rejections during the early post-transplant period and would be of great value. The study objective 
was to evaluate if additional monitoring with measures of total exposure to MPA, pre-transplant 
IMPDH activity, response minimum (Rmin) of IMPDH activity and genotyping of p-gp along with 
the total exposure of tacrolimus can better reflect the incidences of subclinical and clinical 
rejections, during the early post-renal transplant period. A prospective PK study with limited 
sampling design was conducted in n=42 renal transplant recipients around post-transplant day 6 
and followed up around day 90 (n=23) along with a protocol biopsy. There was a trend towards a 
lower total exposure to tacrolimus and MPA on day 6 in patients with subsequent rejection at 3 
months, though differences were not statistically significant. Comparison of combined exposure 
to tacrolimus and MPA with respective AUC cut off values of 150 ng*h/mL and 45 µg*h/mL, 
revealed a two-fold higher incidence of rejection in patients with lower exposure to both drugs 
when compared to patients who had optimal exposure to both tacrolimus and MPA (46 vs 23 %, 
NS) with an odds ratio of 3.0 [95% CI: 0.31- 28.84; p =0.3414] for rejection. Patients with a higher 
pre-transplant IMPDH activity (>140 µM XMP/mol AMP/sec) and sub-optimal inhibition of 
IMPDH activity during therapy (Rmin >30 µM XMP/mol AMP/sec) had rejection despite optimal 
exposure to both tacrolimus and MPA. A composite scoring developed based on sum of poor 
prognostic factors like sub-optimal expsoures or high pre-trasnplant activity with sub-optimal Rmin 
or high p-gp efflux activity, revealed that patients with higher scores around day 6 tend to have 
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higher incidence of rejection at 3 months. Hence, the combined monitoring of factors related to 
exposure and efficacy of MPA and exposure of tacrolimus by limited sampling during the early 
post-transplant period, can provide an additional opportunity for optimization of 
immunosuppression and improve the long-term graft outcomes in renal transplant patients.  
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6.2 INTRODUCTION 
The true success in organ transplantation is realized by maintaining optimal function of the 
transplanted graft in the recipients. Though the short-term graft survival has improved since use 
of initial induction therapy followed by maintenance therapy with potent immunosuppression 
using tacrolimus and mycophenolate mofetil (MMF), a 10–20% of the renal transplant recipients 
still suffer from an acute rejection in the first 12 months after transplantation267. In addition, there 
is a higher prevalence of subclinical rejections (SCR) during the initial post-transplant period268,269 
which may decrease during the stable post-transplant phase158. Protocol biopsies obtained at fixed 
periods after transplantation provide histological evidence of SCR, which could include tubulo-
interstitial mononuclear cell infiltration without detectable deterioration in renal function as 
evident with clinical monitoring based on serum creatinine levels. As several transplant centers do 
not perform routine protocol biopsies, the SCR is often overlooked, though longitudinal studies 
have shown SCR to originate very early after transplantation and to contribute to chronic damage 
to the kidney228,229, irrespective of any immediate change in renal function. Taken together acute 
rejection (clinical and subclinical) can adversely affect the long term graft survival270 by causing 
chronic allograft nephropathy271,272, and lack of improvement in the long term graft survival for 
renal transplant patients273.  
Maintenance immunosuppression with tacrolimus/MMF combination in comparison to 
cyclosporine-based therapy is an important factor in the prevention or minimization of rejections 
(clinical and subclinical) 269.  Achieving optimal exposure to both tacrolimus and MPA72,73,109,157, 
as measured by the 12 h Area Under the Curve (AUC)) of tacrolimus and MPA has shown better 
association with rejection outcomes. However, in therapeutic drug monitoring of (TDM) of renal 
transplant patients on tacrolimus/MMF therapy, only the trough concentrations for tacrolimus are 
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routinely monitored as a surrogate for tacrolimus exposure. For MMF, a fixed dosing strategy is 
currently adopted and MPA trough concentrations are not monitored due to its poor correlation 
with MPA exposure as measured by AUC.  
The recommended target AUC for MPA is 30-60 µg*h/mL, but many patients on a fixed 
dose of MMF do not reach the intended target MPA AUC90,105,113,131, due to the high interpatient 
variability especially during the early post-transplant period252,257. As early post-transplant period 
is associated with higher risk for rejections, monitoring of MPA exposure at specific time points 
during early post-transplant can improve outcomes with a reduction in rejection episodes. MPA is 
a non-competitive and reversible inhibitor of ionosine monophosphate-5′-dehydrogenase 
(IMPDH) types 1 and 2 activities and inhibits the proliferation of T and B-lymphocytes. A previous 
study showed an association between higher pre-transplant IMPDH activity and increased 
incidence of  acute rejections during a 3-year follow up of renal transplant patients on MMF 
therapy 136. It is also known that rejections may occur in recipients with MPA AUCs exceeding 30 
µg*h/mL and it might be due to inadequate inhibition of IMPDH by MPA in such patients. 
Monitoring of IMPDH activity may improve outcomes in conjunction with MPA PK monitoring.  
The single time point (trough blood level) of tacrolimus has been used in TDM for convenience 
as well as to minimize cost. However, the prevalence of SCR and clinical rejections even when 
tacrolimus blood levels are within the therapeutic range and the association of intracellular 
concentrations to histological rejections in renal transplant patients 231 may suggest that whole 
blood levels may not accurately represent the concentration at the site of action. However, 
measurement of intracellular concentrations of tacrolimus is tedious, time consuming and not 
practical on a routine basis. Consideration of the activity of ABCB1 (p-gp) transporter that can 
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efflux tacrolimus out of the PBMCs might impact intracellular levels and may provide a more 
reasonable surrogate marker of tacrolimus exposure in PBMCs 69,274.  
The 12 h exposure for both MPA and tacrolimus can be simultaneously estimated from 
limited sampling strategies combined with Bayesian estimation77,99. There is a lack of systematic 
evaluation of markers like pre-transplant IMDPH activity, response minimum of IMPDH activity, 
effect of efflux transporter genotype in lymphocytes in conjunction with the estimated 12 h 
exposures for both MPA and tacrolimus on the association with rejections (both clinical and 
subclinical) during early post-transplant period. Our hypothesis is that determination and inclusion 
of additional markers like pre and post-transplant IMPDH activity, genotyping of p-gp and 
combined exposure measurement of tacrolimus and MPA by limited sampling apart from the 
routine trough levels can improve the therapeutic outcomes post renal transplantation. The purpose 
of this chapter is to investigate the association of IMPDH activity and p-gp genotypes in 
conjunction with the total exposure to MPA and tacrolimus, on the incidence of early post-
transplant rejections and infections in renal transplant recipients. 
6.3 METHODS 
The study protocol was approved by the IRB (Approval No. PRO16050030, dated 20 Oct 
2016, titled “Exposure to Mycophenolic acid/Tacrolimus and outcomes in renal transplant 
recipients”). The details of IRB approval, inclusion exclusion criterion, screening of patients, 
enrollment, study design and time points are provided in chapter 4. As mentioned earlier, enrolled 
patients were studied on two separate occasions (periods) during their post-transplant follow-up 
visits. The period-I was scheduled to be completed within 14 days post-transplant and period-II 
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was scheduled along with the 3-month protocol biopsy. The exposures to tacrolimus and 
mycophenolic acid as well as inhibition of IMPDH activity were determined by sparse sampling 
at predose, 1.5 h and 3.5 h after oral dosing of the immunosuppressants. 
6.3.1 Histology 
Patients who participated in both periods had a protocol biopsy taken at 3rd month (period 
II), that was used for assessment of primary efficacy endpoint. Biopsy results were assessed by a 
transplant pathologist and the scores were defined as per the 2015 Banff classification system275. 
Acute (t, i, v, and g) and chronic (ct, ci, cv, and cg) scores were assessed and recorded for each 
biopsy. The chronic damage indices derived were interstitial fibrosis and tubular atrophy (IFTA 
‘ci’+‘ct’) and interstitial fibrosis with inflammation (‘ci’ + ‘i’ as ‘ci’ > 1 and i >1). Biopsy proven 
rejection was graded based on histological scores of 1 (mild), II (moderate) or III (severe). Sub-
clinical rejection was based on protocol biopsy findings of borderline changes in the setting of 
stable graft function. Mild TCMR was treated with 3 doses of intravenous Solumedrol (250 mg 
each) with addition of maintenance Prednisone 5 mg daily. Moderate to severe (Banff grade >2A) 
rejections were treated with Thymoglobulin 1.5 mg/kg day for a total dose of 6 mg/kg. 
Biopsy was also examined for the presence of BKV nephropathy. The assessment of BK 
viremia, viruria, CMV infections, presence of DSA-I and DSA-II were also carried out during the 
3-month protocol biopsy and all results were obtained from the electronic records. The outcomes 
measures for rejection included both clinical, subclinical rejections at 3-month protocol biopsy and 
measures for infection included incidence of any infection (BKV or CMV) during the 12-month 
follow-up period. 
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6.3.2 Clinical information 
Demographic, clinical data including the calculated panel reactive antibody values (cPRA) 
and estimated eGFR was obtained from the electronic records. The estimated GFR (eGFR) was 
calculated by CKD-EPI formula as described earlier in chapter 4. 
6.3.3 Data analysis and statistics 
The clinically recommended cut-off values for Area Under the curve (AUC) of tacrolimus 
and MPA were used for expression of exposure to tacrolimus and MPA as categorical variables 
(AUC above or below cut off for tacrolimus or MPA, expressed as values 0 and 1, respectively). 
Similarly, scores were assigned based on genotype of P-glycoprotein as 0, 1 and 2 corresponding 
to literature reports of low, medium and high efflux activities, respectively. The median values for 
response minimum (Rmin <30 µM XMP/mol AMP/sec) and pre-transplant (baseline <140 µM 
XMP/mol AMP/sec) IMPDH activities were used as cut off for optimal inhibition  or normal 
baseline, respectively and assigned a score of 0 or 1, if otherwise. The composite score (sum of 
scores based on sub-optimal exposure to MPA/ tacrolimus, high predicted p-gp efflux activity, 
high baseline IMPDH activity and high response minimum Rmin of IMPDH activity) for every 
patient ranged between 0 to 6 and was used for comparisons with incidence of rejections or 
infections.  
The distribution of data was examined for normality using Shapiro-Wilk test and results 
were summarized as mean (±) sd or median (range), as appropriate. The independent student t-test 
or Mann-whitney test were used for univariate comparison of the clinical characteristics, 
pharmacokinetic and pharmacodynamic parameters between patients without versus with outcome 
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events (rejection or infection). The Pearson chi-square test was used for comparisons between 
different categorical groups. The probability of rejection as a function of exposure to MPA and 
tacrolimus was analyzed using logistic regression. Exploratory plots were made to visualize the 
correlation between different categories of tacrolimus or MPA exposure or P-glycoprotein 
genotypes or IMPDH activities and the incidence of acute rejections or infections. The statistical 
analysis and graphical figures were performed using SAS® (version 9.4, SAS Institute, NC, US) 
and SPSS® (version 25, IBM corporation, US). 
6.4 RESULTS 
The demographic and clinical variables in study patients during periods I and II are 
summarized in Table 4.2 of chapter 4. Only the data from patients who had a protocol biopsy at 3 
months were used for assessment of biopsy-proven rejection outcomes (n=33) while all patients 
were considered for assessment of infection outcomes, as it was obtained from electronic records 
corresponding to a follow-up duration of 12-months (n=42). 
6.4.1 Rejections (clinical and subclinical) 
The comparison of demographic variables between patients with rejection outcomes versus 
non-rejectors is shown in Table 6.1. The distribution of age, gender, genotype, dose of 
thymoglobulin (mg/kg) and incidence of infection were comparable between the two outcome 
groups. The Area under the curve (AUC) for MPA, AUC and trough concentrations for tacrolimus 
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and efficacy measures for MPA during period I (median 6 days), was compared between patients 
with rejection versus non-rejectors, as shown in Table 6.2. 
Table 6.1. Demographics of patients with and without rejection (clinical and subclinical) at 3 months post-renal 
transplantation 
 
All 
Patients Rejection No rejection p-value 
n=33 n=14 n=19 
Age (years), mean ± sd  50.1 ± 10.5 47.5 ± 13.2 0.52 
Male, n (%) 19 (57.6) 8 (57.1) 11 (57.9) 1.0 
Race, n (%)    0.14 
White 23 (69.7) 8 (57.1) 15 (79.0)  
African American 7 (21.2) 3 (21.4) 4 (21.1)  
Other 3 (9.1) 3 (21.4) 0 (0.0)  
Living donor 12 (36.4) 4 (28.6) 8 (42.1) 0.42 
Thymoglobulin (mg/kg) 5.17 (0.6) 5.21 (0.5) 5.16 (0.7) 0.84 
Genotype missing, n (%) 5 (15.2) 2 (14.3) 3 (15.8) 1.00 
PGP_C3435T 4 (12.1) 1 (7.1 ) 3 (15.8) 0.86 
PGP_C1236T 8 (24.2) 4 (28.6) 4 (21.1) 0.89 
PGP_G2677T_A 23 (69.7) 12 (85.7) 11 (57.9 ) 0.14 
PGP_G1199A 27 (81.8) 12 (85.7) 15 (79.0) 1.00 
Genotype score, n (%)    0.47 
Low efflux score 1 (3.0) 0 (0.0) 1 (5.3)  
Medium efflux score 23 (69.7) 11 (78.6) 12 (63.2)  
High efflux score 4 (12.1) 1 (7.1) 3 (15.8)  
Infection outcomes  
any infection, n (%) 10 (30.3) 4 (28.6) 6 (31.6) 1.00 
CMV 2 (6.1) 1 (7.1) 1 (5.3) 0.37 
BK virus urine  (3 month) 6 (18.2) 3 (21.4) 3 (15.8) 1.00 
BK virus urine  (12 month) 7 (21.2) 2 (14.3) 5 (26.3) 0.43 
 
No significant difference in total AUC for tacrolimus and MPA as well as measures of 
IMPDH activity was observed between rejection versus non-rejection groups. In addition, Figure 
6.1 shows no significant difference in the incidence of rejections between patients who had optimal 
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tacrolimus or MPA exposure versus patients with sub-optimal exposure, less than the 
recommended 150 ng*h/mL or 45 µg*h/mL for tacrolimus and MPA, respectively. 
Table 6.2. Pharmacokinetic and efficacy endpoints for tacrolimus and MPA in recipients with  
 versus without rejection (clinical and subclinical) at 3 months post-renal transplantation 
 All Patients Rejection No rejection p-value 
n=33 n=14 n=19 
Tacrolimus trough (ng/mL)  
missing, n 2 1 1  
Mean ± SD 7.1 ±  4.1 7.2 ±  4.8 7.1 ±  3.6 0.92 
median [IQR] 6.4  [4.1, 9.4] 
5.8  
[3.3, 10.0] 
6.6  
[5.1, 8.5] 
 
Tacrolimus AUC (ng*h/mL)  
missing, n 1 1 0  
Mean ± SD 167.8 ± 94.0 146.2 ± 80.7 182.5 ± 101.5 0.29 
median [IQR] 147.1 [98.0, 217.2] 
126.4 
[95.0, 182.8] 
194.9 
[126.1, 220.8] 0.43 
MPA AUC 
(µg*h/mL) 
 
missing, n 0 0 0  
Mean ± SD 45.1 ± 2.1 42.7 ± 28.8 46.9 ± 18.4 0.64 
median [IQR] 40.7 [29.7, 59.6] 
34.1 
[15.4, 54.3] 
44.2 
[31.5, 62.6] 0.47 
Exposure Group, n (%)    0.036 
Low/Low 8 (25.0) 6 (46.2) 2 (10.5)  
Low/ High 18 (56.3) 4 (30.8) 14 (73.7)  
High / High 6 (18.8) 3 (23.1) 3 (15.8)  
 IMPDH activity 
Pretransplant IMPDH 
(Baseline) 
(µm XMP/mol AMP/sec) 
 
Mean ± SD 120.8 ± 51.0 135.2 ± 43.1 109.3 ± 55.2 0.20 
median [IQR] 141.7 [77.5, 162.0] 
144.7 
[93.1, 175.3] 
96.6 
[64.4, 157.3] 0.20 
Rmin (Response minimum of 
IMPDH) 
(µm XMP/mol AMP/sec) 
 
Mean ± SD 35.1 ± 27.5 44.9 ± 33.4 27.2 ±19.4 0.10 
median [IQR] 30.0 [14.7, 44.5] 
43.0 
[18.0, 66.6] 
23.9 
[14.7, 36.8] 0.12 
Pre-dose IMPDH  
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a) b) 
 All Patients Rejection No rejection p-value 
n=33 n=14 n=19 
(µm XMP/mol AMP/sec) 
Mean ± SD 73.5 ± 58.4 70.8 ± 49.4 75.7 ± 66.4 0.83 
median [IQR] 55.4 [39.4, 106.6] 
49.4 
[40.7, 111.8] 
61.4 
[30.1, 101.1] 0.97 
% INHIBITION  
(Pre-dose to Rmin) 
 
Mean ± SD 46.2 ± 30.4 37.3 ± 28.8 53.3 ± 30.6 0.18 
median [IQR] 54.9 [20.5, 67.8] 
44.3 
[7.6, 60.4] 
55.9 
[24.3, 73.4] 0.20 
IMPDH, n miss 6 2 4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Incidence of rejections (acute and subclinical) during 3-month protocol biopsy in   
relation to total AUC of a) Tacrolimus and b) MPA (Period I, median day 6 post-renal transplant) 
  
The cumulative 90-day exposure of tacrolimus did not differ between patients with versus 
without rejections (794.3 vs 837.9 ng.day/mL, NS).  
For further analysis, categorical scores were given to patient exposures based on clinically 
recommended cut-off values for tacrolimus and MPA AUCs, for the simultaneous comparison of 
both drug exposures between rejection versus non-rejector groups. Hence, patients having low 
(sub-optimal) exposure to both immunosuppressants were defined as LL (tacrolimus AUC<=150 
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ng*h/mL; MPA AUC<= 45 µg*h/mL). HH was defined as optimal exposure to both tacrolimus 
and MPA (>150 ng*h/mL and >45 µg*h/mL, respectively).  
 
Dotted lines indicate 45 µg*h/mL and 150 ng*h/mL cut-off for total 12 h AUC for MPA and tacrolimus, 
respectively 
Figure 6.2. Incidence of rejections (acute and subclinical) during 3-month protocol biopsy in relation to 
total AUC of a) Tacrolimus and b) MPA (Period I, median day 6 post-renal transplant) 
 
LH was defined as optimal exposure to either of the immunosuppressant (tacrolimus 
AUC<=150 ng*h/mL; MPA AUC >45 µg*h/mL or tacrolimus AUC>150 ng*h/mL; MPA 
AUC<45 µg*h/mL). Overall, 25, 19 and 56 % of patients were categorized under the LL, HH and 
LH groups, respectively.  As shown in Figure 6.2, there was a trend towards higher incidence in 
acute rejections in the LL cohort when compared with HH cohort (46 vs 23 %).    
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Table 6.3. Estimates of odds ratio for acute rejection among 3 cohorts based on    
combined total exposure to MPA and Tacrolimus 
 
 
The odds of acute rejection in LL and LH were compared to HH as the reference group 
with logistic regression analysis and results are summarized in Table 6.3. The odds of rejection 
were higher in the LL group versus the HH group [odds ratio 3.0 (95% CI:0.31, 28.84)], but this 
was not statistically significant (p = 0.3414). The odds of rejection in the LH group did not differ 
significantly from the HH group [odds ratio  0.286 (95% CI:0.041, 2.00), p= 0.2076)]. Based on 
individual patient genotypes for p-gp efflux pump, a low, medium or high efflux of Tacrolimus 
from lymphocytes was predicted in 1 (3.0 %), 23 (69.7 %), and 4 (12.1 %) of the 33 patients with 
biopsy outcomes, respectively.   All the rejectors were predicted to have either medium or high 
efflux activities and majority of such patients were in the LL cohort with low exposure to both 
tacrolimus as well as MPA. Owing to low sample size, no further distinctive pattern with p-gp 
genotype on rejection outcomes were observed. 
Effect Point Estimate 
95% Wald 
p value 
Confidence Limits 
LL group vs HH 3 0.312 28.841 0.3414 
LH group vs HH 0.286 0.041 2.005 0.2076 
LL (group with low exposure to both MPA and Tacrolimus); 
HH (group with optimal exposure to both MPA and Tacrolimus); 
LH (group with low exposure only to either MPA or Tacrolimus) 
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Figure 6.3. Explorative analysis of rejection, combined exposure to MPA and Tacrolimus and  
 predicted efflux activity based on genotypes of ABCB1 (p-glycoprotein) 
 
The IMPDH activity (both pre-transplant baseline and response minimum Rmin in response 
to MPA therapy) and combined exposure to MPA and tacrolimus with corresponding incidence of 
rejections, were examined in scatter plot shown in Figure 6.4. The plot has 16 quadrants each 
representing a unique combination of exposure to tacrolimus/MPA, pre-transplant IMPDH and 
Rmin for IMPDH with corresponding incidence of rejections. As seen in the figure, almost 50% of 
rejections were in two quadrants that had low exposures to both MPA and tacrolimus with a 
corresponding high Rmin for IMPDH. When different cohort of patients were compared, the 
majority of rejection incidence (42 %) was observed in the cohort of patients with high pre-
transplant and high Rmin (sub-optimal inhibition of IMPDH activity). 
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Dotted lines indicate 45 µg*h/mL and 150 ng*h/mL cut-off for total 12 h AUC for MPA and tacrolimus, 
respectively 
Figure 6.4. Scatter plot of IMPDH activity in PBMCs and combined total AUCs for MPA and tacrolimus 
(AUC0-12 h) during Period I with corresponding incidence of rejections (3 month) after renal transplantation 
 
Among patients who were rejecting their kidney with higher than cut-off values for Rmin, 
sub-optimal MPA exposure was the main factor (6 out of 8 patients), while despite optimal MPA 
exposure the remaining 2 patients also had higher than cut-off values for pre-transplant IMPDH. 
Hence, in addition to monitoring optimal exposure to MPA/ tacrolimus, IMPDH activity provided 
an additional dimension for examining or predicting rejection outcomes. Examination of cohort of 
patients rejecting their transplanted kidney with normal pre-transplant and optimal Rmin, however, 
revealed sub-optimal exposure to MPA and occasionally tacrolimus, as the sole discriminating 
factor. 
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Patient gets score 1 each for MPA AUC < 45 µg*h/mL, Tacrolimus AUC < 150ng*h/mL, predicted p-gp medium 
efflux activity (2 for high efflux activity),  IMPDH Rmin > 30 µM XMP/mol AMP/sec, baseline IMPDH > 140  µM 
XMP/mol AMP/sec and score 0 each, if otherwise. Patient was excluded if values for any one parameter was missing; 
(maximum possible score =6, minimum =0) 
Figure 6.5. Prevalence of acute rejection in patients according to the composite score (higher scores for 
sub-optimal exposures to MPA/Tacrolimus or higher IMPDH activities  or higher predicted p-gp efflux 
activity) 
 
A composite scoring for individual patients was generated from the sum of scores assigned 
for poor exposure to MPA, tacrolimus, a high predicted activity of p-gp to efflux tacrolimus out 
of lymphocytes and a high pre-transplant IMPDH activity with sub-optimal inhibition of IMPDH 
activity in response to MPA therapy, as indicated in Figure 6.5 and was compared with incidence 
of biopsy proven rejection. Non-availability of any one of the parameters, led to exclusion of 
patient from this comparison and hence only 23 out of the 33 patients with biopsy outcomes were 
included in the analysis. Majority of patients (44 %) received a score of 4 out of possible 6. As 
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shown in Figure 6.5, a trend to an increased incidence of rejection was observed in patients with a 
higher composite score, obtained from the monitoring of PK and PD parameters. 
6.4.2 Infections (CMV or BK virus) 
During the one year follow up after renal transplantation, about one third of patients (n=14, 
33.3 %) developed at least one incidence of infection with BK virus or CMV or both, as shown in 
Table 6.4. Comparison of demographic factors between patients developing infections versus 
infection-free patients did not reveal any significant differences. 
Table 6.4. Demographics of patients with and without infections during the 12-month follow-up   
post-renal transplantation 
 All Patients Any Infection Infection Free p-value 
n=42 n=14 n=28 
Age (years),  
Mean ± SD 50.4 ± 12.1 53.5 ± 9.9 48.9 ± 12.9 0.21 
Male, n (%) 24 (57.1) 6 (42.9) 18 (64.3) 0.19 
Race, n (%)    0.26 
White 32 (76.2) 11 (78.6) 21 (75.0)  
African American 7 (16.7) 1 (7.1) 6 (21.4)  
Other 3 (7.1) 2 (14.3) 1 (3.6)  
Living donor 13 (31.0) 3 (21.4) 10 (35.7) 0.49 
Genotype missing,  
n (%) 5 (11.9) 5 (17.9) 0 (0.0) 0.15 
PGP_C3435T 7 (16.7) 1 (7.1) 6 (26.1) 0.22 
PGP_C1236T 12 (28.6) 3 (21.4) 9 (39.1) 0.31 
PGP_G2677T_A 31 (73.8) 12 (85.7) 19 (82.6) 1.00 
PGP_G1199A 34 (81.0) 14 (100.0) 20 (87.0) 0.27 
Genotype copies, n (%)    0.23 
Low efflux score 2 (4.8) 0 (0) 2 (7.1)  
Medium efflux score 29 (69.0) 13 (92.9) 16 (57.1)  
High efflux score 6 (14.3) 1 (7.1) 5 (17.9)  
Outcomes  
Acute rejection 14 (33.3) 4 (28.6) 10 (35.7) 0.74 
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 All Patients Any Infection Infection Free p-value 
n=42 n=14 n=28 
any CMV 2 (4.8) 2 (14.3) -  
CMV 3 month 1 (2.3) 1 (3.6) -  
CMV 12 month 0 (0.0) 0 (0.0) -  
BK virus urine  (3 month) 10 (23.8) 10 (71.4) -  
BK virus urine  (12 month) 8 (19.0) 8 (57.1) -  
 
The comparison of pharmacokinetic parameters for tacrolimus and MPA as well as the 
efficacy measures for MPA during period I (median 6 days), between patients with infections 
versus infection-free patients, showed a trend for higher tacrolimus exposure in patients with 
infections, although none of the differences were statistically significant (Table 6.5). 
Table 6.5. Pharmacokinetic and efficacy endpoints for tacrolimus and MPA in recipients with versus 
without infections during the 12 months follow-up post-renal transplantation 
 All Patients Any Infection Infection Free p-value 
n=42 n=14 n=28 
Tacrolimus trough 
(ng/mL) 
 
Mean ± SD 7.0 ± 3.7 8.2 ± 3.7 6.4 ± 3.7 0.16 
median [IQR] 6.4 [4.1, 9.2] 
8.0 
[6.0, 9.6] 
5.8 
[3.5, 8.2] 0.09 
Tacrolimus AUC 
(ng*h/mL) 
 
Mean ± SD 161.8 ±  87.9 171.2 ± 62.1 157.3 ± 98.6 0.59 
median [IQR] 143.1 [94.9, 211.4] 
168.0 
[128.0, 214.5] 
133.4 
[86.1, 213.6] 0.36 
MPA AUC 
(µg*h/mL) 
 
Mean ± SD 43.9 ± 21.7 48.0 ± 22.1 41.9 ± 21.6 0.40 
median [IQR] 39.6 [29.7, 59.6] 
46.5 
[31.5, 63.9] 
37.1 
[26.2, 51.2] 0.29 
Exposure Group, n (%)    0.49 
Low/Low 11 (27.5) 2 (15.4) 9 (33.3)  
Low/ High 21 (52.5) 8 (61.5) 13 (48.2)  
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 All Patients Any Infection Infection Free p-value 
n=42 n=14 n=28 
High / High 8 (20.0) 3 (23.1) 5 (18.5)  
Pretransplant IMPDH 
(Baseline) 
(µm XMP/mol AMP/sec) 
 
Mean ± SD 119.7 ± 55.3 132.7 ± 56.0 113.2 ± 55.0 0.35 
median [IQR] 141.7 [72.1, 174.8] 
153.1 
[66.7, 181.9] 
111.2 
[72.1, 157.3] 0.30 
Rmin (Response 
minimum of IMPDH) 
(µm XMP/mol AMP/sec) 
 
Mean ± SD 47.2 ± 28.8 38.3 ± 23.5 31.5± 32.3 0.4838 
median [IQR] 27.0 [13.9, 44.1] 
37.4 
[17.8, 54.3] 
22.0 
[13.3, 39.4]  
Pre-dose IMPDH 
(µm XMP/mol AMP/sec) 
 
Mean ± SD 74.4 ± 59.8 98.4 ± 78.2 61.4 ± 43.7 0.1505 
median [IQR] 54.8 [30.6, 106.6] 
76.7 
[38.5, 146.2] 
53.1 
[30.1, 105.2] 
 
% INHIBITION 
(Pre-dose to Rmin) 
 
Mean ± SD 33.8 ± 29.4 47.1 ± 27.5 47.2 ± 30.2 0.988 
median [IQR] 52.5 [21.9, 67.8] 
47.7 
[23.1, 63.1] 
55.4 
[16.4, 68.3] 
 
IMPDH, n miss 8 2 6  
 
As defined earlier, categorical classification based on the optimal combined exposure to 
tacrolimus and MPA was done for further examination with corresponding incidence of infections, 
as shown in the scatter plot (Figure 6.6).  Around 62 % of infections (8 out of 13) occurred in 
patients with higher than optimal exposure for tacrolimus corresponding to the trend for higher 
tacrolimus exposure in patients with infections, that was noted earlier. On the contrary, the LL 
cohort showed least incidence of infections in contrast to the highest incidence of rejections 
observed in this cohort. 
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Dotted lines indicate 45 µg*h/mL and 150 ng*h/mL cut-off for total 12 h AUC for MPA and tacrolimus, 
respectively 
Figure 6.6. Scatter plot of combined total AUCs for MPA and tacrolimus (AUC0-12 h) during   
Period I and incidence of infection (BK virus and CMV) over 12 months post-renal transplantation 
 
Based on p-gp genotype information available in 37 patients, a low, medium or high efflux 
of tacrolimus from lymphocytes was predicted in 2 (4.8 %), 29 (69.0 %), and 6 (14.3 %) of the 
patients, respectively and compared with respective incidence of infection. High efflux of 
tacrolimus by p-gp could decrease intracellular concentrations within lymphocytes and might 
counteract the risk of infection by avoiding over immunosuppression. Figure 6.7 showed majority 
of the predicted high effluxers to be infection-free, though further statistical inference was not 
done owing to low sample size. 
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Figure 6.7. Explorative analysis of infections, combined exposure to MPA and Tacrolimus  
and predicted efflux activity based on genotypes of ABCB1 (p-glycoprotein) 
 
The composite score generated earlier in individual patients was compared with incidence 
of infections in Figure 6.8. The scores ranged between all the possible values from 0-6, however 
majority of patients received a score of 4. Again, the exploratory analysis revealed a sharp contrast 
in observations with infection compared to rejections, as patients with highest scores (low 
exposures) were found to have the lowest incidence of infections.  
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Patient gets score 1 each for MPA AUC < 45 µg*h/mL, Tacrolimus AUC < 150ng*h/mL, predicted p-gp medium 
efflux activity (2 for high efflux activity),  IMPDH Rmin > 30 µM XMP/mol AMP/sec, baseline IMPDH > 140  µM 
XMP/mol AMP/sec and score 0 each, if otherwise. Patient was excluded if values for any one parameter was missing; 
(maximum possible score =6, minimum =0). 
 
Figure 6.8. Prevalence of infections in patients according to the composite score (higher scores for sub-optimal 
exposures to MPA/Tacrolimus or higher IMPDH activities or higher predicted p-gp efflux activity) 
6.5  DISCUSSION  
In the present chapter, a comprehensive analysis was performed to determine the effect of 
combined exposure to both tacrolimus and MPA including markers like predicted efflux activity 
by p-glycoprotein (p-gp) along with IMPDH activity on the early post-transplant incidence of 
biopsy proven rejections (clinical and subclinical) as well as infections. The biopsy proven 
outcome in this study were obtained after systematic evaluation of 3-month protocol biopsies using 
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BANFF 2015 criterion and included both subclinical and clinical rejections. Though trough blood 
level-based dose adjustment for tacrolimus was done in this study, patients were on a fixed dose 
of MMF. The Area under curve (AUC 0-12 h) or total exposure is generally considered as the ideal 
marker of drug exposure. Hence, total exposure to both tacrolimus as well as MPA was estimated 
from limited sampling strategy and were used along with IMPDH activity, to reveal associations 
with early post-transplant outcomes. The genotype based predicted efflux activity of MDR1 (p-
gp) was also considered for analysis as the intracellular tacrolimus concentrations at the site of 
action within PBMCs may be affected by p-gp mediated efflux of tacrolimus resulting in lack of 
correlation with whole blood levels. 
In this prospective evaluation, early protocol biopsy done at 3rd month post-transplant 
revealed subclinical changes in renal allograft in addition to clinical rejections in around 40% of 
the patients. The routinely determined tacrolimus trough concentrations (period I, median day 6) 
were comparable between patients with and without rejections during the 3rd month post-
transplant.  The total exposure to tacrolimus was determined by limited sampling strategy (LSS) 
during period I and was not found to be significantly different in patients with rejections versus 
non-rejectors. Undre et al had previously shown tacrolimus AUC on day-2 post-transplantation 
was significantly less in patients with rejection  (157 vs 215 ng*h/mL) and also indicated lower 
incidence of rejection above 200 ng*h/mL75. The study had higher number of patients (n=56) but 
examined different doses of MMF as co-therapy and was only focused on acute rejections without 
a clear specification of the time for evaluation of rejections. In another study, tacrolimus AUC was 
however not different when compared at 3 as well as 12 months in patients with subclinical 
rejection versus non-rejectors in 125 renal transplant patients 228. In the current study, an empirical 
cut-off value for AUC with 150 ng*h/mL was used for comparison of rejections, in line with the 
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current consensus on the TDM of tacrolimus230 which was based on previous observational studies. 
Though majority (8/13) patients with rejection had tacrolimus exposure below the cut-off values, 
the differences were not statistically significant. It is possible that further lower levels of tacrolimus 
than that are targeted during the initial 3 months could be differentiative of rejections or a higher 
sample size is needed for differentiation between rejection versus non-rejectors.  
Apart from the whole blood exposure, few studies have suggested that intracellular 
concentrations of tacrolimus within lymphocytes or the kidney could be affected by the p-gp efflux 
pump variants, thereby altering outcomes like rejection or nephrotoxicity, respectively231,274. 
Efflux activities of p-gp were predicted from genotyping based on prior reports of activity using 
rhodamine 123 efflux assays. For example, all the TT carriers in variants for C3435T or G2677T 
or C1236T were shown to have lower p-gp efflux activity than non-carriers276. In the case of 
G2677T/A at exon 21, two different amino acid changes may occur leading to drastic decrease in 
the ability of p-gp to drive the efflux of tacrolimus277,278. Interestingly, synergism in the case of 
mutated alleles at 2 different SNPs of  3435 T and 1199 A was also shown to result in a very low 
activity which might be predicted to result in higher intracellular concentrations and possibly 
higher efficacy for tacrolimus231. It was also shown that the expression of p-gp in lymphocytes had 
high inter-patient variability in renal transplant patients but did not differ during rejection or in 
comparison to healthy controls279. The distribution of genotypic variants or the predicted scores 
for efflux activity did not differ between patients with rejection versus non-rejectors. However, 
majority of patients were assigned a medium efflux score and less than 20% of patients had low 
or high efflux scores. Exploratory charts showed high efflux in combination with poor exposure 
to both tacrolimus as well as MPA had a rejection while other patients with high efflux score and 
optimal exposure were rejection free.  
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In addition to these possibilities that focus only on tacrolimus exposure versus rejections, 
other factors like the exposure and efficacy of MPA were also considered in this study. The LSS 
based total 12 h exposure determination for MPA has been shown to be superior measure of MPA 
exposure than single time point based monitoring. Like tacrolimus there was no significant 
difference in the total MPA exposure on period I (median day 6) when compared between rejectors 
versus non-rejectors. Again, analyzing MPA exposure as a dichotomous variable with cut off 
values above and below the recommended cut-off value of 45 µg*h/mL also failed to reveal a 
significant difference. In the study by Undre et al75, the day-2 AUC of MPA following 1 g or 2g 
of MMF did not differ in patients with versus without rejections, but the timeline for evaluation of 
rejections were not provided. A similar finding was reported in an earlier study with a smaller 
sample size of n=10 patients on tacrolimus co-therapy280. In addition to the smaller sample size, 
the study however focused only on BPAR without considering subclinical rejections within first 
month and also used 6 h AUC in lieu of the total MPA exposure.  
The main objective of this study, however, was to demonstrate the benefit of examining 
the combined exposure to both tacrolimus and MPA as both tacrolimus and MPA are involved in 
the prevention of rejections. The combined exposures to both the drugs in patients during period I 
were expressed using previously defined cut-off values of 150 ng*h/mL and 45 µg*h/mL for 
tacrolimus and MPA, respectively. The resulting four quadrants (patient cohorts) with low-low 
(LL) or high-high (HH) or high-low (HL) or low-high (LH) were found to differ in the incidence 
of rejections, with a 2-fold increase in LL cohort compared to HH cohort, reinforcing the 
importance for achieving target exposure for both drugs. In addition, the incidence of rejection 
was also less in LH/ HL cohorts, when exposure only to either tacrolimus or MPA was sub-optimal 
when  compared to LL cohort, with sub-optimal exposure to both drugs. As the number of patients 
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with sub-optimal exposure considering tacrolimus or MPA alone were comparable during period 
I, so were the incidence of rejections in the LH and HL cohorts. There was 3 times higher odds of 
rejection in the LL cohort versus HH cohort, though was not statistically significant probably due 
to the decrease in power with dichotomous variables as well as due to scattered incidences of 
rejection across all cohorts. However, the results demonstrate the importance of ensuring optimal 
exposure to both tacrolimus and MPA during the early post-transplant period. 
In the prospective study by Kuypers et al72,133, exposure to MPA or tacrolimus in relation 
to very early acute rejections on day 7 was evaluated. There was no relation of MPA or tacrolimus 
exposure with acute rejection when considered individually, however, a tendency for lower acute 
rejections were demonstrated when adequate AUCs for both tacrolimus (>150 ng*h/mL) and MPA 
(>45 µg*h/mL) were achieved on day 7. In addition to general early post-transplant period, the 
implications of adequate MPA exposure will also be important to consider both in the case of 
nephrotoxicity associated dose reduction required for tacrolimus or tapering of tacrolimus dose 
beyond 3 months post-transplant.  As previously shown for early cyclosporine withdrawal in 
patients, the risk for acute rejections was significantly increased in patients manifesting subclinical 
rejections along with an inadequate exposure to MPA114. 
The comparison of combined exposure to tacrolimus and MPA in rejection versus non-
rejectors also revealed incidence of rejections in few patients despite optimal exposure to both 
drugs. In line with our hypothesis for the benefit in determination of pretransplant IMPDH activity, 
the rejecting patients with optimal exposures were also found to have a high pre-transplant activity 
as well as sub-optimal inhibition of IMPDH activity during MPA therapy (period I). Hence, it is 
possible that high IMPDH activity at both pretransplant as well as at  Rmin  (response minimum), 
could indicate poor responders to MPA therapy. Alternately, higher IMPDH activity (Rmin, if not 
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pretransplant) might also be a response to the ongoing rejection process, as was reported in an 
earlier study141. It should also be noted however, that PD values were obtained around day-6 post-
transplant, in comparison to rejections that were observed at 3rd month. However, this exploratory 
observation needs to be confirmed in larger number of such patients and alternate dosing or 
treatment strategies may need to be explored. 
Next, the effect of exposures to tacrolimus and MPA were examined in relation to the 
incidence of infections (including BV viral and CMV infections). Though exposures during period 
I were not statistically different between patients with or without infections, majority of patients 
had higher total as well as trough exposure to tacrolimus during early post-transplant irrespective 
of the associated exposure in MPA. In the study by Kuypers et al, the tacrolimus AUC but not the 
trough levels were significantly higher during day 7 as well as week 6,  only in patients with 
infections while the MPA AUC was similar in both groups72.  Examination of the effect of 
combined exposure revealed the lowest number of infections in the LL cohort in contrast to the 
observations with exposure-rejection relationship, while the cohort with higher exposure to 
tacrolimus showed an increased incidence of infections. The p-gp driven  efflux of tacrolimus can 
decrease intracellular concentrations within lymphocytes and may counteract the potential 
overimmunosuppression. When the predicted p-gp efflux was explored against the incidence of 
infection,  5 out of 6 patients with high efflux scores were found to be infection free and it could 
suggest that higher p-gp activity may counteract the over-immunosuppressive effects of 
tacrolimus, although confirmation with intracellular tacrolimus concentrations are required in 
future studies. 
The collective impact of individual patient measures obtained during monitoring in period 
I on the incidence of rejections and infections were examined by assigning scores (with equal 
 211 
weight) to each of the measures. The unfavorable aspects for each measure in consideration to 
rejections, as for example, sub-optimal exposure to MPA, tacrolimus or high efflux by p-gp or 
poor inhibition of IMPDH activity were each assigned a score of 1, versus 0, if otherwise.    
The composite score was the sum of individual scores with higher scores hypothesized to result in 
rejections. Majority of patients received a high score of 4 out of possible 6, highlighting the 
increased risks during early post-transplant period. In addition, a trend towards higher incidence 
of rejections (week 13) was noted in patients with high composite scores, which considered several 
measures that were obtained during the pre-transplant or early post-transplant (week 1) monitoring 
of renal transplant patients.  
Hence, in addition to the TDM of tacrolimus, consideration of total exposure and response 
to MPA therapy along with an estimate of the genotyping based or direct intracellular tacrolimus 
concentrations, during the early post-transplant period can help identify patients at a risk for higher 
rejections (subclinical and clinical). Further exploration is required on  the impact of individualized 
preemptive dose adjustment in patients based on the respective pharmacologic measures in 
decreasing the incidence of subclinical and clinical rejections during the follow up period. In 
conclusion, monitoring of the combined exposure to both tacrolimus and MPA in addition to 
determination of IMPDH activity or p-gp genotyping, during the early post-transplant period can 
provide a composite measure for improved prediction of clinical/subclinical rejections and an 
opportunity for individual optimization of immunosuppression in renal transplant patients. 
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7.0  SUMMARY AND FUTURE DIRECTIONS 
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7.1 SUMMARY AND CONCLUSIONS 
Renal transplantation provides the best treatment option for patients with end-stage renal 
diseases (ESRD). Ever since the first successful transplantation in 1954, a variety of improvements 
in surgical techniques as well as introduction of potent immunosuppression drugs have increased 
the number of transplants performed and improved the short-term outcomes by decreasing 
rejections. The benefits of renal transplantation are however limited by the availability of kidneys 
for transplantation in comparison to the number of patients with ESRD. Renal transplant data for 
2018 showed that, out of an estimated active waiting list of around 65,500 patients with ESRD, 
only around 21,167 received a kidney transplant8,9 and almost 70% of these transplanted kidneys 
were from cadaveric donors. Hence, to meet the high demand, better utilization of kidneys from 
marginal donors as well as reducing the number of discarded kidneys are being pursued as viable 
alternatives10. As cadaveric kidneys are more susceptible to ischemia reperfusion injury (IRI), 
strategies aimed at preventing or minimizing IRI would be beneficial for post-transplant graft and 
patient survival. The pharmacologic approach to minimize IRI is one such strategy that can target 
and attenuate different IRI associated pathways by supplementation of preservation solution with 
appropriate agents. This approach can increase the utility of kidneys from the finite donor pool 
and improve the short term and long-term outcomes after renal transplantation. 
The first part of the dissertation focused on evaluation of treprostinil as a pharmacological 
agent to improve the preservation of renal grafts. Treprostinil is a prostacyclin (PGI2) analogue 
approved by the U.S. FDA for the treatment of pulmonary artery hypertension (PAH). The 
pharmacological properties of treprostinil are expected to decrease ischemic damage by restoring 
blood flow and also to minimize damaging effects of the reactive oxygen species and inflammatory 
mediators during reperfusion. Treprostinil was shown to attenuate the decrease in ATP content 
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during 24 h cold preservation of livers and decrease hepatic IR injury in an orthotopic rat liver 
transplant model53. Due to the beneficial effects in liver transplantation, treprostinil was chosen as 
the pharmacological agent for ex vivo addition to the kidneys that are subjected to cold 
preservation as well as for protective treatment during the reperfusion of cold preserved kidneys. 
The overall hypothesis is that the ex-vivo addition of treprostinil to cold storage solution can 
attenuate the IR injury and preserve the function of the kidney graft by its vasodilatory action on 
renal endothelial cells and by the decrease of reperfusion induced activation of inflammatory and 
coagulation pathways.  
In chapter 2, a model for ischemia reperfusion injury was established in isolated rat kidney 
perfusion system. Isolated rat kidneys were cold stored (CS) at 4 °C for 24 h with or without 
treprostinil and reperfused with an oxygenated acellular perfusion solution to evaluate renal 
function as well as changes in mRNA expression. During the 2 h reperfusion, CS kidneys showed 
a significant loss in recovery of renal function as assessed by the fall in GFR, reabsorption of 
sodium and glucose and tubular secretion, to less than 10% of control values. Treprostinil addition 
(20 ng/mL) to CS kidneys significantly improved the filtration fraction as well as urine flow and 
showed a trend to increase the anionic and cationic tubular secretion. Future evaluations of 
treprostinil with a longer follow-up duration (beyond the 2 h used in the ex vivo perfusion system) 
using an in vivo rat transplant model, might allow for evaluation of the changes in protein 
expression and activity.  
Renal injury after IR is an additive effect due to warm/ cold ischemia and reperfusion, but 
the individual cellular events during each are shown to differ and offer unique opportunities for 
therapeutic interventions40. The effects of IR have been widely studied, but clinically the 
contribution by cold storage or reperfusion is difficult to isolate and has been rarely addressed. In 
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chapter 3, the changes in mRNA expression following cold storage (24, 72 h) or reperfusion of the 
kidneys were individually examined, using a quantitative determination of gene expression using 
Nanostring® technology. The gene targets included important basolateral and luminal drug 
transporters, cyp, ugt enzymes and prostacyclin receptors that are endogenously expressed in rat 
kidney, along with targets like chemokines, cytokines and mediators of inflammation that are 
upregulated during ischemia and reperfusion. The expression of drug transporters and enzymes in 
the naive Sprague Dawley rat kidneys using Nanostring® were found to be in concordance with a 
prior study using microarrays. CS for 72 h significantly upregulated cox-2 expression that was 
attenuated by the addition of treprostinil. In comparison to 24 h CS only, the warm reperfusion for 
2 h after 24 h of CS induced the most pronounced changes in gene expression in the isolated rat 
kidneys. The differentially expressed genes in reperfused 24 h CS kidneys were the transporter 
nhe3, MnSOD, Vitamin D receptor, which were downregulated, and ischemia reperfusion 
inducible protein (irip) that was upregulated, indicating IR induced injury. Treprostinil addition to 
both storage and reperfusion attenuated the differential expression (DE) in all the four genes while 
addition to storage alone attenuated the DE of nhe3 and irip genes. Hence, despite a lack of a 
significant renal functional improvement in the short-term IPRK model, changes in gene 
expression after treprostinil exposure indicated protection against the IR induced effects at a 
molecular level, further suggesting a longer duration of follow up in a rat renal transplant model. 
The second part of the dissertation focused on minimizing incidences of subclinical and clinical 
rejections during early post-transplant period in renal transplant patients. The success of renal 
transplantation is dependent on long duration of graft survival with an optimal renal function in 
the recipient. Renal transplant recipients receive maintenance immunosuppression with tacrolimus 
and mycophenolate mofetil (MMF) for prevention of graft rejection. Monitoring of the renal grafts 
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using early post-transplant protocol biopsies have indicated the occurrence of acute cellular 
rejections (clinical/subclinical) in patients on tacrolimus/MMF which are known to be associated 
with progression of fibrosis at 1 year1, chronic allograft injury14,15 and reduced long term graft 
survival14-16. The initial post-transplant graft conditions can impact the long-term graft survival. 
However, the occurrence of early post-transplant inflammatory changes can be minimized by 
individualization of immunosuppression in the patients using clinical pharmacologic approaches 
encompassing therapeutic monitoring techniques in combination with other genotyping and 
pharmacodynamic assessments. Individualization of immunosuppression is therefore essential for 
improving the long-term outcomes in renal transplant patients. 
The overall hypotheses were  (a) the relationship of tacrolimus exposure and outcome 
(clinical/subclinical rejections) will be influenced by genotype of the MDR1 gene expressed on 
the lymphocytes (PBMC)  (b) personalizing MMF dosing based on MPA exposure (abbreviated 
area under the curve (AUC) and monitoring of the inhibition of IMPDH activity will improve 
outcomes. These early post-transplant pharmacologic measures were obtained in patients and 
evaluated for association with incidence of rejections (clinical and subclinical) and infection in 
renal transplant patients. 
In chapter 4, tacrolimus exposure was evaluated during early post-transplant period (Period 
I; week 1) and follow-up study on the day of the 3-month protocol biopsy (Period II; week 13). 
Patients were also genotyped for CYP3A5 and MDR1 polymorphisms, for further evaluation of 
their associations with rejections due to potential impact on tacrolimus blood and lymphocyte 
concentrations, respectively. The total exposure (AUC0-12 h) was estimated with a population 
model by maximum a posteriori bayesian estimation, using limited sampling time points using 3 
blood samples viz., predose and at 1.5 and 3.5 h in 42 and 23 patients, during the early and follow-
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up periods, respectively. The predicted tacrolimus AUC0-12 h ranged between 39-294 ng*h/mL and 
101-302 ng*h/mL during periods I and II, respectively. Only 55 % and 60 % of the patients had 
exposure above the recommended 150 ng*h/mL during periods I and II, respectively. CYP3A5 
expressers had more than 2-fold higher clearance than non-expressors. However, none of the 
MDR1 genotypes (3435, 2677, 1236, 1199) showed significant differences in tacrolimus exposure. 
Trough concentrations showed a good correlation with predicted AUC (r= 0.8 (0.7-0.9)). In this 
part of the study, the more informative and ideal measure of exposure (AUC0-12 h) for tacrolimus 
was obtained by sparse sampling along with genotype of MDR1 for further evaluations against the 
incidence of subclinical/clinical rejections and infections. 
The therapeutic monitoring is currently performed only for tacrolimus trough levels, at our 
transplant center. The present study however, included estimation of the exposure to MPA in 
parallel with tacrolimus exposure. In chapter 5, the individual exposure to MPA along with its 
effect on the inhibition of its target (IMPDH enzyme) was determined by obtaining plasma and 
PBMCs, respectively in parallel to the whole blood samples obtained for the tacrolimus study. The 
partial exposures to MPA, MPAG and MPAfree were obtained from limited sampling points. The 
total MPA exposure (AUC0-12 h) was estimated with a population model by maximum a posteriori 
bayesian estimation. The mean MPA exposure (predicted AUC0-12 h) was comparable between 
Period I to Period II (48.3 ± 21.4 vs 58.2 ± 32.8, NS) with only 47 and 50 % of patients falling 
within the 30-60 µg*h/mL exposure window, respectively. The partial as well as dose normalized 
exposure of MPAfree as well as the CL/Ffree was unchanged between the two periods, as MPA is a 
low clearance drug. MPAG exposure was inversely related to renal function and hence lower 
exposure was observed in Period II and a similar MPAG/MPA ratio was also suggestive that the 
conjugation activity of UGT enzymes was unaffected during early post-transplant period. 
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The dose normalized total MPA exposure showed an increase during Period II and the 
corresponding IMPDH activity was significantly lowered during period II versus period I, as 
shown by lower values for predose activity (54.8 vs 36.3 µM XMP/M AMP/sec, p =0.04) and the 
response minimum, Rmin (26.1 vs 19.0 µM XMP/M AMP/sec, p=0.01). Pooled analysis showed 
the subset of patients with the lowest MPA exposures (< 30 µg*h/mL) to have significantly higher 
Rmin for IMPDH as well as a trend for higher predose IMPDH activity. The results of this part of 
the study showed a change in MPA exposure and response during early post-transplant and the 
need for post-transplant time-based assessments for MPA PK and PD, which could be enabled by 
sparse sampling in an outpatient setting.  
Chapter 6 examined if the combined measures of total exposure to MPA, pre-transplant 
IMPDH activity, response minimum (Rmin) and genotyping of p-gp along with the total exposure 
of tacrolimus can better reflect the incidences of subclinical and clinical rejections, during the early 
post-renal transplant period. Individual comparisons of total exposure to tacrolimus or MPA did 
not reveal significant differences in relation to rejections at 3rd month. However, comparison of 
the combined exposure to tacrolimus and MPA with respective AUC cut off values of 150 
ng*h/mL and 45 µg*h/mL, revealed a two-fold higher incidence of rejection in patients with lower 
exposure to both drugs when compared to patients that had optimal exposure to both tacrolimus 
and MPA (46 vs 23 %, NS) with an odds ratio of 3.0 [95% CI: 0.31- 28.84; p =0.3414] for 
rejections. A few rejecting patients with optimal exposure to both tacrolimus and MPA were found 
to have higher IMPDH activities both at pre-transplant  (>140 µM XMP/mol AMP/sec) and at 
Rmin (>30 µM XMP/mol AMP/sec) indicating a sub-optimal inhibition of IMPDH activity. A 
composite scoring was developed from the sum of poor prognostic factors such as sub-optimal 
exposures or high pre-transplant activity with sub-optimal Rmin or high p-gp efflux activity. 
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Patients with higher composite scores on week 1 (Period I), tended to have higher incidence of 
rejection at 3 months post-transplant. In contrast to increased rejections with low exposure, the 
highest incidence of infections occurred in patients with higher than optimal exposure for 
tacrolimus (62 % of infections). A trend was observed in predicted p-gp high effluxers to be 
infection-free as higher p-gp activity could decrease intracellular concentrations within 
lymphocytes and might counteract the risk of overimmunosuppression. However, determination 
of intracellular tacrolimus concentrations is needed to provide confirmatory evidence. 
Overall, based on the study results, it is concluded that the combined monitoring of 
pharmacological factors related to exposure and efficacy of MPA (IMPDH activity) and tacrolimus 
by limited sampling during the early post-transplant period, provides an opportunity for 
optimization of immunosuppression and will enable physicians to provide  individualized 
treatment to transplant patients.  
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7.2 LIMITATIONS 
1. Isolated rat kidney perfusion (IPRK) model (Chapter 2) 
Reperfusion in IPRK was performed for a duration of 2 hours, beyond which there could 
be depletion of the perfusate components leading to decrease in renal function. Hence long-term 
evaluation of renal function recovery and characterization of drug effect is not feasible with this 
model. In addition, though the oxygenated buffer solution used for reperfusion of kidneys after 
cold storage is optimized to sustain the function of isolated kidneys, use of rat blood might be ideal 
to mimic the in vivo conditions that are available for recovery of a kidney allograft, however it is 
difficult to obtain rat blood in high volumes to perform in vitro studies. 
2. Measurement of ATP in kidneys (Chapter 2) 
ATP content in CS and treprostinil treated CS kidneys were not evaluated or compared, 
which might have enabled verification of the hypothesis on the beneficial effects of treprostinil at 
cellular level during CS and reperfusion. 
3. Gene expression study (Chapter 3)  
The changes in mRNA expression may not be translatable into protein expression or 
functional changes. Further this model using rat kidney might not account for differences that may 
exist in regulation of gene or protein targets in humans. Nanostring based analysis also showed 
less differentiation or lesser fold-change in differences between groups in relation to the fold-
changes observed with RT-PCR technique. 
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4. Population model (Chapter 4,5) 
There was no reference AUC (0-12 h) available to validate the model with the current study 
population, as a published model developed in renal transplant patients was used. Further, 
population models tend to differ with respect to post-transplant period of study and are also specific 
for either MMF or EC-MPS.  
5. Cut-off values for IMPDH activity (Chapter 6) 
There are no prior reports on cut-off values for IMPDH activity associated with transplant 
outcomes like rejections or infections in renal transplant patients.  Hence, arbitrary cut-off values 
such as median values were used for pre-transplant and Rmin of IMPDH activity. Further, the units 
for IMPDH activity in literature are different in recent versus older studies and are not 
interconvertible.  
6. Genotyping and P-gp efflux activity (Chapter 6) 
The predicted efflux activity was obtained from literature-based reports on rhodamine 
efflux capacity by the different MDR1 (p-gp) genotypes. In addition, the combined effects of all 
genotypes in individual patients cannot be established. Hence, the direct determination of 
intracellular tacrolimus concentrations is better alternative. 
7. Sample size (Chapter 6) 
The sample size in period II was reduced following loss of follow-up in patients, primarily 
due to the cancellation of biopsy or change in the formulation from MMF to EC-MPS. Hence, 
evaluation of the pharmacological measures obtained in period II in relation to outcomes were not 
performed. 
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7.3 FUTURE DIRECTIONS 
1. Rat kidney transplant model: 
The trends in the improvement observed with treprostinil addition to the cold storage 
solution at 20 ng/mL in ex vivo and gene expression studies, needs to be further evaluated in a rat 
kidney transplant model. The transplant model will enable re-perfusion in recipient animal with 
whole blood and as well permit a longer duration (days-weeks) of follow-up in the recipients to 
allow for recovery and differentiation of renal graft function between untreated versus treprostinil 
treated groups. The model can further be expanded to include other pharmacological treatment 
options such as pre-treatment of donor or treatment of recipient with treprostinil during 
reperfusion, along with addition to cold storage solution. Evaluation of mitochondrial function and 
ATP content in tissues exposed to treprostinil should also be possible. 
2. Increment of sample size: 
The trends shown in association of exposures and IMPDH activity with rejection outcomes 
(subclinical and clinical) need to be evaluated further, by developing a receiver operating 
characteristic curve (ROC) for each of the pharmacologic measure in relation to the subclinical 
and clinical rejections, which is possible after obtaining data in additional number of patients. 
3. Intracellular tacrolimus concentrations: 
The concentrations of tacrolimus within PBMCs will provide the true target site 
concentrations for tacrolimus and can account for the differences in efficacy despite identical 
whole blood concentrations. The methodology to isolate PBMCs from whole blood needs to be 
optimized further and validated to ensure prevention of tacrolimus efflux out of lymphocytes 
during the processing of blood for isolation of PBMCs.  
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 APPENDIX A 
A.1 IRB PROTOCOL PRO16050030 
TITLE : Exposure to Mycophenolic acid/Tacrolimus and outcomes in renal transplant 
recipients 
A.1.1 ABSTRACT 
Renal transplantation is the best treatment option for patients with endstage renal diseases. Renal 
transplantation has significantly improved patient survival and quality of life. Though the short- 
and long-term patient and graft survival have improved, around 25% of grafts are lost at 5 years 
due to chronic rejection. Prior episodes of acute rejection and/or the presence of subclinical 
rejection are suggested to contribute to chronic rejection. Unlike the histological changes 
associated with kidney graft dysfunction in acute cellular rejection (ACR), the subclinical rejection 
(SCR) is characterized by histologic findings that are associated with local inflammation in the 
absence of any graft dysfunction (like decreased creatinine clearance). The pathogenesis of SCR 
is not clear, however, there is an undisputed involvement of immune activation and inflammation 
in spite of standard maintenance immunosuppression. Hence, there is a vital need to characterize 
the adequacy of maintenance therapy in renal transplant recipients, receiving tacrolimus and 
mycophenolate mofetil (MMF). We hypothesize that in patients treated with tacrolimus and MMF, 
the incidence of ACR/SCR is mainly due to low exposure at site of action (PBMC) and low 
response to immunosuppressive therapy. We predict that patients with ACR/SCR have inadequate 
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exposure to tacrolimus at the target site and inadequate inhibition of IMPDH, the target of 
mycophenolic acid (active component of MMF). 
A.1.2 AIMS 
Aim 1: To determine plasma and peripheral blood mononuclear cells (PBMC) exposure to MPA 
using limited sampling in renal transplant recipients on MMF. To measure exposure in whole 
blood and PBMC in renal transplant patients on tacrolimus. 
Aim 2: To determine the efficacy of MPA by measuring exvivo IMPDH (target of MPA) activity 
in PBMC of renal transplant recipients on MMF therapy. IMPDH activity will be measured in 
PBMC at pretransplant (baseline), early posttransplant (within first two weeks), around month 3, 
as well as during incidence of subacute or acute rejection or infectious episodes. 
Aim 3: To develop a pharmacodynamic range for IMPDH inhibition in renal transplant recipients 
and to determine associations of the key study parameters like IMPDH baseline activity, IMPDH 
inhibition, measures of MPA and tacrolimus exposure with outcomes like subclinical acute 
rejection, acute cellular rejection, opportunistic infections. The results of this study will associate 
efficacy of MPA using IMPDH inhibition and the exposure to tacrolimus at its target site of action, 
with the short-term clinical outcomes in renal transplant recipients. 
A.1.3 INVESTIGATORS 
Name of the Principal Investigator: 
Puneet Sood 
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Address of Principal Investigator: 
7N Montefiore Hospital N755.3, 
3459 Fifth Avenue, 
Pittsburgh 15213 
List of Co-investigators 
Name Organization 
Hariharan Sundaram School of Medicine 
Humar Abhinav School of Medicine 
Tevar Amit  School of Medicine 
Thanukrishnan Harisudhan School of Pharmacy 
Kalluri Hari Varun School of Pharmacy 
Venkataramanan Raman School of Pharmacy 
A.1.4 BACKGROUND 
Renal transplantation is the best treatment option for patients with end stage renal disease. Renal 
transplantation has significantly improved patient survival and quality of life. Though the short- 
and long-term patient and graft survival have improved, around 25% of grafts are lost at 5 years 
due to chronic rejection. Prior episodes of acute rejection and/or the presence of subclinical 
rejection are suggested to contribute to chronic rejection281. Unlike the histological changes 
associated with kidney graft dysfunction in acute clinical rejection (ACR), the subclinical rejection 
(SCR) is characterized by histologic findings that are associated with local inflammation in the 
absence of any graft dysfunction (like decreased creatinine clearance). The pathogenesis of SCR 
is not clear, however, there is an undisputed involvement of immune activation and inflammation 
leading to downstream effects on the long-term allograft function269. 
Immunosuppression in renal transplantation: 
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At UPMC, the preferred maintenance immunosuppression regimen in renal transplant recipients 
consists of tacrolimus, steroids, and mycophenolate mofetil. Tacrolimus inhibits the early phase 
of T-cell activation by inhibiting calcineurin and its dose is targeted to maintain trough levels of  
510 ng/mL. Mycophenolate mofetil (MMF) is dosed along with tacrolimus, twice daily at a fixed 
dose of 2000 mg/day. MMF is an ester prodrug with highly variable absorption profile and is 
hydrolyzed by esterases in the body to mycophenolic acid (MPA). MPA is a selective 
noncompetitive and reversible inhibitor of the Inosine monophosphate dehydrogenase (IMPDH), 
a key enzyme in the exnovo synthesis of GTP247. The immunosuppressant activity ensues as 
lymphocytes depend on this exnovo GTP synthesis significane for their clonal expansion. 
Clinical experience with MPA dose and exposure (AUC): 
MPA is administered at a fixed dose without a personalized dosing approach. After fixed dose of 
MMF, there is a high variability among patients in the exposure to MPA. Trough concentrations 
of MPA do not correlate with MPA exposure. Several studies have shown association of MPA 
exposure over a dosing interval (AUC) with decreased rejection outcome resulting in a consensus 
document that proposed to target MPA exposure at 30–60 mg*h/L282. But, in clinical practice, 
monitoring of MPA exposure for 12 h is impractical. Herein, we propose to implement a limited 
sampling algorithm reported previously in renal transplant recipients149. They have been validated 
to represent 12 h MPA exposure in adult de-novo recipients and more importantly provide a 
practical option for personalizing MMF dosage. In this study we will evaluate MPA exposure 
based on limited sampling strategy.  
Clinical experience with tacrolimus dosing and exposure (AUC): 
Tacrolimus dosing is personalized using therapeutic drug monitoring in whole blood. However, 
the concentration of tacrolimus at the site of action (T-cell) is controlled by the activity of p-
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glycoprotein in PBMC. Tacrolimus trough concentration and occurrence of ACR has been studied 
with a focus on Pgp efflux transporter expressed in PBMCs. Pgp expression in PBMCs of adult 
liver transplant patients was marginally higher and significantly lower in acute rejection and severe 
infections, respectively than in those with an uneventful evolution283. As tacrolimus is a substrate 
for Pgp, the change in its expression can alter PBMC concentrations of tacrolimus and modulate 
its efficacy. The results of Capron et al231 showed significant differences in tacrolimus 
concentrations attained within PBMCs depending on the genotypic changes in Pgp. In this study 
we will measure tacrolimus levels in whole blood, PBMC and determine the expression of Pgp in 
PBMC.We hypothesize that the incidence of subclinical and clinical acute rejection will be 
associated with high Pgp expression and low tacrolimus concentrations at the target site of action 
viz., within PBMC. 
Efficacy of MPA: 
MPA acts by inhibition of IMPDH. Measurement of IMPDH activity offers a direct means to 
adjust MPA dosing based on response to MPA. Studies with IMPDH monitoring136,284,285 have 
consistently indicated an inverse relationship between MPA concentration and IMPDH activity. A 
wide interindividual pharmacodynamic activity was also observed with comparable MPA 
concentrations exhibiting different degrees of IMPDH inhibition. Glander et al136 have shown dose 
reduction in patients with higher pretransplant IMPDH activity (> 8.53 nmol/mg protein/h) was 
associated with significantly higher incidence of rejection (81.8% vs. 36.4%, p<0.01) over a 3year 
followup of renal transplants. In another study143 using ECMPS formulation, IMPDH inhibition 
was significantly lower in renal transplant patients with BPAR at pretransplant, 1 and 2week time 
points. Further, IMPDH inhibition but not the MPA AUC correlated with acute rejection. In the 
present study we will evaluate pre transplant baseline IMPDH activity and IMPDH activity during 
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early posttransplant period (about 1 week) and at around 1 month and at the time of SCR/AR or 
infections. 
Rejection and Infection phenotypes in renal transplantation: 
Overall it is realized that drug therapy has to be individualized to avoid suboptimal or excess 
immunosuppression leading to ACR/SCR and infections, respectively. As shown in various 
studies, IMPDH inhibition can be a reliable marker for optimizing therapy. However, there is lack 
of a study designed to monitor IMPDH activity changes corresponding with clinical phenotypes 
like infection or rejection as well as to define a level of IMPDH inhibition required during such 
episodes. We hypothesize that the incidence of subclinical and acute rejection in patients on MMF 
dosing will be associated with higher basal IMPDH activity and/or minimal inhibition of IMPDH 
activity. The study will determine quantitative differences in basal IMPDH activity and magnitude 
of IMPDH inhibition among patients with sub clinical rejection, clinical rejection and no rejection. 
We will also evaluate if the magnitude of IMPDH inhibition is associated with MPA exposure as 
measured by abbreviated MPA AUC (total and unbound) in these patients. We also hypothesize 
that incidence of infection (BK virus), will be higher in patients with low basal IMPDH activity 
and/or high inhibition of IMPDH activity. The study will determine quantitative differences in 
basal IMPDH activity and magnitude of IMPDH inhibition among patients with and without 
infections. Results from this study will be used to associate efficacy of MPA using IMPDH 
inhibition and significance to the exposure to tacrolimus at its target site of action, with the short-
term clinical outcomes in renal transplant recipients 
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A.1.5 SIGNIFICANCE 
There are several studies in transplant patients that have related MPA exposure/dose to clinical 
rejections72,286. Studies have also evaluated IMPDH activity as a biomarker in response to MPA 
exposure. Some of these have correlated IMPDH genotypes or pretransplant IMPDH activity to 
outcomes like rejection and adverse events137,139,141. We identified 3 studies so far, that 
prospectively looked into IMPDH activity changes during immediate posttransplant in conjunction 
with acute rejection143,144,285. 
We believe that they all have specific limitations, as listed below: 
1. Previous studies were performed to relate IMPDH activity or genotype to clinical acute 
rejection. Our study, in addition, includes sub clinical rejection, which is increasingly being 
recognized as an important surrogate end point in kidney transplantation227.  
2. Previous studies had used ECMPS based therapy along with cyclosporine. Our protocol will use 
tacrolimus with MMF based therapy which is now the accepted standard of care for majority of 
the institutions worldwide. Moreover, the results of previous studies were contradictory, which 
atleast in part could be related to methodological limitations of the older studies. 
3. Many of the studies were performed several months after transplantation and not early post 
transplantation. Performing our study in early posttransplant period is a strength for our study, as 
it will give us insights into mechanisms of early graft injury and rejection. 
4. So far, none of the previous studies have quantified IMPDH inhibition in renal transplant 
patients with subclinical or acute clinical rejection while on tacrolimus with MMF dosing.  
5. Previous studies had not evaluated and simultaneously taken into account, both total and 
unbound MPA exposure and IMPDH activity, to study the MPA exposure adequately. 
Following are the knowledge gaps that this study intends to fill: 
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I. Previous studies have utilized ECMPS with cyclosporine-based dosing. This study will generate 
information with patients on Tacrolimus regimen, which is more commonly used in renal 
transplant patients along with MPA, currently. This study will utilize MMF based dosing, which 
has not been the case in previous studies. 
II. This study will evaluate a 4-hour abbreviated MPA/tacrolimus exposure with limited blood 
sampling using only three time points and has a potential for adoption in other centers. 
III. Existing results on inhibition of IMPDH activity during acute rejection are contradictory to 
each other. Further, no study has so far reported on subclinical rejection which is an outcome of 
major interest under the current maintenance immunosuppression. Our study has access to protocol 
biopsy which permits detection of subclinical rejection as an outcome. Unlike any other study 
before, this study will test our hypothesis in the context of this outcome which will be of major 
interest to the transplant community. 
IV. Unlike other studies so far, results from this study will be unique to consider both IMPDH 
inhibition and PBMC levels of tacrolimus in the same patient as contributory factors to the clinical 
outcome. 
A.1.6 RESEARCH DESIGN AND METHODS 
Renal transplant recipients in this study would be on Tacrolimus and MMF therapy as their usual 
standard of care and dosing of these drugs would not be done for research purposes. All kidney 
transplant patients are potentially eligible to participate in this study. 
Research activities on subjects: 
After eligible renal transplant recipients are identified and enrolled, the following research 
activities would be carried out on three occasions (as below), at the outpatient transplant clinic in 
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7th floor of Montefiore hospital. The subjects will be monitored by the nursing staff, physician 
investigator and or study staff during the period corresponding to this study. 
a) Pretransplant (baseline value) 
Fifteen mL of blood would be drawn to determine the baseline IMPDH activity as well as to 
genotype the subjects for enzymes and transporters involved in the disposition of 
immunosuppressant drugs like MMF and tacrolimus. This procedure will take around five minutes. 
This will be performed by nursing staff or the physician investigators in the Montefiore hospital 
or transplant clinic. Whenever possible, this pretransplant blood will be drawn on the day of 
transplant before the patients receive a dose of MPA. However, if it was not possible to draw blood 
on the day of transplant, any leftover blood collected at a prior time point will be utilized. 
b) Initial posttransplant (between Days 4-10) 
Subjects will be required to hold their regular tacrolimus and MMF dose and take it in the clinic 
in the presence of investigators. To ensure this, one of the study personnel would call or send 
reminder to participating subjects to hold only their morning dose of immunosuppressants 
(Tacrolimus and MMF only) and bring them to the clinic. They will also be reminded that they 
should continue taking their other drugs as usual. On the study day, subjects will be advised to 
refrain from eating for a period of at least one hour prior to dosing until about 2 hours after dosing. 
They will be notified that drinking water is permitted. Ten ml of blood will be collected for trough 
blood and PBMC tacrolimus levels. Ten ml blood will be collected at least 2 and not more than 3 
time points during the 4 hours following MMF administration. This phase will last approximately 
4 hours and will be coordinated during the time these subjects wait for their standard of care 
clinical tests and results, at the 7th floor clinics of Montefiore hospital by nursing staff or physician 
investigators. Total blood volume drawn will be 40 ml. 
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c) Posttransplant (Around 3 months or routine biopsy visit and episode of acute rejection) 
This phase will be coordinated with the standard of care clinical visit. This approach has been 
successfully practiced in previous studies. Similar to earlier time period (section b), this phase will 
last approximately 4 hours and follow the same fasting, dosing and sampling schedule, as 
described earlier and will take place on the 7th floor of Montefiore hospital by nursing staff or the 
physician investigators. Apart from the above 3month blood draw, if there is a scheduled visit for 
treatment of infection or rejection, for a one-year period, there will be blood draws. This will be 
required to establish any association between posttransplant rejection/infection and therapeutic 
activity of MPA/ tacrolimus. Total blood volume drawn will be 40 ml for 3-month visit and another 
40 mL if visiting during episode of acute rejection or infection. 
Research activity on the blood samples obtained: 
1. Drug levels: MMF, MPA (total and unbound) and its metabolites will be quantified in plasma 
by a validated LCMSMS methodology. Tacrolimus will be measured in whole blood using a 
validated liquid chromatography mass spectrometry (LCMSMS) method. 
2. PBMC isolation: PBMCs will be isolated using Ficoll-Paque Plus gradient centrifugation and 
lysed after being counted. Cell lysate samples will be frozen until analysis. A lysate containing 
approximately 510 million cells will be used for quantifying the IMPDH activity. The IMPDH 
activity will be determined from the conversion of inosine monophosphate (IMP) to xanthosine 
monophosphate (XMP) and normalizing it to intracellular Adenosine Monophosphate (AMP) 
concentration. PBMC count will be used to standardize the IMPDH activity measurement. The 
PBMCs obtained from blood samples will be used to quantify the IMPDH activity and if available, 
to quantify the intracellular tacrolimus levels using a validated LCMSMS methodology. 
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3. Genotyping and other biomarkers: The pretransplant blood sample will be used to genotype 
patients using a DNA extraction kit and DNA stored at −80°C until further analysis. Genotyping 
will be done for enzymes CYP3A5, UGT1A9, UGT2B7 and transporters MRP2, ABCB1. In 
addition, the left-over blood sample from clinical samples drawn for routine monitoring will be 
saved for measurement of cytokines and other biomarkers.  
Other data collected from Standard of care Procedures: 
Clinical, demographic and miscellaneous data generated as a part of routine clinical care for renal 
transplant recipients will be utilized to better characterize the relation of the IMPDH activity, MPA 
exposure to outcomes like rejection, infections, hematological or gastrointestinal side effects. Data 
to be utilized will include but not limited to the following demographic, clinical and outcome data. 
Demographic data for recipients, donors, conditioning and immunosuppression regimens, HLA 
matching and source of graft will be recorded. Clinical details of recipients like age, weight, body 
surface area, gender, ethnicity, concomitant medications, serum albumin levels, renal, liver 
function tests and other relevant laboratory values will be recorded in standardized data collection 
forms. Posttransplant clinical outcomes, including transplant procedure related complications, 
occurrence and severity of delayed graft function, subacute, acute and chronic rejection, 
gastrointestinal and other adverse effects, infection status, recipient survival and other clinical 
endpoints of interest will also be captured using standardized data collection forms. 
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APPENDIX B 
CONSENT TO ACT AS PARTICIPANT IN A RESEARCH STUDY 
TITLE: Exposure to Mycophenolic acid/Tacrolimus and outcomes in renal transplant 
recipients 
 
PRINCIPAL INVESTIGATOR: 
Puneet Sood, M.D. Assistant Professor of Medicine and Surgery  
7N Montefiore Hospital N755.3, 3459 Fifth Avenue, Pittsburgh 15213. 
 
CO-INVESTIGATORS:  
Department of Pharmaceutical Sciences: 
Raman Venkataramanan, Ph.D. Professor of Pharmaceutical Sciences and Pathology  
718 Salk Hall, University of Pittsburgh School of Pharmacy, 3501 Terrace Street, Pittsburgh, PA 
15261. 
 
Harisudhan Thanukrishnan, Graduate student, 731 Salk Hall, 3501 Terrace Street, Pittsburgh, PA, 
15261. 
 
SOURCE OF SUPPORT:  Starzl Transplant Institute (STI) and Clinical Pharmacokinetics 
Laboratory Funds, University of Pittsburgh School of Pharmacy 
 
Why is this research being done? 
After kidney transplantation, you will receive drugs called mycophenolate mofetil or 
mycophenolic acid and tacrolimus to prevent your body from rejection of the transplanted kidney. 
Mycophenolate and tacrolimus are Food and Drug Administration (US FDA) approved for use in 
kidney transplantation. The primary objective of this study is to develop a simple strategy to 
simultaneously measure the level and effect of these drugs in kidney transplant patients, in order 
to facilitate acceptance of the transplanted kidney. The results of this study may provide valuable 
information to the clinicians on how these measurements can better improve efficient dosing of 
these drugs. In the future, results from this study may be used to guide dosing of mycophenolate 
mofetil/tacrolimus after transplant to better prevent rejection, infection and increase patient 
survival. 
 
Who is being asked to take part in this research study? 
You are being invited to take part in this research study because you are between the ages of 18 
and 75 years and will be receiving a kidney transplant. You will participate in this study only if 
you receive mycophenolate mofetil and tacrolimus as part of your clinical treatment as a 
medication to prevent rejection of your transplanted kidney. You will not be given any 
medications for the sake of this research study. This study will take place at the University of 
Pittsburgh Medical Center, Pittsburgh, PA, and will include approximately 90 participants.  
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How will the study be done? 
You will participate in this study only if you receive mycophenolate mofetil and tacrolimus as part 
of your treatment. If you decide to participate in this study, you will undergo a screening procedure 
and participate in the study for at least three time points: Before your transplant; 4-14 days 
following transplantation; at follow-up around 3 months following transplantation. In addition, if 
you make a visit at a time of rejection or infection, you will be seen for a fourth time point. The 
duration of your participation in this study will be around five minutes before transplant and around 
4 hours each on the other time points. The entire period of your participation would be about one 
year following your transplantation. We will be collecting information on your medical and 
surgical history from your hospital, as well as surgical and clinic records during your study 
participation, and for up to 1 year after transplantation. We may also be conducting biochemical 
tests such as assessing the levels of certain enzymes and proteins, on the left-over blood samples 
from routine clinical testing that were taken from the time of your transplant for up to one year. 
This may include genetic testing. Genetic testing is inherited information (a blueprint) about the 
structure and functions of cells in the human body that make up the color of our hair and eyes and 
may influence the way our bodies respond to certain stimuli such as an illness or infections. Any 
and all information collected will be confidentially held and used only for the purposes of the 
research study. 
 
Research Procedures 
Before any study-related tests and procedures are performed, you will be asked to read and sign 
this consent document. 
 
Screening 
Recruitment for this study shall begin with initial review of some of your information to determine 
if you are qualified to take part in this clinical study. This will be done following your selection as 
a recipient for kidney transplantation. To determine if you meet the criteria for participation in this 
study, your doctor will review and collect information about your medical history including but 
not limited to your age, gender, weight, height, medical history, infection status as well as clinical 
laboratory test results indicative of your liver and kidney function. If you are a woman of child-
bearing age, pregnancy testing is normally performed as part of the standard of care. Once you 
meet all the study participation criteria, you will be approached by the investigators to determine 
your interest in participating in this research study. If you express interest, the study will be 
explained to you by one of the coordinators and you will be allowed sufficient time to read and 
understand the consent form and sign the consent. No study procedures will be performed until 
after you sign the informed consent. 
 
Pre-transplant 
Prior to your transplant, 15 mL (one tablespoon) of blood will be drawn for lab and genetic testing 
related to the proteins in your body that handle mycophenolate mofetil/tacrolimus and mediate 
their effect. This activity will take about 5 minutes.   
 
Post-transplant 
After your transplantation, there will be two or in some cases three time points that will coincide 
with your scheduled hospital visits.  
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a) The early post-transplant time point will occur anytime between 4-14 days following 
transplantation along with your early follow-up hospital visit 
b) The 3-month post-transplant time point will occur during your biopsy visit around 3 months.  
c) In addition, if you are scheduled to visit the hospital anytime for one year following 
transplantation, for the treatment of rejection or infections, you will participate in an 
additional time point. 
 
At each of these post-transplant time points, the following will take place. 
 
● Prior to study day, you will get a reminder to hold the morning dose of immunosuppressant 
drugs (tacrolimus and mycophenolate) and bring them with you to the clinic. You will be 
advised to continue taking other drugs as usual.  
● You will also be reminded about the need to refrain from eating or drinking fluids for a period 
of at least one hour prior to dosing until about 2 hours after dosing, on the day of study. 
However, drinking water will be permissible. 
● On the day of study, you will be asked to take your morning dose of mycophenolate mofetil 
and tacrolimus in the clinic.  As reminded earlier, please bring them with you to the clinic. 
● During study, you will be asked to refrain from eating or drinking fluids except water for a 
period of at least one hour prior to dosing with mycophenolate mofetil and tacrolimus until 
about 2 hours after dosing.   
● Blood samples for the study will be drawn from an intravenous catheter inserted in your arm. 
● One blood sample (10 ml or approximately 2 teaspoons) will be collected before you take 
your drugs, along with your scheduled clinical sample for tacrolimus monitoring. 
● You will be asked to take your morning dose of mycophenolate mofetil and tacrolimus in the 
clinic.   
● Blood samples (10mL) will be collected for not more than 3 time points during a period of 4 
hours after taking the dose. A total of 40 mL (approx. 3 tablespoons) of blood will be 
collected over a duration of 4 hours.  
The total volume of blood that will be drawn for entire study including the possible visit at the 
time of infection/rejection will be 135 mL (approximately 9 tablespoons). In addition, if you are 
making adequate urine, you may be requested to void and provide the total urine excreted during 
the study period. 
Biological Samples for Future Research 
All biological samples collected during your clinical visits may also be used for future testing 
related to this study or related to the use of medications in transplant recipients. The samples that 
will be collected in this study include blood, plasma and a type of cell within the blood known as 
peripheral blood mononuclear cells (PBMCs) as well as urine. The samples will be stored 
indefinitely in the Clinical Pharmacokinetics Laboratory at the University of Pittsburgh under the 
direct supervision of the research investigator Dr. Raman Venkataramanan. Only members of the 
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research team or laboratory personnel conducting the laboratory tests will have access to the 
samples. Samples will be labeled with the numerical code assigned to each subject in order to 
correlate with clinical data obtained during the study and only the authorized study team members 
will know to whom the sample belongs. You will not be notified about pending results on these 
tests, as they have no bearing on your medical management.  These samples may be shared with 
other investigators who are interested in transplant, but none of the samples shared will contain 
your identifiers. 
 
What are the possible risks, side effects, and discomforts of this research study? 
There may be certain possible risks associated with participation in this study.  These may include 
the following:  
I. Blood draws or Intravenous (IV) catheter insertion: 
Bruising, bleeding, swelling and pain. Subjects (participants) may also be subject to the 
rare risk of infectious contamination associated with the blood draw. To minimize these 
risks, subjects will be monitored after blood draws for bleeding or signs of fainting, and 
blood will not be drawn if hemoglobin is less than 7 g/dL (low blood count). Blood 
sampling will only be done by experienced individuals.   
 
II. Breach of Confidentiality: 
There is also a remote risk associated with breach of confidentiality related to genetic 
testing. There is a possibility that, if the results of the research studies involving your 
biologic materials were to become generally known, this information could impact future 
insurability, employability, or reproduction plans, or have a negative impact on family 
relationships, and/or result in stigmatization. To minimize this risk, any information about 
you obtained from this research will be kept as confidential (private) as possible. All 
records or samples related to your involvement in this research study will be stored in a 
secure, double-locked area or password-protected computer database that is accessible only 
by members of the research team. Your identity on these records and samples will be 
indicated by your subject identification number rather than by your name, and the 
information linking your subject identification number with your identity will be kept 
separate from the research records. 
 
What are possible benefits from taking part in this study? 
There is no direct benefit from participating in this study. However, the information learned from 
this study may help others who undergo transplantation in the future. 
 
What treatment or procedures are available if I decide not to take part in this research study?  
If you decide not to take part in this research study, you will undergo normal procedures associated 
with the living or deceased donor kidney transplantation. This study will not affect your chance to 
receive a kidney transplant and associated treatment procedures. 
 
If I agree to take part in this research study, will I be told of any new risks that may be found 
during the course of the study? 
You will be promptly notified if, during the conduct of this research study, any new information 
develops which may cause you to change your mind about continuing to participate in this study. 
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 Will my insurance provider or I be charged for the costs of any procedures performed as part 
of this research study? 
Some of the services you will receive during this time are “research only services” that are being 
done only because you are in the study. These services will be paid for by the study and will not 
be billed to your health insurance company or you. Examples are certain blood draws, biochemical 
measurements, and genetic testing. 
 
Some of the procedures that you will undergo during this study are considered to be “routine 
clinical services” that you would have even if you were not in the study. Examples are the actual 
kidney transplant surgery, other transplant-related tests, use of immunosuppressive medications 
and routine care medications, hospitalization and all associated costs. These services will be billed 
to your health insurance company or you, if you do not have health insurance. 
 
Will I be paid if I take part in this research study? 
You will not receive any payment for taking part in this clinical research study.  Your biological 
sample or genetic material may lead, in the future, to new inventions or products. If the research 
investigators are able to develop new products from the use of your biological sample or genetic 
material, there are currently no plans to share with you any money or other rewards that may result 
from the development of the new product. 
  
Who will pay if I am injured as a result of taking part in this study? 
University of Pittsburgh investigators and their associates who provide services at UPMC 
recognize the importance of your voluntary participation in their research studies. These 
individuals and their staff will make every reasonable effort to minimize, control and treat any 
injuries that may arise as a result of this research. If you believe that you are injured as the result 
of the research procedures being performed, please contact the principal investigator or one of the 
investigators listed on the first page of this form. 
  
Emergency medical treatment for injuries solely and directly related to your participation in this 
research study will be provided to you by the hospitals of UPMC. Your insurance provider may 
be billed for the costs of this emergency treatment, but none of those costs will be charged directly 
to you. If your research-related injury requires medical care beyond this emergency treatment, you 
will be responsible for the costs of this follow-up care. At this time, there is no plan for any 
additional financial compensation. 
  
Who will know about my participation in this research study? 
Any information about you obtained from this research will be kept as confidential (private) as 
possible. All records related to your involvement in this research study will be stored in a locked 
file cabinet. Your identity on these records will be indicated by a case number rather than by your 
name, and the information linking these case numbers with your identity will be kept separate from 
the research records. You will not be identified by name in any publication of the research results. 
  
Will this research study involve the use or disclosure of my identifiable medical information? 
This research study will involve the recording of past, current and/or future identifiable (pertaining 
to only you) medical information from your hospital and/or other (e.g., physician office) records. 
The information that will be recorded will be limited to information concerning your transplant 
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(e.g., diagnostic information, lab results, medications, medical history).  This information will be 
used to determine your eligibility for this study and to follow your response once you are enrolled 
in the study.  
This research study will not result in identifiable information that will be placed into your medical 
records held at UPMC. If the results of this study are published or presented at meetings, you will 
not be identified. 
Who will have access to identifiable information related to my participation in this research 
study? 
In addition to the investigators listed on the first page of this authorization (consent) form and 
their research staff, the following individuals will or may have access to identifiable information 
(which may include your identifiable medical information) related to your participation in this 
research study:  
 
I. Authorized representatives of the University of Pittsburgh Research Conduct and Compliance 
Office may review your identifiable research information (which may include your identifiable 
medical information) for the purpose of monitoring the appropriate conduct of this research 
study.  
 
II. Authorized representatives of UPMC hospitals or other affiliated health care providers may 
have access to identifiable information (which may include your identifiable medical 
information) related to your participation in this research study for the purpose of (1) fulfilling 
orders, made by the investigators, for hospital and health care services (e.g., laboratory tests, 
diagnostic procedures) associated with research study participation; (2) addressing correct 
payment for tests and procedures ordered by the investigators; and/or (3) for internal hospital 
operations (i.e. quality assurance). 
 
III. In unusual cases, the investigators may be required to release identifiable information (which 
may include your identifiable medical information) related to your participation in this research 
study in response to an order from a court of law.  If the investigators learn that you or 
someone with whom you are involved is in serious danger or potential harm, they will need to 
inform, as required by Pennsylvania law, the appropriate agencies. 
 
Records of your participation in this study will be held confidential except as disclosure is 
required by law or as described in this informed consent document.  
 
For how long will the investigators be permitted to use and disclose identifiable information 
related to my participation in this research study? 
The investigators may continue to use and disclose, for the purposes described above, identifiable 
information (which may include your identifiable medical information) related to your 
participation in this research study for a minimum of seven years after final completion or 
publication of the project and for as long (indefinite) as it may take to complete this research study. 
 
Is my participation in this research study voluntary? 
Your participation in this research study, to include the use and disclosure of your identifiable 
information for the purposes described above, is completely voluntary. (Note, however, that if you 
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do not provide your consent for the use and disclosure of your identifiable information for the 
purposes described above, you will not be allowed to participate in the research study). Whether 
or not you provide your consent for participation in this research study will have no effect on your 
current and future care at a UPMC hospital or affiliated health care provider or your current or 
future relationship with a health care insurance provider. If you choose not to participate in this 
study, it will not impact your care or your chances of receiving a kidney transplant. 
 
Your doctor may be an investigator in this research study, and as an investigator, is interested both 
in your medical care and in the conduct of this research. Before entering this study or at any time 
during the research, you may discuss your care with another doctor who is in no way associated 
with this research project. You are not under any obligation to participate in any research study 
offered by your doctor. 
 
May I withdraw, at a future date, my consent for participation in this research study? 
You may withdraw, at any time, your consent for participation in this research study, to include 
the use and disclosure of your identifiable information for the purposes described above.  (Note, 
however, that if you withdraw your consent for the use and disclosure of your identifiable medical 
record information for the purposes described above, you will also be withdrawn, in general, from 
further participation in this research study).  Any identifiable research or medical information 
recorded for, or resulting from, your participation in this research study or blood samples collected 
prior to the date that you formally withdrew your consent may continue to be used and disclosed 
by the investigators for the purposes described above.  
To formally withdraw your consent for participation in this research study you will be requested 
to provide a written and dated notice of this decision to the principal investigator of this research 
study at the address listed on the first page of this form. 
  
If I agree to take part in this research study, can I be removed from the study without my 
consent? 
It is possible that you may be removed from the research study by the researchers if you experience 
unexpected conditions and in the opinion of the investigators that it is in your best interest. If your 
mycophenolate mofetil or tacrolimus is stopped at the recommendation of your physician, you will 
also be removed from the study.  If this happens, your data may still be kept and used depending 
on when your mycophenolate mofetil or tacrolimus is discontinued.   
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VOLUNTARY CONSENT 
 
All of the above has been explained to me and all of my current questions have been answered.  I 
understand that I am encouraged to ask questions about any aspect of this research study during 
the course of this study, and that such future questions will be answered by the researchers listed 
on the first page of this form. 
  
Any questions which I have about my rights as a research participant will be answered by the 
Human Subject Protection Advocate of the IRB Office, University of Pittsburgh (1-866-212-
2668).   By signing this form, I consent to participate in this research study and provide my 
authorization to share my medical records with the research team.  A copy of this consent form 
will be given to me. 
  
 
________________________________                 ________________________ 
Participant’s Signature                                               Date/Time 
 
 
  
CERTIFICATION OF INFORMED CONSENT 
 
I certify that I have explained the nature and purpose of this research study to the above-named 
individual(s), and I have discussed the potential benefits and possible risks of study participation.  
Any questions the individual(s) have about this study have been answered, and we will always be 
available to address future questions as they arise. I further certify that no research component of 
this protocol was begun until after this consent form was signed. 
  
 
___________________________________                ________________________ 
Printed Name of Person Obtaining Consent                Role in Research Study 
  
  
_________________________________                  ________________________ 
Signature of Person Obtaining Consent                    Date/Time 
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